Compositions and methods for inhibiting expression of Hepatitis B virus (HBV) proteins
Double-stranded RNA agents target and inhibit HBV gene expression, offering a potential 'functional cure' for chronic hepatitis B by reducing viral antigens and achieving seroclearance, overcoming the limitations of current therapies.
Patent Information
- Application Number
- JP2024531569
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-11-29
- Filing Date
- 2022-11-29
- Publication Date
- 2024-11-08
AI Technical Summary
Current treatments for chronic hepatitis B infection, such as nucleotide analogs and pegylated interferons, fail to achieve a 'functional cure' by inhibiting hepatitis B virus (HBV) protein expression effectively, leading to persistent viral antigens and high morbidity and mortality rates.
Development of double-stranded ribonucleic acid (dsRNA) agents that specifically target and inhibit HBV gene expression by utilizing sense and antisense strands with complementary regions to HBV RNA transcripts, potentially achieving a 'functional cure' by reducing HBV antigen levels.
The dsRNA agents effectively inhibit HBV gene expression, leading to reduced levels of viral antigens and a potential 'functional cure' indicated by seroclearance of hepatitis B surface antigen (HBsAg), thereby addressing the limitations of existing treatments.
Smart Images

Figure 2024541559000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates, in part, to compositions and methods that can be used to inhibit Hepatitis B virus (HBV) protein expression. [Background technology]
[0002] Chronic hepatitis B infection (CHB) affects more than 350 million people worldwide and is estimated to be one of the leading causes of liver-related disease and death from hepatocellular carcinoma (HCC) (www.cdc.gov / hepatitis / hbv / pdfs / hepbatrisk.pdf). Although hepatitis B virus (HBV) vaccines provide an effective method of preventing new cases of HBV infection, there exists a large unmet medical need for therapeutic agents and methods to treat existing HBV infections as well as HBV-related diseases and pathologies.
[0003] HBV virions contain a compact 3.2 kilobase (kb) genome that exists as a partially double-stranded relaxed circular (rcDNA) with terminal overlaps of 7-9 bases, which is converted into a covalently closed circular DNA (cccDNA) in the nucleus of hepatocytes, thereby serving as a minichromosome for HBV transcription (Bock CT, et al., J Mol Biol. 2001;307:183-196). Host RNA polymerase II transcribes HBV genes on the cccDNA to generate five viral RNAs: (1) a transcript encoding the precore (HBeAg), (2) a pregenomic RNA (pgRNA) that encodes the structural capsid protein (core) and polymerase and is reverse transcribed to generate rcDNA, (3) a preS1 transcript encoding the large S surface protein, (4) another transcript encoding preS2 and S surface proteins (middle and small S), and (5) the X gene mRNA. The three surface proteins collectively comprise HBsAg. All HBV transcripts are encoded in overlapping reading frames, have a common 3' end, and utilize the same polyadenylation signal (PAS). HBsAg forms an envelope around each core (the encapsidated, partially double-stranded HBV genome) within the lipid bilayer.
[0004] The natural development of chronic HBV infection involves four successive stages: (1) an early "immunological tolerance" stage involving high levels of viral replication and minimal hepatitis; (2) an immune-responsive stage involving marked hepatitis and elevated serum aminotransferases; (3) some patients progress to a "non-replicating" stage involving seroconversion to anti-HBeAg, undetectable or low levels of viremia (<2000 IU / ml by PCR-based assays), and resolution of hepatitis; and (4) HBeAg-negative chronic hepatitis B due to the emergence of specific viral mutations that prevent the production of HBeAg but do not impede viral replication. The fourth stage is a form of chronic hepatitis B (CHB) that can present as HBeAg-positive or HBeAg-negative CHB and is characterized by fluctuating serum HBV DNA and serum aminotransferase (ALT and AST) levels, as well as progressive liver disease.
[0005] Although cccDNA is considered a facilitator of HBV transcription and replication, HBV DNA can be integrated into the host genome. The levels of cccDNA are higher in HBeAg-positive patients than in HBeAg-negative patients, whereas the levels of integrated HBV are higher in HBeAg-negative patients. In addition to cccDNA, studies have shown that integrated HBV DNA can be a source of HBsAg (Wooddell et al.,Sci Transl.Med.2017 Sep 27;9(409):eaan0241.doi:10.1126 / scitranslmed.aan0241). HBeAg and HBsAg are thought to play an important role in chronic infection, leading to T cell tolerance and exhaustion (Kakimi et el.,J Virol.2002;76:8609-8620). Loss of HBsAg is considered a hallmark of effective immune control of HBV. In CHB patients, seroclearance of HBsAg is the desired treatment endpoint ("functional cure") with improved long-term prognosis.
[0006] The rate of functional cure achievable by currently available therapies is relatively slow. Nucleotide (nucleoside) analogues (NUC) and pegylated interferon (PEG-IFN) are the two currently available treatment options for CHB. Administration of NUC can be effective in controlling viral replication and is associated with reduced adverse outcomes, but does not prevent the production or secretion of viral antigens. NUC therapy rarely achieves a "functional cure" for CHB. PEG-IFN treatment can induce long-term immunological control, but is extremely ineffective in achieving a "functional cure." Lau et al. have shown that after 48 weeks of PEG-IFN monotherapy, only 3% of treated individuals achieved HBsAg seroclearance (Lau et al., N Engl J Med. 2005;352(26):2682-95.). Chronic hepatitis B and other HBV-related diseases and conditions remain a significant health problem worldwide, and effective treatment approaches are needed.
Prior Art Documents
Non-Patent Documents
[0007]
Non-Patent Document 1
Non-Patent Document 2
Non-Patent Document 3
Non-Patent Document 4
Summary of the Invention
[0008] According to one aspect of the invention, a double-stranded ribonucleic acid (dsRNA) agent for inhibiting expression of Hepatitis B virus (HBV) in a cell is provided, the dsRNA agent comprising a sense strand and an antisense strand, and nucleotide positions 2-18 of the antisense strand comprise a region of complementarity to an HBV RNA transcript, the region of complementarity comprising at least 15 contiguous nucleotides that differ by 0, 1, 2 or 3 nucleotides from one of the antisense sequences listed in one of Tables 1-4, and optionally comprising a targeting ligand. In some embodiments, the region of complementarity to an HBV RNA transcript comprises at least 15, 16, 17, 18 or 19 contiguous nucleotides that differ by no more than 3 nucleotides from one of the antisense sequences listed in one of Tables 1-4. In certain embodiments, the antisense strand of the dsRNA is at least substantially complementary to any one of the target regions of SEQ ID NO: 673, provided in any one of Tables 1-4. In some embodiments, the antisense strand of the dsRNA is fully complementary to any one of the target regions of SEQ ID NO: 673 and is provided in any one of Tables 1-4. In some embodiments, the dsRNA agent comprises a sense strand sequence set forth in any one of Tables 1-4, where the sense strand sequence is at least substantially complementary to the antisense strand sequence in the dsRNA agent. In certain embodiments, the dsRNA agent comprises a sense strand sequence set forth in any one of Tables 1-4, where the sense strand sequence is fully complementary to the antisense strand sequence in the dsRNA agent. In some embodiments, the dsRNA agent comprises an antisense strand sequence set forth in any one of Tables 1-4. In some embodiments, the dsRNA agent comprises a sequence set forth as a duplex sequence in any of Tables 1-4. In some embodiments, the antisense strand of the dsRNA consists of the nucleotide sequence II: 5'-z1uugucaacaagaaaaaz2-3', where z1 is selected from c, g, a, or u, and z2 is the nucleotide sequence IV. In certain embodiments, z1 is u. In certain embodiments, nucleotide sequence IV is 0 to 15 nucleotides in length.In certain embodiments, the nucleotide sequence IV is selected from c, cu, ca, cc, cg, ccu, cca, ccc, ccg, cccc, cccu, ccca, cccg, ccccg, ccccgc, ccccgcc, ccccgccu, ccccgccug, ccccgccuguaacac, cccguu, or cccgga. In certain embodiments, the nucleotide sequence IV is 1, 2, 3, or 4 nucleotides in length. In certain embodiments, the nucleotide sequence IV is selected from c, cu, ca, cc, cg, ccu, cca, ccc, ccg, cccc, cccu, ccca, or cccg. In some embodiments, the sense strand of the dsRNA consists of the nucleotide sequence III: 5'-z3uuuuucuuguugacaaz4-3', where z3 is the nucleotide sequence V, and z4 is selected from c, g, a, or u. In certain embodiments, z4 is a. In certain embodiments, the nucleotide sequence V is 0-15 nucleotides in length. In certain embodiments, the nucleotide sequence V is selected from g, ag, ug, gg, cg, agg, ugg, ggg, cgg, gggg, aggg, uggg, cggg, cgggg, gcgggg, ggcgggg, aggcgggg, caggcgggg, or guguuacaggcgggg. In certain embodiments, the nucleotide sequence V is 1, 2, 3, or 4 nucleotides in length. In certain embodiments, the nucleotide sequence V is selected from g, ag, ug, gg, cg, agg, ugg, ggg, cgg, gggg, agggg, uggg, or cggg. In some embodiments, the antisense strand of the dsRNA consists of the nucleotide sequence VI: 5'-z5ugucaacaagaaaaacz6-3', where z5 is selected from c, g, a, or u, and z6 is the nucleotide sequence VIII. In certain embodiments, z5 is a. In certain embodiments, the nucleotide sequence VIII is 0-15 nucleotides in length.In certain embodiments, nucleotide sequence VIII is selected from c, cc, ccu, cca, ccc, ccg, cccu, ccca, cccc, cccg, ccug, cccuc, cccuu, cccua, cccgc, cccgcc, ccuguu, cccugga, cccgcc, cccgcc, ccuguu, cccgccu, cccgccug, cccgccugu, cccgccuguaacacg. In certain embodiments, nucleotide sequence VIII is 1, 2, 3 or 4 nucleotides in length. In certain embodiments, nucleotide sequence VIII is selected from c, cc, ccu, cca, ccc, ccg, cccu, ccca, cccc, cccg or ccug. In some embodiments, the sense strand of the dsRNA is comprised of nucleotide sequence VII: 5'-z7guuuuucuuguugacaz8-3', z7 is nucleotide sequence IX and z8 is selected from c, g, a or u. In certain embodiments, z8 is u. In certain embodiments, the nucleotide sequence IX is 0-15 nucleotides in length. In certain embodiments, the nucleotide sequence IX is selected from g, ag, ug, gg, cg, agg, ugg, ggg, cgg, ggag, aagg, uagg, cagg, gcggg, ggcggg, aggcggg, caggcggg, acaggcggg, or cguguuacaggcggg. In certain embodiments, the nucleotide sequence IX is 1, 2, 3, or 4 nucleotides in length. In certain embodiments, the nucleotide sequence IX is selected from g, ag, ug, gg, cg, agg, ugg, ggg, cgg, ggag, aagg, uagg, or cagg. In some embodiments, z1 is a nucleotide sequence complementary to z4. In some embodiments, z2 is a nucleotide sequence complementary to z3. In some embodiments, z5 is a nucleotide sequence complementary to z8. In some embodiments, z6 is a nucleotide sequence complementary to z7. In some embodiments, the dsRNA agent comprises a sense strand and an antisense strand, wherein the antisense strand of the dsRNA consists of nucleotide sequence II or VI above, and the sense strand is 30 nucleotides or less in length, including a region of complementarity to the antisense strand that includes at least 15, 16, 17, 18, or 19 nucleotides.In some embodiments, the dsRNA agent comprises a sense strand and an antisense strand, the sense strand of the dsRNA consists of nucleotide sequence III, the antisense strand of the dsRNA consists of nucleotide sequence II, and nucleotide sequences II and III are as described above. In some embodiments, the dsRNA agent comprises a sense strand and an antisense strand, the sense strand of the dsRNA consists of nucleotide sequence VII, and the antisense strand of the dsRNA consists of nucleotide sequence VI, and nucleotide sequences VI and VII are as described above. In some embodiments, nucleotide sequence II comprises a 3' overhang of at least one nucleotide. In some embodiments, nucleotide sequence II comprises a 3' overhang of at least two nucleotides. In certain embodiments, the 3' overhang of nucleotide sequence II is selected from uu or ga. In some embodiments, nucleotide sequence VI comprises a 3' overhang of at least one nucleotide. In some embodiments, nucleotide sequence VI comprises a 3' overhang of at least two nucleotides. In certain embodiments, the 3' overhang of nucleotide sequence VI is selected from uu or ga.
[0009] In some embodiments, the dsRNA comprises a sense strand and an antisense strand, wherein the antisense strand comprises a region of complementarity comprising at least 15 contiguous nucleotides that differ by 0, 1, 2 or 3 nucleotides from any one of the nucleotide sequences selected from the group consisting of: 5'-uuugucaacaagaaaaacccc-3' (SEQ ID NO: 143) 5'-uacaaaagaaaauugguaaca-3' (SEQ ID NO: 152) 5'-uugucaacaagaaaaaccccg-3' (SEQ ID NO: 162) 5'-ugaacaaauggcacuaguaaa-3' (SEQ ID NO: 166)
[0010] In certain embodiments, the sense and antisense strands comprise a nucleotide sequence comprising at least 15 contiguous nucleotides that differ by 0, 1, 2 or 3 nucleotides from any one of the nucleotide sequences selected from the group consisting of: 5'-gggguuuuucuuguugacaaa-3' (SEQ ID NO:5) 5'-uuugucaacaagaaaaacccc-3' (SEQ ID NO: 143) 5'-uguuaccaauuuucuuuugua-3' (SEQ ID NO: 14) 5'-uacaaaagaaaauugguaaca-3' (SEQ ID NO: 152) 5'-cgggguuuuucuuguugacaa-3' (SEQ ID NO: 24) 5'-uugucaacaagaaaaaccccg-3' (SEQ ID NO: 162) 5'-uuuacuagugccauuuguuca-3' (SEQ ID NO:28) 5'-ugaacaaauggcacuaguaaa-3' (SEQ ID NO: 166)
[0011] In certain embodiments, the dsRNA agent comprises at least one modified nucleotide.In some embodiments, all or substantially all of the nucleotides of the antisense strand are modified nucleotides.In certain embodiments, the at least one modified nucleotide comprises 2'-O-methyl nucleotide, 2'-fluoro nucleotide, 2'-deoxy nucleotide, 2'3'-seco nucleotide mimic, locked nucleotide, non-locked nucleic acid nucleotide (UNA), glycol nucleic acid nucleotide (GNA), 2'-F-arabino nucleotide, 2'-methoxyethyl nucleotide, abasic nucleotide, ribitol, inverted nucleotide, inverted abasic nucleotide, inverted 2'-OMe nucleotide, inverted 2'-deoxy nucleotide, 2'-amino modified nucleotide, 2'-alkyl modified nucleotide, morpholino nucleotide, and 3'-OMe nucleotide, nucleotide that comprises 5'-phosphorothioate group, or terminal nucleotide that is linked to cholesteryl derivative or dodecanoic acid bisdecyl amide group, 2'-amino modified nucleotide, phosphoramidate, or non-natural base-containing nucleotide. In some embodiments, the dsRNA agent comprises an E-vinyl phosphonate nucleotide at the 5' end of the antisense strand. In some embodiments, the dsRNA agent comprises at least one phosphorothioate internucleoside linkage. In some embodiments, the sense strand comprises at least one phosphorothioate internucleoside linkage. In certain embodiments, the antisense strand comprises at least one phosphorothioate internucleoside linkage. In some embodiments, the sense strand comprises 1, 2, 3, 4, 5, or 6 phosphorothioate internucleoside linkages. In some embodiments, the antisense strand comprises 1, 2, 3, 4, 5, or 6 phosphorothioate internucleoside linkages. In certain embodiments, all or substantially all of the nucleotides of the sense strand and the antisense strand are modified nucleotides. In some embodiments, the antisense strand comprises 15 or more modified nucleotides independently selected from 2'-O-methyl nucleotides and 2'-fluoro nucleotides, and less than 6 modified nucleotides are 2'-fluoro nucleotides.In certain embodiments, the antisense strand comprises 3 or 5 2'-fluoro nucleotides. In some embodiments, the antisense strand comprises 15 or more modified nucleotides independently selected from 2'-O-methyl nucleotides and 2'-fluoro nucleotides, wherein at least 14, 15 or 16 modified nucleotides are 2'-O-methyl nucleotides, and the nucleotides at positions 2, 7, 12, 14 and / or 16 from the 5' end of the antisense strand are 2'-fluoro nucleotides. In some embodiments, the dsRNA comprises a sense strand and an antisense strand, wherein the antisense strand is complementary to at least a portion of the mRNA corresponding to the target gene, wherein the antisense strand of the dsRNA comprises a nucleotide sequence shown as formula (C), and the sense strand of the dsRNA comprises a nucleotide sequence shown as formula (D). 3'-(N L ) n N M1 N L N M2 N L N F N L N M3 N L N M4 N L N M5 N M6 N L N M7 N M8 N L N F N L -5' Formula (C) 5'-(N' L ) n’ N' L N' L N' L N' N1 N' N2 N' N3 N' N4 N' F N' L N' N5 N' N6 N' L N' L N' L N' L N' L N' L N' L-3' Formula (D) In the formula, each N F or N' F represents a 2'-fluoro modified nucleotide, and N M1 , N M2 , N M3 , N M4 , N M5 , N M6 , N M7 , N M8 , N' N1 , N' N2 , N' N3 , N' N4 , N' N5 and N' N6 each independently represents a modified or unmodified nucleotide; N M4 , N M5 , N M7 and N M8 is not a 2'-fluoro modified nucleotide, L or N' L independently represent a modified or unmodified nucleotide, but does not represent a 2'-fluoro modified nucleotide, and n and n' can be integers from 0 to 7.
[0012] In some embodiments, the dsRNA comprises a sense strand and an antisense strand, wherein the antisense strand comprises a region of complementarity comprising at least 15 contiguous nucleotides that differ by 0, 1, 2 or 3 nucleotides from any one of the nucleotide sequences selected from the group consisting of: 5'-u*U*ugucAacaaGaAaAacc*c*c-3' (SEQ ID NO:582) 5'-u*A*cuuuCcaauCaAuAggc*c*u-3' (SEQ ID NO:585) 5'-u*G*uaaaGagagGuGcGccc*c*g-3' (SEQ ID NO:588) 5'-u*A*caaaAgaaaAuUgGuaa*c*a-3' (SEQ ID NO:592) 5'-u*C*aaaaGaaaaUuGgUaac*a*g-3' (SEQ ID NO:594) 5'-u*U*gucaAcaagAaAaAccc*c*g-3' (SEQ ID NO:596) 5'-u*G*aacaAauggCaCuAgua*a*a-3' (SEQ ID NO:597) 5'-u*A*gacaAaagaAaAuUggu*a*a-3' (SEQ ID NO:598) 5'-a*U*gucaAcaagAaAaAccc*u*g-3' (SEQ ID NO: 666)
[0013] In some embodiments, the modified sense strand is a modified sense strand sequence set forth in one of Tables 2-4. In certain embodiments, the modified antisense strand is a modified antisense strand sequence set forth in one of Tables 2-4. In certain embodiments, the sense strand is complementary or substantially complementary to the antisense strand, and the region of complementarity is 16-23 nucleotides in length. In some embodiments, the region of complementarity is 19-21 nucleotides in length. In certain embodiments, the region of complementarity is 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides in length. In some embodiments, each strand is 40 nucleotides or less in length. In some embodiments, each strand is 30 nucleotides or less in length. In certain embodiments, each strand is 27 nucleotides or less in length. In certain embodiments, each strand is 25 nucleotides or less in length. In certain embodiments, each strand is 23 nucleotides or less in length. In some embodiments, each strand is 21 nucleotides or less in length. In certain embodiments, each strand is 19-32 nucleotides in length. In certain embodiments, each strand is 19, 20, 21, 22, 23, 24, 25, 26, 32 nucleotides in length. In some embodiments, the dsRNA agent comprises at least one modified nucleotide and further comprises one or more targeting groups or linking groups. In some embodiments, the one or more targeting groups or linking groups are conjugated to the sense strand. In some embodiments, the targeting group or linking group comprises N-acetyl-galactosamine (GalNAc). In certain embodiments, the targeting group has the following structure:
[0014] [ka]
change
change
change
change
change
change
change
change
change
change
change
[0015] In some embodiments, the dsRNA agent comprises a targeting group conjugated to the 5' end of the sense strand. In some embodiments, the dsRNA agent comprises a targeting group conjugated to the 3' end of the sense strand. In certain embodiments, the antisense strand comprises one inverted abasic residue at the 3' end. In certain embodiments, the sense strand comprises one or two inverted abasic residues at the 3' end and / or 5' end. In some embodiments, the dsRNA agent has two blunt ends. In certain embodiments, at least one strand comprises a 3' overhang of at least one nucleotide. In some embodiments, at least one strand comprises a 3' overhang of at least two nucleotides. In some embodiments, the sense strand comprises one of SEQ ID NOs: 281, 290, 295, 300, 304, 306, 307, 331, 557, 567, 569, 571, 572, 573, 560, 563, 607, 628-637, or 918-921. In some embodiments, the antisense strand comprises one of SEQ ID NOs: 419, 428, 433, 438, 442, 444, 445, 469, 582, 592, 594, 596, 597, 598, 585, 588, 642, 663-672, or 922-925.In certain embodiments, the dsRNA agent is selected from the group consisting of SEQ ID NO:281 and SEQ ID NO:419; SEQ ID NO:290 and SEQ ID NO:428; SEQ ID NO:295 and SEQ ID NO:433; SEQ ID NO:300 and SEQ ID NO:438; SEQ ID NO:304 and SEQ ID NO:442; SEQ ID NO:306 and SEQ ID NO:444; SEQ ID NO:307 and SEQ ID NO:445; SEQ ID NO:331 and SEQ ID NO:469; SEQ ID NO:557 and SEQ ID NO:582; SEQ ID NO:567 and SEQ ID NO:592; SEQ ID NO:569 and SEQ ID NO:594; SEQ ID NO:571 and SEQ ID NO:596; SEQ ID NO:572 and SEQ ID NO:597; SEQ ID NO:573 and SEQ ID NO:598; SEQ ID NO:560 and SEQ ID NO:585; SEQ ID NO:563 and SEQ ID NO:588; SEQ ID NO:607 and SEQ ID NO:642; SEQ ID NO:628 and SEQ ID NO:663; SEQ ID NO:629 and SEQ ID NO:664; SEQ ID NO:630 and SEQ ID NO:665; SEQ ID NO:631 and SEQ ID NO:666; SEQ ID NO:632 and SEQ ID NO:667; SEQ ID NO:633 and SEQ ID NO:668; SEQ ID NO:634 and SEQ ID NO:669; SEQ ID NO:635 and SEQ ID NO:670; SEQ ID NO:636 and SEQ ID NO:671; SEQ ID NO:637 and SEQ ID NO:672; SEQ ID NO:918 and SEQ ID NO:922; SEQ ID NO:919 and SEQ ID NO:923; SEQ ID NO:920 and SEQ ID NO:924; or SEQ ID NO:921 and SEQ ID NO:925. In certain embodiments, the dsRNA comprises a duplex selected from the group consisting of AD00170, AD00378, AD00170-1, AD00263, AD00265, AD00267, AD00268, AD00269, AD00173, AD00176, AD00383, AD00384, AD00378-1, AD00170-2, AD00268-2, and AD00263-2.
[0016] According to another aspect of the present invention, there is provided a composition comprising one, two, three or more dsRNA agents of any of the embodiments of any of the aforementioned dsRNA agents. In some embodiments, the composition also comprises a pharma- ceutically acceptable carrier. In certain embodiments, the composition also comprises one or more additional therapeutic agents. In certain embodiments, the composition is packaged in a kit, container, pack, dispenser, pre-filled syringe or vial. In some embodiments, the composition is formulated for subcutaneous administration or formulated for intravenous (IV) administration. In some embodiments, the sense strand of at least one of the dsRNA agents comprises one of SEQ ID NOs: 281, 290, 295, 300, 304, 306, 307, 331, 557, 567, 569, 571, 572, 573, 560, 563, 607, 628-637, or 918-921. In some embodiments, the antisense strand of at least one of the dsRNA agents comprises one of SEQ ID NOs: 419, 428, 433, 438, 442, 444, 445, 469, 582, 592, 594, 596, 597, 598, 585, 588, 642, 663-672, or 922-925.In certain embodiments, the dsRNA agent is selected from the group consisting of SEQ ID NO:281 and SEQ ID NO:419; SEQ ID NO:290 and SEQ ID NO:428; SEQ ID NO:295 and SEQ ID NO:433; SEQ ID NO:300 and SEQ ID NO:438; SEQ ID NO:304 and SEQ ID NO:442; SEQ ID NO:306 and SEQ ID NO:444; SEQ ID NO:307 and SEQ ID NO:445; SEQ ID NO:331 and SEQ ID NO:469; SEQ ID NO:557 and SEQ ID NO:582; SEQ ID NO:567 and SEQ ID NO:592; SEQ ID NO:569 and SEQ ID NO:594; SEQ ID NO:571 and SEQ ID NO:596; SEQ ID NO:572 and SEQ ID NO:597; SEQ ID NO:573 and SEQ ID NO:598; SEQ ID NO:560 and SEQ ID NO:585; SEQ ID NO:563 and SEQ ID NO:588; SEQ ID NO:607 and SEQ ID NO:642; SEQ ID NO:628 and SEQ ID NO:663; SEQ ID NO:629 and SEQ ID NO:664; SEQ ID NO:630 and SEQ ID NO:665; SEQ ID NO:631 and SEQ ID NO:666; SEQ ID NO:632 and SEQ ID NO:667; SEQ ID NO:633 and SEQ ID NO:668; SEQ ID NO:634 and SEQ ID NO:669; SEQ ID NO:635 and SEQ ID NO:670; SEQ ID NO:636 and SEQ ID NO:671; SEQ ID NO:637 and SEQ ID NO:672; SEQ ID NO:918 and SEQ ID NO:922; SEQ ID NO:919 and SEQ ID NO:923; SEQ ID NO:920 and SEQ ID NO:924; or SEQ ID NO:921 and SEQ ID NO:925. In certain embodiments, the dsRNA comprises a duplex selected from the group consisting of AD00170, AD00378, AD00170-1, AD00263, AD00265, AD00267, AD00268, AD00269, AD00173, AD00383, AD00384, AD00378-1, AD00170-2, AD00268-2, AD00263-2, and AD00176.
[0017] According to another aspect of the invention, there is provided a cell comprising a dsRNA agent according to any of the embodiments of the previous aspects of the invention. In some embodiments, the cell is a mammalian cell, optionally a human cell.
[0018] According to another aspect of the invention, there is provided a method of inhibiting expression of a Hepatitis B virus (HBV) gene in a cell, comprising (i) preparing a cell comprising an effective amount of one or more double-stranded ribonucleic acid (dsRNA) agents of any embodiment of the aforementioned dsRNA agent aspects of the invention or any embodiment of the composition of any of the aforementioned aspects of the invention. In some embodiments, the method also comprises (ii) maintaining the prepared cell for a sufficient time to obtain degradation of mRNA transcripts of the HBV gene, thereby inhibiting expression of the HBV gene in the cell, inhibiting replication of HBV in the cell, and reducing the level of HBV antigen in the cell. In some embodiments, the one or more HBV antigens are HBcAg, HBsAg, and HBeAg. In certain embodiments, the cell is in a subject and the dsRNA agent is administered to the subject subcutaneously. In some embodiments, the cell is in a subject and the dsRNA agent is administered to the subject by IV administration. In some embodiments, the cell is in a subject. In some embodiments, two, three, four, or more dsRNA agents are administered to the subject. In certain embodiments, the method also includes evaluating the inhibition of HBV genes after administration of the dsRNA agent to the subject, and the means for evaluation includes (i) determining one or more physiological characteristics of the subject's HBV-related disease or HBV-related pathology, and (ii) comparing the determined physiological characteristics with a baseline pre-treatment physiological characteristic of the HBV-related disease or HBV-related pathology and / or a control physiological characteristic of the HBV-related disease or HBV-related pathology, the comparison indicating one or more of the presence or absence of inhibition of expression of HBV genes in the subject. In some embodiments, the control physiological characteristic is a physiological characteristic in a subject infected with HBV and not administered the dsRNA agent.In some embodiments, the determined physiological characteristic in the subject is one or more of the following: alanine aminotransferase (ALT) level in the subject, aspartate aminotransferase (AST) level in the subject; HBV viral load in the subject; HBV covalently closed circular DNA (cccDNA) level in the subject; one or more HBV antigens level in the subject; one or more HBcAg, HBsAg and HBeAg level in the subject; presence, absence and / or level of one or more anti-hepatitis B virus antibodies in the subject. In some embodiments, the physiological characteristic is determined in a biological sample obtained from the subject. In certain embodiments, the biological sample comprises one or more of a serum sample, a tissue sample, a cell sample and a liver sample. In some embodiments, the determined physiological characteristic in the subject is abnormal compared to a control level of the physiological characteristic. In some embodiments, the level of one or more of ALT; AST; HBV viral load, HBV covalently closed circular DNA (cccDNA); one or more HBV antigens; one or more of HBcAg, HBsAg and HBeAg; and one or more anti-Hepatitis B virus antibodies in a subject that is determined to be statistically significantly higher than the control physiological characteristic of HBV-related disease or HBV-related pathology and / or the baseline pre-treatment physiological characteristic of HBV-related disease or HBV-related pathology indicates the state of HBV gene expression in the subject.In certain embodiments, the control physiological characteristic is the physiological characteristic in a subject infected with HBV and not administered a dsRNA agent.In certain embodiments, the reduction of one or more of ALT; AST; HBV viral load, HBV covalently closed circular DNA (cccDNA); one or more HBV antigens; HBcAg; HBsAg; and HBeAg in a subject indicates the reduction of HBV gene expression in the subject. In some embodiments, an increase in anti-Hepatitis B virus antibodies in the subject compared to control physiological characteristics of HBV-related disease or HBV-related pathology and / or baseline pre-treatment physiological characteristics of HBV-related disease or HBV-related pathology indicates a decrease in HBV gene expression in the subject.In some embodiments, the HBV-related disease or condition is one or more of the following: the disease or condition is one or more of hepatitis B, chronic hepatitis B, hepatitis D virus infection (delta hepatitis or HDV), liver injury, liver cirrhosis, acute hepatitis B, acute fulminant hepatitis, and liver fibrosis, hepatitis, and hepatocellular carcinoma. In certain embodiments, the HBV-related disease or condition is one or more of hepatitis B, chronic hepatitis B, hepatitis D virus infection (delta hepatitis or HDV), and acute hepatitis B.
[0019] According to another aspect of the present invention, there is provided a method of inhibiting the expression of HBV genes in a subject, comprising administering to the subject an effective amount of one or more double-stranded ribonucleic acid (dsRNA) agents of any of the embodiments of the above-mentioned dsRNA agent aspects of the present invention or any of the embodiments of the above-mentioned compositions of the present invention. In some embodiments, two, three, four or more of the dsRNA agents are administered to the subject. In some embodiments, the dsRNA agents are administered to the subject subcutaneously. In certain embodiments, the dsRNA agents are administered to the subject by IV administration. In some embodiments, the method also includes evaluating the inhibition of HBV genes after administration of one or more dsRNA agents, the means for evaluating including (i) determining one or more physiological characteristics of the subject's HBV-related disease or HBV-related pathology, and (ii) comparing the determined physiological characteristics with a baseline pre-treatment physiological characteristic of the HBV-related disease or HBV-related pathology and / or a control physiological characteristic of the HBV-related disease or HBV-related pathology, the comparison indicating one or more of the presence or absence of inhibition of the expression of HBV genes in the subject. In some embodiments, the determined physiological characteristic in the subject is one or more of the following: alanine aminotransferase (ALT) level in the subject, aspartate aminotransferase (AST) level in the subject; HBV viral load in the subject; HBV covalently closed circular DNA (cccDNA) level in the subject; one or more HBV antigens level in the subject; one or more levels of HBcAg, HBsAg and HBeAg in the subject; the presence, absence and / or level of one or more anti-Hepatitis B virus antibodies in the subject. In some embodiments, the physiological characteristic is determined in a biological sample obtained from the subject. In certain embodiments, the biological sample comprises one or more of a serum sample, a cell sample, a tissue sample and a liver sample. In some embodiments, the determined physiological characteristic in the subject is more abnormal compared to a baseline pre-treatment physiological characteristic of HBV-related disease or HBV-related pathology and / or a control physiological characteristic of HBV-related disease or HBV-related pathology.In some embodiments, the levels of one or more of ALT; AST; HBV viral load, HBV covalently closed circular DNA (cccDNA); one or more HBV antigens; one or more of HBcAg, HBsAg and HBeAg; and one or more anti-Hepatitis B virus antibodies in a subject that are determined to be statistically significantly higher, lower or unchanged compared to baseline pre-treatment physiological characteristics of HBV-related disease or HBV-related pathology and / or control physiological characteristics of HBV-related disease or HBV-related pathology indicate the status of HBV gene expression in the subject.In certain embodiments, the reduction of one or more of ALT; AST; HBV viral load, HBV covalently closed circular DNA (cccDNA); one or more HBV antigens; HBcAg; HBsAg; and HBeAg in a subject indicates the reduction of HBV gene expression in the subject. In some embodiments, the increase in anti-hepatitis B virus antibody in the subject compared with the baseline pre-treatment physiological characteristics of HBV-related disease or HBV-related pathology and / or the control physiological characteristics of HBV-related disease or HBV-related pathology indicates the decrease in HBV gene expression in the subject.In certain embodiments, the HBV-related disease or HBV-related pathology is one or more of hepatitis B, chronic hepatitis B, acute hepatitis B, hepatocellular carcinoma, end-stage liver disease, liver fibrosis, hepatitis, liver injury, liver cirrhosis and hepatitis D virus infection (delta hepatitis or HDV).In certain embodiments, the HBV-related disease or HBV-related pathology is one or more of the following: the disease or pathology is one or more of hepatitis B, chronic hepatitis B, hepatitis D virus infection (delta hepatitis or HDV) and acute hepatitis B.
[0020] According to another aspect of the present invention, there is provided a method of treating a disease or condition associated with the presence of a Hepatitis B Virus (HBV) protein, comprising administering to a subject an effective amount of one or more double-stranded ribonucleic acid (dsRNA) agents of any of the embodiments of the above-mentioned aspects of the dsRNA agent of the present invention or any of the embodiments of the above-mentioned compositions of the present invention to inhibit the expression of an HBV gene encoding an HBV protein. In some embodiments, the method comprises administering to the subject two, three, four or more dsRNA agents. In some embodiments, the disease or condition is one or more of hepatitis B, chronic hepatitis B, hepatitis D virus infection (delta hepatitis or HDV), liver injury, liver cirrhosis, acute hepatitis B, acute fulminant hepatitis, hepatitis, liver fibrosis and hepatocellular carcinoma. In certain embodiments, the method also comprises administering to the subject an additional therapeutic regimen. In certain embodiments, the additional therapeutic regimen comprises administering to the subject one or more HBV antisense polynucleotides, additional HBV dsRNA therapeutics, non-HBV dsRNA therapeutics, HBV non-dsRNA therapeutics and behavioral modification. In some embodiments, the non-HBV dsRNA therapeutic agent is one or more of an antiviral agent, an antiviral nucleoside or nucleotide analog (NUC), a viral polymerase inhibitor, a reverse transcriptase inhibitor, an immunostimulant, a therapeutic vaccine, a viral entry inhibitor, an oligonucleotide that inhibits secretion or release of HBsAg, a capsid inhibitor, a covalently closed circular (ccc) HBV DNA inhibitor. In some embodiments, the NUC is tenofovir disoproxil fumarate (TDF), tenofovir alafenamide, lamivudine, adefovir dipivoxil, entecavir (ETV) or telbivudine. In some embodiments, the immunostimulant is pegylated interferon alpha 2a (PEG-IFN-a2a), interferon alpha-2b, recombinant human interleukin-7, a Toll-like receptor 7 (TLR7) agonist or a checkpoint inhibitor (e.g., a PD1 inhibitor). In certain embodiments, the one or more dsRNA agents are administered subcutaneously to the subject. In certain embodiments, one or more dsRNA agents are administered to a subject by IV administration.In some embodiments, the method also includes determining the effectiveness of the administered one or more double-stranded ribonucleic acid (dsRNA) agents in the subject. In certain embodiments, the means for determining the effectiveness of treatment in the subject includes (i) determining one or more physiological characteristics of the subject's HBV-related disease or HBV-related pathology, and (ii) comparing the determined physiological characteristics with a baseline pre-treatment physiological characteristic of the HBV-related disease or HBV-related pathology, the comparison indicating one or more of the presence, absence, and level of effectiveness of administering the double-stranded ribonucleic acid (dsRNA) agent to the subject. In some embodiments, the physiological characteristic determined in the subject is one or more of the following: alanine aminotransferase (ALT) level in the subject, aspartate aminotransferase (AST) level in the subject; HBV viral load in the subject; HBV covalently closed circular DNA (cccDNA) level in the subject; one or more HBV antigens level in the subject; one or more levels of HBcAg, HBsAg and HBeAg in the subject; presence, absence and / or level of one or more anti-hepatitis B virus antibodies in the subject. In certain embodiments, the physiological characteristic is determined in a biological sample obtained from the subject. In some embodiments, the biological sample comprises one or more of a serum sample, a cell sample, a tissue sample and a liver sample. In some embodiments, the physiological characteristic determined in the subject is different from a baseline pre-treatment physiological characteristic of HBV-related disease or HBV-related pathology, or compared to a control level of the physiological characteristic. In certain embodiments, the level of one or more of ALT; AST; HBV viral load, HBV covalently closed circular DNA (cccDNA); one or more HBV antigens; HBcAg, HBsAg and HBeAg in the subject that is determined to be statistically significantly lower compared to baseline pre-treatment physiological characteristics of HBV-related disease or HBV-related pathology indicates a state of reduced HBV gene expression in the subject.In some embodiments, an increase in anti-hepatitis B virus antibody in the subject compared to baseline pre-treatment anti-hepatitis B virus antibody or control level of anti-hepatitis B virus antibody indicates a decrease in HBV gene expression in the subject.In some embodiments, the HBV-related disease or condition is one or more of hepatitis B, chronic hepatitis B, acute hepatitis B, hepatocellular carcinoma, end-stage liver disease, acute fulminant hepatitis, hepatitis, liver injury, cirrhosis, liver fibrosis, and hepatitis D virus infection (delta hepatitis or HDV).
[0021] According to another aspect of the present invention, there is provided a method for reducing the level of HBV protein in a subject, compared to the baseline pre-treatment level of HBV protein in the subject, comprising administering to the subject an effective amount of one or more of the double-stranded ribonucleic acid (dsRNA) agents of any of the embodiments of the above-mentioned aspects of the dsRNA agent of the present invention or any of the embodiments of the above-mentioned composition of the present invention to reduce the level of HBV gene expression. In certain embodiments, the dsRNA agent is administered to the subject subcutaneously or by IV administration.
[0022] According to another aspect of the present invention, there is provided a method of altering the physiological characteristics of a Hepatitis B virus (HBV)-related disease or HBV-related pathology in a subject, compared to the baseline pre-treatment physiological characteristics of the HBV-related disease or HBV-related pathology in the subject, comprising administering to the subject an effective amount of one or more double-stranded ribonucleic acid (dsRNA) agents of any of the embodiments of the above-mentioned aspects of the dsRNA agent of the present invention or any of the embodiments of the above-mentioned compositions of the present invention to alter the physiological characteristics of the HBV-related disease or HBV-related pathology in the subject. In some embodiments, the one or more dsRNA agents are administered to the subject subcutaneously or by IV administration. In certain embodiments, one or more of the determined physiological characteristics in the subject are one or more of: alanine aminotransferase (ALT) level in the subject, aspartate aminotransferase (AST) level in the subject; HBV viral load in the subject; HBV covalently closed circular DNA (cccDNA) level in the subject; level of one or more HBV antigens in the subject; level of one or more of HBcAg, HBsAg and HBeAg in the subject; presence, absence and / or level of one or more anti-Hepatitis B virus antibodies in the subject.
[0023] According to another aspect of the present invention, the above-mentioned dsRNA agent is provided for use in the method for treating the disease or pathology associated with HBV gene expression.In some embodiments, the disease or pathology is one or more of hepatitis B, chronic hepatitis B, hepatitis D virus infection (δ hepatitis or HDV), liver injury, liver cirrhosis, acute hepatitis B, acute fulminant hepatitis, and liver fibrosis, hepatitis, and hepatocellular carcinoma.
[0024] In certain embodiments of any of the aforementioned methods of the invention, the sense strand of the dsRNA agent comprises one of SEQ ID NOs: 281, 290, 295, 300, 304, 306, 307, 331, 557, 567, 569, 571, 572, 573, 560, 563, 607, 628-637, or 918-921. In some embodiments of any of the aforementioned methods of the invention, the antisense strand of the dsRNA agent comprises one of SEQ ID NOs: 419, 428, 433, 438, 442, 444, 445, 469, 582, 592, 594, 596, 597, 598, 585, 588, 642, 663-672, or 922-925. In certain embodiments of any of the aforementioned methods of the invention, the dsRNA agent is SEQ ID NO:281 and SEQ ID NO:419; SEQ ID NO:290 and SEQ ID NO:428; SEQ ID NO:295 and SEQ ID NO:433; SEQ ID NO:300 and SEQ ID NO:438; SEQ ID NO:304 and SEQ ID NO:442; SEQ ID NO:306 and SEQ ID NO:444; SEQ ID NO:307 and SEQ ID NO:445; SEQ ID NO:331 and SEQ ID NO:469; SEQ ID NO:557 and SEQ ID NO:582; SEQ ID NO:567 and SEQ ID NO:592; SEQ ID NO:569 and SEQ ID NO:594; SEQ ID NO:571 and SEQ ID NO:596; SEQ ID NO:572 and SEQ ID NO:597; SEQ ID NO:573 and SEQ ID NO:598; SEQ ID NO:560 and SEQ ID NO: 585; SEQ ID NO:563 and SEQ ID NO:588; SEQ ID NO:607 and SEQ ID NO:642; SEQ ID NO:628 and SEQ ID NO:663; SEQ ID NO:629 and SEQ ID NO:664; SEQ ID NO:630 and SEQ ID NO:665; SEQ ID NO:631 and SEQ ID NO:666; SEQ ID NO:632 and SEQ ID NO:667; SEQ ID NO:633 and SEQ ID NO:668; SEQ ID NO:634 and SEQ ID NO:669; SEQ ID NO:635 and SEQ ID NO:670; SEQ ID NO:636 and SEQ ID NO:671; SEQ ID NO:637 and SEQ ID NO:672; SEQ ID NO:918 and SEQ ID NO:922; SEQ ID NO:919 and SEQ ID NO:923; SEQ ID NO:920 and SEQ ID NO:924; or SEQ ID NO:921 and SEQ ID NO:925.In certain embodiments, the dsRNA comprises a duplex selected from the group consisting of AD00170, AD00378, AD00170-1, AD00263, AD00265, AD00267, AD00268, AD00269, AD00173, AD00383, AD00384, AD00378-1, AD00170-2, AD00268-2, AD00263-2, and AD00176.
[0025] [Brief description of the sequence] SEQ ID NOs: 1 to 138, 674 to 734 are shown in Table 1 and are sense strand sequences.
[0026] SEQ ID NOs: 139 to 276 and 735 to 795 are shown in Table 1 and are antisense strand sequences.
[0027] SEQ ID NOs: 277 to 414, 796 to 856 are sense strand sequences, and SEQ ID NOs: 415 to 552, 857 to 917 are antisense strand sequences, as shown in Table 2, with chemical modifications indicated by uppercase letters: 2'-Fluoro; lowercase letters: 2'-OMe; and thiophosphate: *.
[0028] SEQ ID NOs:553-577 are the sense strand sequences and SEQ ID NOs:578-602 are the antisense strand sequences and are shown in Table 3. The delivery molecule is shown at the 3' end of each sense strand as "GLO-0". Chemical modifications are shown as follows: uppercase: 2'-Fluoro; lowercase: 2'-OMe; and thiophosphate: *.
[0029] SEQ ID NOs:603-637, 918-921 are sense strand sequences, and 638-672, 922-925 are antisense strand sequences, shown in Table 4. Chemical modifications are shown as follows: upper case: 2'-Fluoro; lower case: 2'-OMe; thiophosphate: *; and Invab = inverted abasic.
[0030] SEQ ID NO: 673 is the human (Homo sapiens) Hepatitis B virus (HBV) mRNA sequence [NCBI Reference Sequence: AM282986]: [Brief description of the drawings]
[0031] [Figure 1] FIG. 1 is a graph showing HBsAg levels in serum of AAV-HBV mice following a single subcutaneous administration of 3 mg / kg of siRNA compound. [Diagram 2] FIG. 2 is a graph showing HBV DNA levels in serum of AAV-HBV mice following a single subcutaneous administration of 3 mg / kg of siRNA compound. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0032] The present invention includes, in part, RNAi agents, including but not limited to, double-stranded (ds) RNAi agents that can inhibit Hepatitis B Virus (HBV) gene expression. The anti-HBV dsRNA agents of the present invention can target all five HBV transcripts, resulting in the suppression of all HBV viral proteins. The compounds, compositions and methods of the present invention provide anti-HBV RNAi therapeutic agents and treatments for chronic hepatitis B (CHB) and / or other HBV-related diseases and HBV-related pathologies. The anti-HBV RNAi agents and compounds delivered to cells using the methods of the present invention can inhibit HBV gene expression, thereby reducing the intracellular activity of the HBV protein product of the gene. The anti-HBV dsRNAi agents of the present invention can be administered to a subject to treat the subject's HBV-related disease and / or HBV-related pathology.
[0033] In certain embodiments of the present invention, the agents, compounds, compositions and methods of the present invention are used to achieve "functional cure" of HBV-related disease and / or HBV-related pathology. Functional cure of HBV infection and / or HBV-related disease or pathology can be indicated by seroclearance of Hepatitis B surface antigen (HBsAg). As used herein, the term "seroclearance" refers to a reduction in a subject's level of detectable serum HBsAg in a subject and / or the complete elimination of detectable HBsAg in the serum of a subject. It is understood that seroclearance can occur in a subject with or without seroconversion to Hepatitis B surface antibody (anti-HBs).
[0034] HBV RNAi as described herein can inhibit the expression of HBV protein.In some embodiments of the present invention, by reducing the expression of HBV in cells or subjects, the disease or pathology associated with the expression of HBV in cells or subjects is treated, respectively.Non-limiting examples of diseases and pathologies that can be treated by reducing HBV activity include hepatitis B, chronic hepatitis B, acute hepatitis B, hepatocellular carcinoma, end-stage liver disease, hepatitis, liver fibrosis, liver injury, liver cirrhosis, acute fulminant hepatitis, hepatitis D virus infection (delta hepatitis or HDV), or other diseases that are medically beneficial to subjects by reducing the level and activity of HBV protein.
[0035] The present invention includes, in part, compositions comprising anti-HBV RNAi agents and methods of using such compositions. Some aspects of the present invention include pharmaceutical compositions comprising one or more HBV dsRNA agents and a pharma- ceutically acceptable carrier. In certain embodiments, the anti-HBV RNAi agents of the present invention are conjugated to a delivery compound capable of delivering the RNAi agent to cells, including, but not limited to, hepatocytes. In some embodiments, the delivery compound is a GalNAc-containing delivery compound. Certain pharmaceutical compositions of the present invention include one, two, three or more independently selected anti-HBV dsRNA agents and may also include one or more independently selected delivery compounds. In some embodiments, two, three, four or more anti-HBV dsRNAs, each capable of targeting one, two, three, four or more different positions / regions of HBV mRNA, are administered to cells and / or subjects.
[0036] The following describes the method of making and using the composition comprising anti-HBV dsRNA agent (duplex) that can inhibit HBV gene expression, and the composition and method for treating the disease and pathology caused and / or regulated by HBV gene expression.As used herein, the disease and / or pathology caused or regulated by the presence and / or level of HBV gene expression is referred to as "HBV-related disease and / or HBV-related pathology".
[0037] As used herein, the term "RNAi" refers to an agent that comprises RNA and can mediate targeted cleavage of RNA transcripts via the RNA-induced silencing complex (RISC) pathway. The terms "RNAi" and "RNAi agent" can be used herein interchangeably with the terms "anti-HBV RNAi" and "anti-HBV RNAi agent"; "HBV RNAi" and "HBV RNAi agent"; "dsRNA" and "dsRNA agent"; "HBV dsRNA" and "HBV dsRNA agent"; and "anti-HBV dsRNA" and "anti-HBV dsRNA agent". As known in the art, an RNAi target region refers to a continuous portion of the nucleotide sequence of an mRNA molecule formed during transcription of a gene, including messenger RNA (mRNA), which is the product of RNA processing of a primary transcript. The target portion of an mRNA molecule (also referred to herein as "target sequence") is at least long enough to function as a substrate for RNAi-directed cleavage at or near that portion. The target sequence may be 8-30 nucleotides in length (inclusive), 10-30 nucleotides in length (inclusive), 12-25 nucleotides in length (inclusive), 15-23 nucleotides in length (inclusive), 16-23 nucleotides in length (inclusive), or 18-23 nucleotides in length (inclusive), including any shorter lengths within each stated range. In certain embodiments, the target sequence is 9-26 nucleotides in length (inclusive), including any subranges and integers therebetween. For example, and not intended to be limiting, in certain embodiments of the invention, the target sequence is one of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides in length, which sequence is fully or at least substantially complementary to at least a portion of an RNA transcript of an HBV gene.
[0038] As used herein, "dsRNA agent" refers to a composition that contains an RNA or RNA-like (e.g., chemically modified RNA) oligonucleotide molecule that can sequence-specifically degrade or inhibit the translation of messenger RNA (mRNA) transcripts of target mRNA.Without wishing to be limited to a particular theory, the dsRNA agent of the present invention may act by RNA interference mechanism [i.e., induce RNA interference through interaction with the RNA interference pathway mechanism (RNA-induced silencing complex or RISC) of mammalian cells], or by any alternative mechanism or pathway. Methods for silencing genes in plant cells, invertebrate cells and vertebrate cells are well known in the art (see, for example, Sharp et al., Genes Dev. 2001, 15:485; Bernstein, et al., (2001) Nature 409:363; Nykanen, et al., (2001) Cell 107:309; and Elbashir, et al., (2001) Genes Dev. 15:188), the entire disclosures of each of which are incorporated herein by reference. ]. To inhibit the expression of HBV, gene silencing procedures known in the art can be used in conjunction with the disclosure provided herein.
[0039] The dsRNA agent disclosed herein is composed of a sense strand and an antisense strand, including, but not limited to, short interfering RNA (siRNA), RNAi agent, microRNA (miRNA), short hairpin RNA (shRNA) and dicer substrate. The antisense strand of the dsRNA agent described herein is at least partially complementary to the mRNA to be targeted. It is understood in the art that dsRNA duplex structures of various lengths can be used to inhibit target gene expression. For example, dsRNAs with duplex structures of 19, 20, 21, 22 and 23 base pairs are known to be effective in inducing RNA interference (Elbashir et al., EMBO 2001, 20:6877-6888), and it is known in the art that shorter or longer RNA duplex structures can also induce RNA interference. HBV dsRNA can include at least one strand with a minimum length of 21 nt, or can have shorter duplexes, in certain embodiments of the present invention. In certain embodiments, the dsRNA agent of the invention is a duplex disclosed in any of Tables 1-4. In some embodiments, the dsRNA agent of the invention is a duplex disclosed in Tables 1-4, but minus 1, 2, 3, or 4 nucleotides at one or both ends of the duplex, which can also reduce expression of HBV. In some embodiments of the invention, the HBV dsRNA agent can have a subsequence of at least 15, 16, 17, 18, 19, 20, or more contiguous nucleotides from one or more sequences in Tables 1-4, and can differ in its ability to inhibit expression of HBV genes by no more than 5%, 10%, 15%, 20%, 25%, or 30% from the level of inhibition resulting from a dsRNA containing the complete sequence. The sense sequences, antisense sequences, and duplexes disclosed in Tables 1-4 may be referred to herein as "parent" sequences, meaning that the sequences disclosed in Tables 1-4 may be modified, shortened, extended, may include substitutions, etc., as described herein, with the resulting sequences retaining all or at least a portion of the effectiveness of those parent sequences in the methods and compositions of the invention. The sense and antisense strands contained in the dsRNA of the present invention are selected independently.As used herein, the term "independently selected" means that each of two or more similar elements can be selected independently of the selection of the other element. For example, and not intended to be limiting, when preparing the dsRNA of the present invention, two strands of "elements" can be selected for inclusion in a duplex. One selected element, the sense sequence, can be SEQ ID NO: 553 (shown in Table 3), and the other selected element, the antisense sequence, can be SEQ ID NO: 578, or SEQ ID NO: 578 modified, shortened, extended, and / or containing one, two or three substitutions compared to its parent sequence, SEQ ID NO: 578. It is understood that the duplex of the present invention does not have to include both the sense and antisense sequences shown as pairs in the duplexes of Tables 1-4.
[0040] Tables 1-4 show certain HBV dsRNA agent antisense strand and sense strand core stretch base sequences. The term "base sequence" is used herein in reference to polynucleotide sequences without chemical modifications or delivery compounds. For example, the sense strand acuucucucaauuuucuagga (SEQ ID NO: 2) shown in Table 1 is the base sequence of SEQ ID NO: 278 in Table 2, which is shown with their chemical modifications. The sequences disclosed herein may be assigned identifiers. For example, single stranded sense sequences may be identified using "sense strand SS#". Single stranded antisense sequences may be identified using "antisense strand AS#" and duplexes comprising a sense strand and an antisense strand may be identified using "duplex AV#" or "duplex AD#".
[0041] Table 1 discloses the sense strand sequence and the antisense strand sequence, and provides the identification number of the duplex formed from the sense strand and the antisense strand in the same row of Table 1. As used herein, the term "matching position" in the sense strand and the antisense strand is the position in each strand that "matches" when the two strands are duplex. For example, in a 21 nucleobase sense strand and a 21 nucleobase antisense strand, the nucleobase at position 1 of the sense strand and the nucleobase at position 21 of the antisense strand are in a "matching position". In yet another non-limiting example, in a 23 nucleobase sense strand and a 23 nucleobase antisense strand, the nucleobase at position 2 of the sense strand and the nucleobase at position 22 of the antisense strand are in a matching position. In another non-limiting example, in an 18 nucleobase sense strand and an 18 nucleobase antisense strand, the nucleobase at position 1 of the sense strand and the nucleobase at position 18 of the antisense strand are in a matching position, and the nucleobase at position 4 of the sense strand and the nucleobase at position 15 of the antisense strand are in a matching position. One of skill in the art would know how to identify matching positions within the sense and antisense strands that are or become duplexed and paired.
[0042] The first column of Table 1 indicates the duplex AV# for a duplex that contains the sense and antisense sequences in the same table row. For example, Table 1 discloses duplex assignment duplex AV# AV00053, which contains sense strand SEQ ID NO: 1 and antisense strand SEQ ID NO: 139. Thus, each row of Table 1 discloses a duplex of the invention, each containing the sense and antisense sequences shown in the same row.
[0043] In some embodiments of the method of the present invention, an RNAi agent comprising a double-stranded sequence disclosed in Table 1 is administered to a subject. In some embodiments of the present invention, the RNAi agent administered to a subject comprises a duplex comprising at least one of the strand sequences described in Table 1, comprising 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24 sequence modifications. In some embodiments of the method of the present invention, an RNAi agent comprising a dsRNA polynucleotide sequence as shown in Table 1 is bound to a delivery molecule, also referred to herein as a delivery compound. A non-limiting example of a delivery compound includes a delivery compound comprising a GalNAc compound.
[0044] Table 1: Unmodified HBV RNAi agent sense and antisense strand sequences. All sequences shown in the 5' to 3' direction. Duplex AV# is the number assigned to the two strands of the duplex in the same row of the table.
[0045] [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] [Table 1-5] [Table 1-6]
[0046] Table 2 shows certain chemically modified HBV RNAi agent sense and antisense strand sequences of the invention. In some embodiments of the methods of the invention, an RNAi agent having a polynucleotide sequence shown in Table 2 is administered to a cell and / or subject. In some embodiments of the invention, the RNAi agent administered to the subject comprises a duplex identified in a row in column 1 of Table 2, and includes sequence modifications shown in the sense and antisense strand sequences in the same row in columns 4 and 7 of Table 2, respectively. In some embodiments of the methods of the invention, the sequences shown in Table 2 can be conjugated (also referred to herein as "conjugated") to a compound capable of delivering the RNAi agent to cells and / or tissues of a subject. Non-limiting examples of delivery compounds that can be used in certain embodiments of the invention include GalNAc-containing compounds. In Table 2, column 1 shows the duplex AV# of the base sequence shown in Table 1. Table 2 discloses the duplex AV# and also shows the chemical modifications included in the sense and antisense sequences of the duplex. For example, Table 1 shows the base single stranded sequences, SEQ ID NO:1 (sense) and SEQ ID NO:139 (antisense), both of which are double stranded duplexes identified as duplex AV# AV00053. Table 2 lists duplex AV# AV00053 and shows that duplexes SEQ ID NO:277 and SEQ ID NO:415 contain the base sequences of SEQ ID NO:1 and SEQ ID NO:139, respectively, but with the chemical modifications shown in the sense and antisense sequences shown in columns 4 and 7, respectively. The "Sense Strand SS#" in the second column of Table 2 is the assigned identifier for the sense sequence (including modifications) shown in the fourth column of the same row. The "Antisense Strand AS#" in the fifth column of Table 2 is the assigned identifier for the antisense sequence (including modifications) shown in column 7.
[0047] Table 2: Chemically modified HBV RNAi agent sense and antisense strand sequences are provided. All sequences are shown 5' to 3'. These sequences were used in certain in vitro testing studies described herein. Chemical modifications are indicated by the following: uppercase: 2'-Fluoro; lowercase: 2'-OMe; thiophosphate: *
[0048]
Table 2-1
Table 2-2
Table 2-3
Table 2-4
Table 2-5
Table 2-6
Table 2-7
[0049] Table 3 discloses certain chemically modified HBV RNAi agent antisense and sense strand sequences and dsRNAs of the invention. In some embodiments of the methods of the invention, an RNAi agent as shown in Table 3 is administered to a cell and / or subject. In some embodiments of the methods of the invention, an RNAi agent comprising a polynucleotide sequence as shown in Table 3 is administered to a subject. In some embodiments of the invention, the RNAi agent administered to the subject comprises a duplex identified in column 1 of Table 3, the duplex comprising the sequence modifications and / or delivery compounds as shown in the sense strand and antisense strand sequences in columns 4 and 7 of the same row of Table 3, respectively. These sequences were used in certain in vivo testing studies described elsewhere herein. The sequences shown in Table 3 may, in some embodiments, be coupled (also referred to herein as "conjugated") to a compound for delivery, a non-limiting example of which is a GalNAc-containing compound. A particular embodiment of a delivery compound is identified in Table 3 as "GLX-0" on the sense strand in column 4. As used herein and shown in Table 3, "GLX-0" refers to a GalNAc-containing compound. It is understood that another GLO-n or GLS-n compound may be used in place of the compound designated as GLO-0, and the resulting compound is included in embodiments of the methods and / or compositions of the invention. In some embodiments of the invention, the delivery compound shown in Table 3 as GLX-0 is replaced by any one of compounds GLS-1, GLS-2, GLS-3, GLS-4, GLS-5, GLS-6, GLS-7, GLS-8, GLS-9, GLS-10, GLS-11, GLS-12, GLS-13, GLS-14, GLS-15, GLS-16, GLO-1, GLO-2, GLO-3, GLO-4, GLO-5, GLO-6, GLO-7, GLO-8, GLO-9, GLO-10, GLO-11, GLO-12, GLO-13, GLO-14, GLO-15, and GLO-16, the structures of each of which are provided elsewhere herein.Those skilled in the art will be able to prepare and use the dsRNA compounds of the present invention, in which the conjugated delivery compound is one of GLS-1, GLS-2, GLS-3, GLS-4, GLS-5, GLS-6, GLS-7, GLS-8, GLS-9, GLS-10, GLS-11, GLS-12, GLS-13, GLS-14, GLS-15, GLS-16, GLO-1, GLO-2, GLO-3, GLO-4, GLO-5, GLO-6, GLO-7, GLO-8, GLO-9, GLO-10, GLO-11, GLO-12, GLO-13, GLO-14, GLO-15, and GLO-16. Each row of Table 3 provides the duplex AD# assigned to the duplex of the sense sequence and antisense sequence of that row of the table. For example, duplex AD# AD00166 is a duplex comprising sense strand SEQ ID NO:553 and antisense strand SEQ ID NO:578. Each row of Table 3 provides a sense strand and an antisense strand and discloses the indicated sense and antisense strand duplex. The "Sense Strand SS#" in the second column of Table 3 is an assigned identifier for the sense sequence (including modifications) shown in the fourth column of the same row. The "Antisense Strand AS#" in the fifth column of Table 3 is an assigned identifier for the antisense sequence (including modifications) shown in the seventh column. The identifier for a particular conjugated GalNAc-containing GLO or GalNAc-containing GLS compound is shown as GLX-0, it being understood that another GLO or GLS compound may replace the compound shown as GLX-0 and the resulting compound is included in the embodiments of the methods and / or compositions of the present invention.
[0050] Table 3 provides the chemically modified HBV RNAi agent sense and antisense strand sequences. All sequences are shown 5' to 3'. These sequences were used in certain in vivo testing studies described herein. The delivery molecule used in the in vivo studies is shown at the 3' end of each sense strand as "GLX-0". Chemical modifications are shown as follows: uppercase: 2'-Fluoro; lowercase: 2'-OMe; thiophosphate: *
[0051] [Table 3]
[0052] Table 4 shows certain chemically modified HBV RNAi agent sense strand sequences and antisense strand sequences of the invention, and identifies duplexes that include sense and antisense. In some embodiments of the methods of the invention, an RNAi agent having a polynucleotide sequence shown in Table 4 is administered to a subject. In some embodiments of the invention, the RNAi agent administered to a subject comprises a duplex identified in a row in column 1 of Table 4, and includes sequence modifications and / or delivery compounds shown in the sense strand sequence and antisense strand sequence in the same row in columns 4 and 7 of Table 4, respectively. In some embodiments, the sequences shown in Table 4 can be attached to a compound that can deliver the dsRNA agent to cells and / or tissues of a subject. Non-limiting examples of delivery compounds that can be used in certain embodiments of the invention include GalNAc-containing compounds. In Table 4, the term "GLS-5" refers to a GalNAc-containing compound in the sense strand as shown. It will be understood that in certain embodiments of the compounds, compositions and methods of the invention, GLS-5 is replaced by any one of the compounds GLS-1, GLS-2, GLS-3, GLS-4, GLS-6, GLS-7, GLS-8, GLS-9, GLS-10, GLS-11, GLS-12, GLS-13, GLS-14, GLS-15, GLS-16, GLO-1, GLO-2, GLO-3, GLO-4, GLO-5, GLO-6, GLO-7, GLO-8, GLO-9, GLO-10, GLO-11, GLO-12, GLO-13, GLO-14, GLO-15, and GLO-16, the structures of each of which are provided elsewhere herein. The first column of Table 4 indicates the duplex identification number of the duplex disclosed in that row.
[0053] Table 4: Chemically modified HBV RNAi agent sense and antisense strand sequences. Sequences were used for certain in vivo studies described elsewhere herein. All sequences are shown 5' to 3'. Chemical modifications are shown as follows: uppercase: 2'-Fluoro; lowercase: 2'-OMe; thiophosphate: *; Invab = inverted abasic.
[0054] [Table 4-1] [Table 4-2]
[0055] In some embodiments of the methods and compositions of the invention, the sense strand of a dsRNA agent of the invention comprises one of SEQ ID NOs: 281, 290, 295, 300, 304, 306, 307, 331, 557, 567, 569, 571, 572, 573, 560, 563, 607, 628-637, or 918-921. In certain embodiments of the methods and compositions of the invention, the antisense strand of a dsRNA agent comprises one of SEQ ID NOs: 419, 428, 433, 438, 442, 444, 445, 469, 582, 592, 594, 596, 597, 598, 585, 588, 642, 663-672, or 922-925. In some embodiments of methods and compositions of the invention, the dsRNA agent is SEQ ID NO:281 and SEQ ID NO:419; SEQ ID NO:290 and SEQ ID NO:428; SEQ ID NO:295 and SEQ ID NO:433; SEQ ID NO:300 and SEQ ID NO:438; SEQ ID NO:304 and SEQ ID NO:442; SEQ ID NO:306 and SEQ ID NO:444; SEQ ID NO:307 and SEQ ID NO:445; SEQ ID NO:331 and SEQ ID NO:469; SEQ ID NO:557 and SEQ ID NO:582; SEQ ID NO:567 and SEQ ID NO:592; SEQ ID NO:569 and SEQ ID NO:594; SEQ ID NO:571 and SEQ ID NO:596; SEQ ID NO:572 and SEQ ID NO:597; SEQ ID NO:573 and SEQ ID NO:598; SEQ ID NO:560 and SEQ ID NO: No. 585; SEQ ID NO: 563 and SEQ ID NO: 588; SEQ ID NO: 607 and SEQ ID NO: 642; SEQ ID NO: 628 and SEQ ID NO: 663; SEQ ID NO: 629 and SEQ ID NO: 664; SEQ ID NO: 630 and SEQ ID NO: 665; SEQ ID NO: 631 and SEQ ID NO: 666; SEQ ID NO: 632 and SEQ ID NO: 667; SEQ ID NO: 633 and SEQ ID NO: 668; SEQ ID NO: 634 and SEQ ID NO: 669; SEQ ID NO: 635 and SEQ ID NO: 670; SEQ ID NO: 636 and SEQ ID NO: 671; SEQ ID NO: 637 and SEQ ID NO: 672; SEQ ID NO: 918 and SEQ ID NO: 922; SEQ ID NO: 919 and SEQ ID NO: 923; SEQ ID NO: 920 and SEQ ID NO: 924; or SEQ ID NO: 921 and SEQ ID NO: 925.
[0056] In certain embodiments of the invention, the dsRNA (also referred to herein as a "duplex") is one disclosed in one of Tables 1-4. Each row of Tables 1-4 discloses a duplex comprising the sequence of the sense strand and the sequence of the antisense strand of that table row. In addition to the duplexes disclosed in Tables 1-4, it is understood that in some embodiments, a duplex of the invention can comprise a sense sequence and an antisense sequence as shown in Tables 1-4 that differ from the sequences shown in Tables 1-4 by 0, 1, 2 or 3 nucleotides. Thus, in some embodiments, the antisense strand in a duplex of the invention can be SEQ ID NO: 139 that differs from that of SEQ ID NO: 139 by 0, 1, 2 or 3 nucleotides.
[0057] It is understood that the sequences of the sense strand and the antisense strand in the duplex of the invention can be selected independently. Thus, the dsRNA of the invention can include the sense and antisense strands of the duplex disclosed in the rows of Tables 1-4. Alternatively, in the dsRNA of the invention, one or both of the selected sense and antisense strands in the dsRNA can include the sequences shown in Tables 1-4, but one or both of the sense and antisense sequences include one, two, three or more nucleobase substitutions from the parent sequence. The selected sequences can be longer or shorter than their parent sequences in some embodiments. Thus, the dsRNA agents included in the invention can, but need not, include the exact sequences of the sense and antisense pairs disclosed as duplexes in Tables 1-4.
[0058] In some embodiments, the dsRNA agent comprises a sense strand and an antisense strand, and nucleotide positions 2-18 of the antisense strand comprise a region of complementarity to an HBV RNA transcript, the region of complementarity comprising at least 15 contiguous nucleotides that differ from one of the antisense sequences listed in one of Tables 1-4 by 0, 1, 2 or 3 nucleotides, and optionally a targeting ligand. In some examples, the region of complementarity to an HBV RNA transcript comprises at least 15, 16, 17, 18 or 19 contiguous nucleotides that differ from one of the antisense sequences listed in one of Tables 1-4 by no more than 3 nucleotides. In some embodiments of the dsRNA agent of the invention, the antisense strand of the dsRNA is at least substantially complementary to any one of the target regions of SEQ ID NO: 673, provided in any one of Tables 1-4. In some embodiments, the antisense strand of the dsRNA agent of the invention is fully complementary to any one of the target regions of SEQ ID NO: 673, provided in any one of Tables 1-4. In some embodiments, the dsRNA agent comprises a sense strand sequence set forth in any one of Tables 1-4, where the sense strand sequence is at least substantially complementary to the antisense strand sequence in the dsRNA agent. In other embodiments, the dsRNA agent of the invention comprises a sense strand sequence set forth in any one of Tables 1-4, where the sense strand sequence is fully complementary to the antisense strand sequence in the dsRNA agent. In some examples, the dsRNA agent of the invention comprises an antisense strand sequence set forth in any one of Tables 1-4. Some embodiments of the dsRNA agent of the invention comprise a sense sequence and an antisense sequence that are disclosed as a duplex in any of Tables 1-4. It is understood that the sense strand and the antisense strand in a duplex of the invention can be independently selected, as described herein.
[0059] mismatch It is known to those skilled in the art that mismatches are tolerated for efficacy in dsRNA, especially when the mismatch is in the terminal region of the dsRNA. Certain mismatches are well tolerated in dsRNA, for example, mismatches with wobble base pairs G:U and A:C are well tolerated for efficacy (Du et al., Nucleic Acids Res. 2005 Mar 21; 33(5): 1671-7). In some embodiments of the methods and compounds of the present invention, the HBV dsRNA agent can contain one or more mismatches to the HBV target sequence. In some embodiments, the HBV dsRNA agent of the present invention does not contain a mismatch. In certain embodiments, the HBV dsRNA agent of the present invention contains no more than one, no more than two, or no more than three mismatches to the HBV target sequence. In some embodiments of the present invention, the antisense strand of the HBV dsRNA agent contains a mismatch to the HBV target sequence that is not located in the center of the complementary region. In some embodiments, the antisense strand of the HBV dsRNA agent contains 1, 2, 3, 4 or more mismatches within the last 5, 4, 3, 2 or 1 nucleotide from either or both of the 5' and 3' ends of the complementary region. Methods described herein and / or known in the art can be used to determine whether an HBV dsRNA agent containing mismatches to an HBV target sequence is effective in inhibiting expression of an HBV gene.
[0060] Complementarity As used herein, unless otherwise specified, the term "complementary" when used to describe a first nucleotide sequence (e.g., an HBV dsRNA agent sense strand) in relation to a second nucleotide sequence (e.g., an HBV dsRNA agent antisense strand) refers to the ability of an oligonucleotide or polynucleotide comprising the first nucleotide sequence to hybridize [form base pair hydrogen bonds under mammalian physiological conditions (or similar conditions in vitro)] and form a duplex or double helix structure with an oligonucleotide or polynucleotide comprising the second nucleotide sequence under specific conditions. Other conditions may be applied, such as physiologically relevant conditions that may be encountered inside an organism. Those skilled in the art will be able to determine the most suitable set of conditions for testing the complementarity of two sequences according to the ultimate use of the hybridized nucleotides. Complementary sequences include Watson-Crick base pairs or non-Watson-Crick base pairs and include natural or modified nucleotides or nucleotide mimetics, so long as at least the hybridization requirements described above are met. Sequence identity or complementarity is independent of modifications.
[0061] For example, a complementary sequence in an HBV dsRNA described herein includes base pairing between an oligonucleotide or polynucleotide comprising a first nucleotide sequence and an oligonucleotide or polynucleotide comprising a second nucleotide sequence over the entire length of one or both nucleotide sequences. Such sequences may be referred to herein as "fully complementary" to each other. In embodiments where two oligonucleotides are designed to form one or more single-stranded overhangs upon hybridization, it is understood that such overhangs are not considered as mismatches for purposes of determining complementarity herein. For example, an HBV dsRNA agent comprising one 19-nucleotide long oligonucleotide and another 20-nucleotide long oligonucleotide, where the longer oligonucleotide comprises a 19-nucleotide sequence that is fully complementary to the shorter oligonucleotide, may be referred to as "fully complementary" for purposes described herein. Thus, as used herein, "fully complementary" means that all (100%) of the bases in a contiguous sequence of a first polynucleotide hybridize with the same number of bases in a contiguous sequence of a second polynucleotide. The contiguous sequence can include all or a portion of the first or second nucleotide sequence.
[0062] As used herein, the term "substantially complementary" means that in a hybridized pair of nucleobase sequences, at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% but not all of the bases in a contiguous sequence of a first polynucleotide hybridize to the same number of bases in a contiguous sequence of a second polynucleotide. The term "substantially complementary" may be used in reference to a first sequence with respect to a second sequence when the two sequences contain one or more, e.g., at least 1, 2, 3, 4 or 5 mismatched base pairs upon hybridization to a duplex of up to 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 base pairs (bp), while retaining the ability to hybridize under conditions most suitable for their ultimate use, e.g., inhibition of HBV gene expression via the RISC pathway.
[0063] The term "partially complementary" may be used herein in reference to a hybridized pair of nucleobase sequences in which at least 75%, but not all, of the bases in a contiguous sequence of a first polynucleotide hybridize to the same number of bases in a contiguous sequence of a second polynucleotide. In some embodiments, "partially complementary" means that at least 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% of the bases in a contiguous sequence of a first polynucleotide hybridize to the same number of bases in a contiguous sequence of a second polynucleotide.
[0064] The terms "complementary," "fully complementary," "substantially complementary," and "partially complementary" are used herein to refer to base matching between the sense and antisense strands of an HBV dsRNA agent, or between the antisense strand of an HBV dsRNA agent and the sequence of a target HBV mRNA. It is understood that the term "antisense strand of an HBV dsRNA agent" can refer to the same sequence of an "HBV antisense polynucleotide agent."
[0065] As used herein, the term "substantially identical" or "substantial identity" used in reference to a nucleic acid sequence refers to a nucleic acid sequence comprising a sequence having at least about 85% or more, preferably at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity compared to a reference sequence. The percentage of sequence identity is determined by comparing two optimally aligned sequences over a comparison window. The percentage is calculated by determining the number of positions where identical nucleic acid bases occur in both sequences to obtain the number of matched positions, dividing the number of matched positions by the total number of positions in the comparison window, and multiplying the result by 100 to obtain the percentage of sequence identity. The invention disclosed herein encompasses nucleotide sequences that are substantially identical to those disclosed herein, for example, in Tables 1-4. In some embodiments, the sequences disclosed herein are completely identical or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% percent identical to the sequences disclosed herein, e.g., in Tables 1-4.
[0066] As used herein, the term "strand comprising a sequence" refers to an oligonucleotide comprising a strand of nucleotides, represented by a sequence referred to using standard nucleotide nomenclature. As used herein, the term "double-stranded RNA" or "dsRNA" refers to an RNA molecule having a hybridized duplex region comprising two antiparallel and substantially or completely complementary nucleic acid strands, referred to as having a "sense" and an "antisense" orientation with respect to the target HBV RNA, or an RNAi comprising a complex of molecules. The duplex region can be of any length that allows for specific degradation of the desired target HBV RNA via the RISC pathway, but typically ranges from 9 to 30 base pairs in length, e.g., 15 to 30 base pairs in length. Considering a duplex of 9-30 base pairs, the duplex may be any length within this range, for example, but not limited to, 15-30 base pairs, 15-26 base pairs, 15-23 base pairs, 15-22 base pairs, 15-21 base pairs, 15-20 base pairs, 15-19 base pairs, 15-18 base pairs, 15-17 base pairs, 18-30 base pairs, 18-26 base pairs, 18-23 base pairs, 18-22 base pairs, 18-21 base pairs, 18-20 base pairs, 19-30 base pairs, 19-26 base pairs, 19-23 base pairs, 19-2 ... The amino acid sequence may be 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30, including 21 base pairs, 19-20 base pairs, 20-30 base pairs, 20-26 base pairs, 20-25 base pairs, 20-24 base pairs, 20-23 base pairs, 20-22 base pairs, 20-21 base pairs, 21-30 base pairs, 21-26 base pairs, 21-25 base pairs, 21-24 base pairs, 21-23 base pairs or 21-22 base pairs, and any subrange therebetween.
[0067] HBV dsRNA agents, which are generated intracellularly by processing by Dicer and similar enzymes, generally range from 19 to 22 base pairs in length. One strand of the duplex region of the HBV dsDNA agent contains a sequence that is substantially complementary to a region of the target HBV RNA. The two strands forming the duplex structure may be derived from a single RNA molecule having at least one self-complementary region, or may be formed from two or more separate RNA molecules. When the duplex region is formed from two strands of a single molecule, the molecule may have a duplex region separated by a single strand of nucleotides (referred to herein as a "hairpin loop") between the 3' end of one strand and the 5' end of each of the other strands that form the duplex structure. In some embodiments of the invention, the hairpin shaped appearance includes at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more unpaired nucleotides. When the two substantially complementary strands of HBV dsRNA agent are composed of separate RNA molecules, these molecules can, but do not necessarily, be covalently linked.When the two strands are covalently linked by means other than hairpin loop, the linking structure is called "linker".In addition, the term "siRNA" is used herein to refer to the dsRNA agent described herein.
[0068] In some embodiments of the present invention, HBV dsRNA agent can comprise sense and antisense sequences that do not have unpaired nucleotides or unpaired nucleotide analogs at one or both ends of dsRNA agent.Ends that do not have unpaired nucleotides are called "blunt ends" and do not have nucleotide overhangs.If both ends of dsRNA agent are blunt, dsRNA is called "blunt end".In some embodiments of the present invention, only the first end of dsRNA agent is blunt, in some embodiments, only the second end of dsRNA agent is blunt, and in certain embodiments of the present invention, both ends of HBV dsRNA agent are blunt.
[0069] In some embodiments of the dsRNA agent of the present invention, the dsRNA does not have one or two blunt ends. In such cases, there is at least one unpaired nucleotide at the end of the strand of the dsRNA agent. For example, when the 3' end of one strand of the dsRNA extends beyond the 5' end of the other strand, or vice versa, there is a nucleotide overhang. The dsRNA can include at least 1, 2, 3, 4, 5, 6 or more nucleotide overhangs. The nucleotide overhang can include or consist of nucleotide / nucleoside analogs, including deoxynucleotides / nucleosides. In some embodiments, the nucleotide overhang is on the sense strand of the dsRNA agent, on the antisense strand of the dsRNA agent, or on both ends of the dsRNA agent, and it is understood that the nucleotides of the overhang can be at the 5' end, 3' end, or both ends of either the antisense strand or the sense strand of the dsRNA. In certain embodiments of the present invention, one or more of the nucleotides in the overhang are replaced by nucleoside thiophosphates.
[0070] As used herein, the term "antisense strand" or "guide strand" refers to the strand of an HBV dsRNA agent that includes a region that is at least substantially complementary to an HBV target sequence.As used herein, the term "sense strand" or "passenger strand" refers to the strand of an HBV dsRNA agent that includes a region that is at least substantially complementary to a region of the antisense strand of the HBV dsRNA agent.
[0071] qualification In some embodiments of the invention, the RNA of the HBV RNAi agent is chemically modified to enhance stability and / or one or more other beneficial properties. Nucleic acids, in certain embodiments of the invention, can be synthesized and / or modified by methods well established in the art, such as those described in "Current protocols in Nucleic Acid Chemistry," Beaucage, SLet al. (Eds.), John Wiley & Sons, Inc., New York, NY, USA, which is incorporated herein by reference. Modifications that may be present in certain embodiments of the HBV dsRNA agent of the present invention include, for example, (a) terminal modifications, such as 5'-end modifications (phosphorylation, conjugation, inverted linkage, etc.) 3'-end modifications (conjugation, DNA nucleotide, inverted linkage, etc.); (b) base modifications, such as stabilizing bases, destabilizing bases, or bases that base-pair with a wide range of partners, removing bases (abasic nucleotides), or conjugated bases; (c) sugar modifications (e.g., at the 2' or 4' position), or sugar replacements; and (d) backbone modifications, including modifications or replacements of phosphodiester linkages. Specific examples of RNA compounds useful in certain embodiments of the HBV dsRNA agent, HBV antisense polynucleotide, and HBV sense polynucleotide of the present invention include, but are not limited to, RNAs that contain modified backbones or do not contain natural internucleoside linkages. As a non-limiting example, RNAs with modified backbones may not have a phosphorus atom in the backbone. RNA that does not have a phosphorus atom in its internucleoside backbone may be called an oligonucleoside. In certain embodiments of the invention, the modified RNA has a phosphorus atom in its internucleoside backbone.
[0072] The term "RNA molecule" or "RNA" or "ribonucleic acid molecule" is understood to include not only naturally expressed or found RNA molecules, but also RNA analogs and derivatives, including one or more ribonucleotide / ribonucleoside analogs or derivatives described herein or known in the art. The terms "ribonucleoside" and "ribonucleotide" can be used interchangeably herein. RNA molecules can be modified, for example, in the nucleobase structure or in the ribose-phosphate backbone structure, as described herein below, and molecules that include ribonucleoside analogs or ribonucleoside derivatives must retain the ability to form duplexes. As non-limiting examples, the RNA molecule can also include at least one modified ribonucleoside containing a non-natural base, including, but not limited to, a 2'-O-methyl modified nucleoside, a nucleoside containing a 5' phosphorothioate group, a terminal nucleoside linked to a cholesteryl derivative or a dodecanoic acid bisdecylamide group, a locked nucleoside, an abasic nucleoside, a 2'-deoxy-2'-fluoro modified nucleoside, a 2'-amino modified nucleoside, a 2'-alkyl modified nucleoside, a morpholino nucleoside, a phosphoramidate, or a nucleoside, or any combination thereof. In some embodiments of the invention, an RNA molecule includes at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 ribonucleosides of an HBV dsRNA agent molecule that are modified ribonucleosides, or up to the entire length of an HBV dsRNA agent molecule that is a modified ribonucleoside. The modification need not be the same for each of such multiple modified ribonucleosides within an RNA molecule.
[0073] A dsRNA agent, HBV antisense polynucleotide and / or HBV sense polynucleotide of the invention may, in some embodiments, include one or more independently selected modified nucleotides, and / or one or more independently selected non-phosphodiester linkages. As used herein, the term "independently selected," as used in reference to selected elements, e.g., modified nucleotides, non-phosphodiester linkages, targeting agents, dsRNA agents, duplexes, etc. of the invention, means that two or more selected elements can be, but need not be, the same as one another.
[0074] As used herein, a "nucleotide base", "nucleotide" or "nucleobase" is a heterocyclic pyrimidine or purine compound that is a standard building block of all nucleic acids, including the bases that form the nucleotides adenine (a), guanine (g), cytosine (c), thymine (t) and uracil (u). Nucleobases can be further modified to include, but are not intended to be limiting, universal bases, hydrophobic bases, promiscuous bases, size-expanded bases and fluorinated bases. The term "ribonucleotide" or "nucleotide" can be used herein to refer to unmodified nucleotides, modified nucleotides or surrogate replacement moieties. Those skilled in the art will recognize that guanine, cytosine, adenine and uracil can be substituted by other moieties without substantially altering the base pairing properties of oligonucleotides that contain nucleotides with such replacement moieties.
[0075] In one embodiment, the modified RNA contemplated for use in the methods and compositions described herein is a peptide nucleic acid (PNA) that has the ability to form the required double-stranded structure and allows or mediates the specific degradation of the target RNA via the RISC pathway. In a specific embodiment of the present invention, the HBV RNA interference agent comprises a single-stranded RNA that interacts with the target HBV RNA sequence and directs the cleavage of the target HBV RNA.
[0076] Modified RNA backbones can include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methylphosphonates, and other alkyl phosphonates, including 3'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates, including 3'-amino phosphoramidates and aminoalkyl phosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates with normal 3'-5' linkages, their 2'-5' linkage analogs, and those with reverse polarity, in which adjacent pairs of nucleoside units are linked 3'-5' to 5'-3' or 2'-5' to 5'-2'.Various salts, mixed salts, and free acid forms are also included. Means for preparing phosphorus-containing linkages are routinely practiced in the art, and such methods may be used to prepare the specific modified HBV dsRNA agents, specific modified HBV antisense polynucleotides, and / or specific modified HBV sense polynucleotides of the invention.
[0077] Modified RNA backbones that do not contain phosphorus atoms have backbones formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatom or heterocyclic internucleoside linkages. These include those with morpholino linkages (formed in part from the sugar portion of the nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methyleneformacetyl and thioformacetyl backbones; alkene-containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others with mixed N, O, S and CH2 constituent moieties. Means for preparing modified RNA backbones that do not contain a phosphorus atom are routinely practiced in the art, and such methods may be used to prepare certain modified HBV dsRNA agents, certain modified HBV antisense polynucleotides, and / or certain modified HBV sense polynucleotides of the invention.
[0078] In certain embodiments of the present invention, RNA mimics are included in HBV dsRNA, HBV antisense polynucleotides and / or HBV sense polynucleotides, including but not limited to, the replacement of sugar and internucleoside linkages, i.e., backbone of nucleotide units, with novel groups. In such embodiments, base units are maintained for hybridization with appropriate HBV nucleic acid target compounds. One such oligomeric compound, RNA mimics that has been shown to have excellent hybridization properties, is called peptide nucleic acid (PNA). In PNA compounds, the sugar backbone of RNA is replaced by an amide-containing backbone, particularly an aminoethylglycine backbone. Nucleic acid bases are retained and are directly or indirectly bound to the aza nitrogen atom of the amide portion of the backbone. The means of preparing RNA mimics are routinely practiced in the art, and such methods can be used to prepare certain modified HBV dsRNA agents of the present invention.
[0079] Some embodiments of the invention include RNA with phosphorothioate backbones and oligonucleosides with heteroatom backbones, particularly --CH2--NH--CH2-, --CH2--N(CH3)--O--CH2-- [known as methylene (methylimino) or MMI backbones], --CH2--O--N(CH3)--CH2--, --CH2--N(CH3)--N(CH3)--CH2--, and --N(CH3)--CH2---- [the natural phosphodiester backbone is represented as --O--P--O--CH2--]. Means for preparing RNA with phosphorothioate backbones and oligonucleosides with heteroatom backbones are routinely practiced in the art, and such methods may be used to prepare the specific modified HBV dsRNA agents, specific HBV antisense polynucleotides, and / or specific HBV sense polynucleotides of the invention.
[0080] The modified RNA can also contain one or more substituted sugar moieties. The HBV dsRNA, HBV antisense polynucleotide and / or HBV sense polynucleotide of the present invention can include one of OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S-, or N-alkynyl; or O-alkyl-O-alkyl at the 2' position, where alkyl, alkenyl, and alkynyl are substituted or unsubstituted C1-C6. 10 Alkyl, or C2-C 10 It can be alkenyl and alkynyl. Exemplary suitable modifications include O[(CH2) n O] m CH3, O(CH2) n OCH3, O(CH2) n NH2, O(CH2) n CH3, O(CH2) n ONH2, and O(CH2) n ON [(CH2) n In another embodiment, the dsRNA includes a C1-C3 10At the 2' position, the HBV dsRNA agent comprises one of the following substituents: lower alkyl, substituted lower alkyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH3, OCN, Cl, Br, CN, CF3, OCF3, SOCH3, SO2CH3, ONO2, NO2, N3, NH2, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an HBV dsRNA agent, or a group for improving the pharmacodynamic properties of an HBV dsRNA agent, HBV antisense polynucleotide and / or HBV sense polynucleotide, and other substituents having similar properties. In some embodiments, the modification includes 2'-methoxyethoxy (2'-O-(2-methoxyethyl), or 2'-O-CH2CHOCH3, also known as 2'-MOE) (Martin et al., Helv. Chim. Acta, 1995, 78:486-504), i.e., an alkoxy-alkoxy group. Another exemplary modification is 2'-dimethylaminooxyethoxy, i.e., O(CH2)2ON(CH3)2, also known as 2'-DMAOE, as described in the Examples herein below, and 2'-dimethylaminoethoxyethoxy (also known in the art as 2'-O-dimethylaminoethoxyethyl, or 2'-DMAEOE), i.e., 2'-O-CH2-O-CH2-N(CH2). The means for preparing modified RNAs as described are routinely practiced in the art, and such methods can be used to prepare certain modified HBV dsRNA agents of the invention.
[0081] Other modifications include 2'-methoxy (2'-OCH3), 2'-aminopropoxy (2'-OCH2CH2CH2NH2), and 2'-fluoro (2'-F). Similar modifications can also be made at other positions on the RNA of the HBV dsRNA agent, HBV antisense polynucleotide and / or HBV sense polynucleotide of the invention, particularly at the 3' position of the sugar on the 3' terminal nucleotide or in a 2'-5' linked HBV dsRNA, HBV antisense polynucleotide or HBV sense polynucleotide, and at the 5' position of the 5' terminal nucleotide. The HBV dsRNA agent, HBV antisense polynucleotide and / or HBV sense polynucleotide may also have a sugar mimic such as a cyclobutyl moiety in place of the pentofuranosyl sugar. Means for preparing modified RNA as described are routinely practiced in the art, and such methods can be used to prepare the specific modified HBV dsRNA agent, HBV antisense polynucleotide and / or HBV sense polynucleotide of the invention.
[0082] HBV dsRNA agents, HBV antisense polynucleotides and / or HBV sense polynucleotides may, in some embodiments, include modifications or substitutions of nucleobases (often referred to in the art simply as "bases"). As used herein, "unmodified" or "natural" nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified nucleobases include other synthetic and natural nucleobases, such as 5-methylcytosine (5-me-C), 5-hydroxymethylcytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyluracil and cytosine, 6-azouracil, cytosine and thymine, 5 -uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo, especially 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and adenine, 8-azaguanine and adenine, 7-deazaguanine and 7-daazaadenine and 3-deazaguanine and 3-deazaadenine.Additional nucleobases that may be included in certain embodiments of the HBV dsRNA agents of the invention are known in the art, see, e.g., Modified Nucleosides in Biochemistry, Biotechnology and Medicine, Herdewijn, P. Ed. Wiley-VCH, 2008; The Concise Encyclopedia Of Polymer Science And Engineering, pages 858-859, Kroschwitz, JL, Ed. John Wiley & Sons, 1990; English et al., Angewandte Chemie, International Edition, 1991, 30, 613, Sanghvi, Y S., Chapter 15, dsRNA Research and Applications, pages 289-302, Crooke, ST and Lebleu, B., Ed., CRC Press, 1993. Means for preparing dsRNA, HBV antisense strand polynucleotides and / or HBV sense strand polynucleotides containing nucleobase modifications and / or substitutions, such as those described herein, are routinely practiced in the art, and such methods may be used to prepare certain modified HBV dsRNA agents, HBV sense polynucleotides and / or HBV antisense polynucleotides of the invention.
[0083] Certain embodiments of the HBV dsRNA agents, HBV antisense polynucleotides and / or HBV sense polynucleotides of the present invention include RNAs modified to contain one or more locked nucleic acids (LNAs). Locked nucleic acids are nucleotides that have a modified ribose moiety that contains an extra bridge connecting the 2' and 4' carbons. This structure effectively "locks" the ribose in a 3'-endo structural conformation. The addition of a locked nucleic acid to the HBV dsRNA agents, HBV antisense polynucleotides and / or HBV sense polynucleotides of the invention can increase stability in serum and reduce off-target effects (Elmen, J. et al., (2005) Nucleic Acids Research 33(1):439-447; Mook, O R. et al., (2007) Mol Canc Ther 6(3):833-843; Grunweller, A. et al., (2003) Nucleic Acids Research 31(12):3185-3193). Means for preparing dsRNA agents, HBV antisense polynucleotides and / or HBV sense polynucleotides that include locked nucleic acids are routinely practiced in the art, and such methods can be used to prepare certain modified HBV dsRNA agents of the invention.
[0084] Particular embodiments of the HBV dsRNA compounds, sense polynucleotides and / or antisense polynucleotides of the present invention comprise at least one modified nucleotide, which comprises 2'-O-methyl nucleotides, 2'-fluoro nucleotides, 2'-deoxy nucleotides, 2'3'-seco nucleotide mimics, locked nucleotides, 2'-F-arabino nucleotides, 2'-methoxyethyl nucleotides, 2'-amino modified nucleotides, 2'-alkyl modified nucleotides, morpholino nucleotides, and 3'-OMe nucleotides, nucleotides containing 5'-phosphorothioate groups, or terminal nucleotides linked to cholesteryl derivatives or dodecanoic acid bisdecyl amide groups, 2'-amino modified nucleotides, phosphoramidates, or non-natural base-containing nucleotides. In some embodiments, the HBV dsRNA compounds comprise E-vinyl phosphonate nucleotides at the 5' end of the antisense strand, also referred to herein as the guide strand.
[0085] Particular embodiments of the HBV dsRNA compounds of the present invention, the 3' and 5' ends of the sense polynucleotide and / or the 3' end of the antisense polynucleotide comprise at least one modified nucleotide, and the at least one modified nucleotide comprises an abasic nucleotide, a ribitol, an inverted nucleotide, an inverted abasic nucleotide, an inverted 2'-OMe nucleotide, an inverted 2'-deoxy nucleotide. Those skilled in the art are aware that the inclusion of an abasic nucleotide or an inverted abasic nucleotide at the end of an oligonucleotide enhances stability (Czauderna et al. Nucleic Acids Res. 2003;31(11):2705-2716. doi:10.1093 / nar / gkg393).
[0086] Certain embodiments of the HBV dsRNA compounds, antisense polynucleotides of the present invention comprise at least one modified nucleotide, and at least one modified nucleotide comprises non-locked nucleic acid nucleotide (UNA) or / and glycol nucleic acid nucleotide (GNA). UNA and GNA are thermolabile chemical modifications, and are known by those skilled in the art to significantly improve the off-target profile of siRNA compounds (Janas, et al., Nat Commun. 2018; 9(1): 723. doi: 10.1038 / s41467-018-02989-4; Laursen et al., Mol BioSyst. 2010; 6: 862-70).
[0087] Another modification that can be included in the RNA of the HBV dsRNA agent, HBV antisense polynucleotide and / or HBV sense polynucleotide of the present invention in certain embodiments includes chemically linking one or more ligands, moieties or conjugates to the RNA, which enhance one or more properties of the HBV dsRNA agent, HBV antisense polynucleotide and / or HBV sense polynucleotide, respectively.Non-limiting examples of properties that can be enhanced include the activity of the HBV dsRNA agent, HBV antisense polynucleotide and / or HBV sense polynucleotide, the cellular distribution, the delivery of the HBV dsRNA agent, the pharmacokinetic properties of the HBV dsRNA agent, and the cellular uptake of the HBV dsRNA agent.In some embodiments of the present invention, the HBV dsRNA agent includes one or more targeting or linking groups that are conjugated to the sense strand in certain embodiments of the HBV dsRNA agent of the present invention.Non-limiting examples of targeting groups include compounds that include N-acetyl-galactosamine (GalNAc). The terms "targeting group", "targeting agent", "linking agent", "targeting compound" and "targeting ligand" may be used interchangeably herein. In certain embodiments of the invention, the HBV dsRNA agent comprises a targeting compound conjugated to the 5' end of the sense strand. In certain embodiments of the invention, the HBV dsRNA agent comprises a targeting compound conjugated to the 3' end of the sense strand. In some embodiments of the invention, the HBV dsRNA agent comprises a targeting group that includes GalNAc. In certain embodiments of the invention, the HBV dsRNA agent does not include a targeting compound conjugated to one or both of the 3' and 5' ends of the sense strand. In certain embodiments of the invention, the HBV dsRNA agent does not include a GalNAc-containing targeting compound conjugated to one or both of the 5' and 3' ends of the sense strand.
[0088] Additional targeting agents and linking agents are well known in the art, and for example, targeting agents and linking agents that may be used in certain embodiments of the invention include, but are not limited to, lipid moieties, such as cholesterol moieties (Letsinger et al., Proc. Natl. Acid. Sci. USA, 1989, 86:6553-6556), cholic acid (Manoharan et al., Biorg. Med. Chem. Let., 1994, 4:1053-1060), thioethers, such as beryl-S-tritylthiol (Manoharan et al., Ann. NY Acad. Sci., 1992, 660:306-309; Manoharan et al., Biorg. Med. Chem. Let., 1993, 3:2765-2770), thiocholesterol (Oberhauser et al., Nucl. Acids, 1997, 1:131-132), and the like. Res., 1992, 20:533-538), aliphatic chains such as dodecanediol or undecyl residues (Saison-Behmoaras et al., EMBO J, 1991, 10:1111-1118; Kabanov et al., FEBS Lett., 1990, 259:327-330; Svinarchuk et al., Biochimie, 1993, 75:49-54), phospholipids such as di-hexadecyl-rac-glycerol or triethyl-ammonium 1,2-di-O-hexadecyl-rac-glycero-3-phosphonate (Manoharan et al., Tetrahedron Lett., 1995, 36:3651-3654; Shea et al., Nucl. Acids, 1999, 37:1121-1122; Res., 1990,18:3777-3783), polyamine or polyethylene glycol chains (Manoharan et al., Nucleosides & Nucleotides, 1995,14:969-973), or adamantane acetic acid (Manoharan et al., Tetrahedron Lett., 1995,36:3651-3654), palmityl moieties (Mishra et al., Biochim. Biophys.Acta, 1995, 1264:229-237), or octadecylamine or hexylamino-carbonyloxycholesterol moieties (Crooke et al., J. Pharmacol. Exp. Ther., 1996, 277:923-937).
[0089] Certain embodiments of compositions comprising HBV dsRNA agents, HBV antisense polynucleotides and / or HBV sense polynucleotides may include ligands that alter the distribution, targeting, etc., of the HBV dsRNA agents. In some embodiments of compositions comprising HBV dsRNA agents of the invention, the ligand increases the affinity for a selected target, e.g., a molecule, a cell or cell type, a compartment, e.g., a cellular or organ compartment, a tissue, an organ, or an area of the body, e.g., compared to a species lacking such a ligand. Ligands useful in the compositions and / or methods of the invention may be naturally occurring substances, e.g., proteins (e.g., human serum albumin (HSA), low density lipoprotein (LDL) or globulin); carbohydrates (e.g., dextran, pullulan, chitin, chitosan, inulin, cyclodextrin or hyaluronic acid); or lipids. Ligands may also be recombinant or synthetic molecules, such as synthetic polymers, e.g., synthetic polyamino acids or synthetic polyamines. Examples of polyamino acids include polylysine (PLL), poly-L-aspartic acid, poly-L-glutamic acid, styrene-maleic anhydride copolymer, poly(L-lactide-co-glycolide) copolymer, divinyl ether-maleic anhydride copolymer, N-(2-hydroxypropyl)methacrylamide copolymer (HMPA), polyethylene glycol (PEG), polyvinyl alcohol (PVA), polyurethane, poly(2-ethylacrylic acid), N-isopropylacrylamide polymer, or polyphosphazine. Examples of polyamines include polyethyleneimine, polylysine (PLL), spermine, spermidine, polyamine, pseudopeptide-polyamine, peptidomimetic polyamine, dendrimer polyamine, arginine, amidine, protamine, cationic lipid, cationic porphyrin, quaternary salt of polyamine, or alpha helical peptide.
[0090] The ligands included in the compositions and / or methods of the invention may include targeting groups, non-limiting examples of which include cell or tissue targeting agents, such as lectins, glycoproteins, lipids or proteins, such as antibodies that bind to specific cell types, such as kidney or liver cells. The targeting group may be thyrotropin, melanotropin, lectins, glycoproteins, surfactant protein A, mucin carbohydrates, polyvalent lactose, polyvalent galactose, N-acetyl-galactosamine, N-acetyl-glucosamine polyvalent mannose, polyvalent fucose, glycosylated polyamino acids, polyvalent galactose, transferrin, bisphosphonates, polyglutamates, polyaspartates, lipids, cholesterol, steroids, bile acids, folate, vitamin B12, vitamin A, biotin, or an RGD peptide or RGD peptide mimetic.
[0091] Other examples of ligands include dyes, intercalating agents (e.g., acridine), crosslinkers (e.g., psoralens, mitomycin C), porphyrins (TPPC4, texaphyrin, sapphyrin), polycyclic aromatic hydrocarbons (e.g., phenazine, dihydrophenazine), artificial endonucleases (e.g., EDTA), lipophilic molecules such as cholesterol, cholic acid, adamantane acetic acid, 1-pyrenebutyric acid, dihydrotestosterone, 1,3-bis-O(hexadecyl)glycerol, geranyloxyhexyl group, hexadecylglycerol, borneol, menthol, 1,3-propanediol, heptadecyl group, palmitic acid, myristic acid, O3-(oleoyl)lithocholic acid, O3-(oleoyl)cholenic acid (cholenic acid), acid), dimethoxytrityl or phenoxazine) and peptide conjugates (e.g., antennapedia peptide, Tat peptide), alkylating agents, phosphate, amino, mercapto, PEG (e.g., PEG-40K), MPEG, [MPEG]2, polyamino, alkyl, substituted alkyl, radiolabeled markers, enzymes, haptens (e.g., biotin), transport / absorption enhancers (e.g., aspirin, vitamin E, folic acid), synthetic ribonucleases (e.g., imidazole, bisimidazole, histamine, imidazole clusters, acridine-imidazole conjugates, Eu3+ complexes of tetraazamacrocycles), dinitrophenyl, HRP or AP.
[0092] The ligand included in the composition and / or method of the present invention can be a protein, e.g., a glycoprotein or peptide, e.g., a molecule with specific affinity for a co-ligand, or an antibody, e.g., an antibody that binds to a specific cell type, such as, but not limited to, a hepatocyte. The ligand useful in the composition and / or method embodiments of the present invention can be a hormone or a hormone receptor. The ligand useful in the composition and / or method embodiments of the present invention can be a lipid, a lectin, a carbohydrate, a vitamin, a cofactor, multivalent lactose, multivalent galactose, N-acetyl-galactosamine, N-acetyl-glucosamine multivalent mannose, or multivalent fucose. The ligand useful in the composition and / or method embodiments of the present invention can be a substance that can increase the uptake of an HBV dsRNA agent into a cell, e.g., by disrupting the cytoskeleton of the cell, e.g., by disrupting the microtubules, microfilaments, and / or intermediate filaments of the cell. Non-limiting examples of this type of agent include taxon, vincristine, vinblastine, cytochalasin, nocodazole, japlakinolide, latrunculin A, phalloidin, swinholide A, indanocine, and myoservin.
[0093] In some embodiments, the ligand attached to the HBV dsRNA agent of the present invention functions as a pharmacokinetic (PK) modulator. Examples of PK modulators that can be used in the compositions and methods of the present invention include, but are not limited to, lipophilic substances, bile acids, steroids, phospholipid analogs, peptides, protein binders, PEG, vitamins, cholesterol, fatty acids, cholic acid, lithocholic acid, dialkyl glycerides, diacyl glycerides, phospholipids, sphingolipids, naproxen, ibuprofen, vitamin E, biotin, aptamers that bind to serum proteins, etc. Oligonucleotides that contain multiple phosphorothioate linkages are also known to bind to serum proteins, and therefore short oligonucleotides that contain multiple phosphorothioate linkages in the backbone, such as oligonucleotides of about 5 bases, 10 bases, 15 bases, or 20 bases, can also be used in the compositions and / or methods of the present invention as ligands.
[0094] HBV dsRNA agent composition In some embodiments of the present invention, the HBV dsRNA agent is in a composition. The composition of the present invention may include one or more HBV dsRNA agents, and optionally one or more of pharma- ceutically acceptable carriers, delivery agents, targeting agents, detectable labels, etc. Non-limiting examples of targeting agents that may be useful according to some embodiments of the method of the present invention include agents that direct the HBV dsRNA agent of the present invention to and / or within the cells to be treated. The targeting agent selected depends on factors such as the nature of the HBV-associated disease or HBV-associated pathology, and the cell type to be targeted. In a non-limiting example, in some embodiments of the present invention, it may be desirable to target the HBV dsRNA agent to and / or within hepatocytes. It is understood that in some embodiments of the method of the present invention, the therapeutic agent includes an HBV dsRNA agent that has only a delivery agent, such as a delivery agent that includes N-acetylgalactosamine (GalNAc), and does not have additional elements attached. For example, in some embodiments of the invention, an HBV dsRNA agent is conjugated to a delivery compound that includes GalNAc and is included in a composition that includes a pharma- ceutically acceptable carrier, and can be administered to a cell or subject without a detectable label or targeting agent or the like attached to the HBV dsRNA agent.
[0095] When the HBV dsRNA agent of the present invention is administered with one or more delivery agents, targeting agents, labeling agents, etc. and / or is bound to one or more delivery agents, targeting agents, labeling agents, etc., a person skilled in the art will be able to recognize, select and use the appropriate agents for use in the method of the present invention. Labeling agents may be used in certain methods of the present invention to determine the location of HBV dsRNA agents in cells and tissues, and may be used to determine the location of cells, tissues or organs of therapeutic compositions containing HBV dsRNA agents administered in the method of the present invention. Procedures for binding and utilizing labeling agents, such as enzyme labels, dyes, radioactive labels, etc., are well known in the art. It is understood that in some embodiments of the compositions and methods of the present invention, labeling agents are bound to one or both of the sense polynucleotide and antisense polynucleotide contained in the HBV dsRNA agent.
[0096] Delivery of HBV dsRNA agents Certain embodiments of the method of the present invention include the delivery of HBV dsRNA agent into cells. As used herein, the term "delivery" means to promote or achieve uptake or absorption into cells. Absorption or uptake of HBV dsRNA agent can occur by unassisted diffusion cellular process or active cellular process, or by using a delivery agent, targeting agent, etc. that can be associated with the HBV dsRNA agent of the present invention. Delivery means suitable for use in the method of the present invention include, but are not limited to, in vivo delivery, where the HBV dsRNA agent is injected into a tissue site or administered systemically. In some embodiments of the present invention, the HBV dsRNA agent is bound to a delivery agent.
[0097] Non-limiting examples of the methods that can be used to deliver HBV dsRNA agents to cells, tissues and / or subjects include HBV dsRNA-GalNAc conjugates, SAMiRNA technology, LNP-based delivery methods and naked RNA delivery.These and other delivery methods have been successfully used in the art to deliver therapeutic RNAi agents to treat various diseases and conditions, such as, but not limited to, liver disease, acute intermittent porphyria (AIP), hemophilia, pulmonary fibrosis, etc. Details of various delivery means can be found in publications such as Nikam, R. R. & K. R. Gore (2018) Nucleic Acid Ther, 28(4), 209-224 Aug 2018; Springer A. D. & S. F. Dowdy (2018) Nucleic Acid Ther. Jun 1; 28(3): 109-118; Lee, K. et al., (2018) Arch Pharm Res, 41(9), 867-874; and Nair, J. K. et al., (2014) J. Am. Chem. Soc. 136: 16958-16961, the contents of each of which are incorporated herein by reference.
[0098] Some embodiments of the present invention include the use of lipid nanoparticles (LNPs) to deliver the HBV dsRNA agent of the present invention to cells, tissues, and / or subjects. LNPs are routinely used for in vivo delivery of HBV dsRNA agents, including therapeutic HBV dsRNA agents. One advantage of using LNPs or other delivery agents is the increased stability of HBV RNA agents when delivered to a subject using LNPs or other delivery agents. In some embodiments of the present invention, LNPs include cationic LNPs to which one or more HBV RNAi molecules of the present invention are added. The LNPs containing HBV RNAi molecules are administered to a subject, and the LNPs and their bound HBV RNAi molecules are taken up into cells via endocytosis, and their presence leads to the release of RNAi trigger molecules, thereby mediating RNAi.
[0099] Another non-limiting example of a delivery agent that can be used in embodiments of the present invention to deliver the HBV dsRNA agent of the present invention to cells, tissues and / or subjects is an agent that contains GalNAc, which binds to the HBV dsRNA agent of the present invention and delivers the HBV dsRNA agent to cells, tissues and / or subjects.Specific examples of additional delivery agents that contain GalNAc that can be used in certain embodiments of the methods and compositions of the present invention are disclosed in PCT Application WO2020191183.Non-limiting examples of GalNAc targeting ligands that can be used in the compositions and methods of the present invention to deliver HBV dsRNA agents to cells include targeting ligand clusters.Examples of targeting ligand clusters presented herein are referred to as GalNAc ligands with phosphodiester linkages (GLO) and GalNAc ligands with phosphorothioate linkages (GLS). The term "GLX-0" may be used herein to indicate that the attached GalNAC-containing compound is any one of compounds GLS-1, GLS-2, GLS-3, GLS-4, GLS-5, GLS-6, GLS-7, GLS-8, GLS-9, GLS-10, GLS-11, GLS-12, GLS-13, GLS-14, GLS-15, GLS-16, GLO-1, GLO-2, GLO-3, GLO-4, GLO-5, GLO-6, GLO-7, GLO-8, GLO-9, GLO-10, GLO-11, GLO-12, GLO-13, GLO-14, GLO-15, and GLO-16, the structures of which are shown below, with the attachment position of a GalNAc targeting ligand to an RNAi agent of the invention at the far right of each (" [ka] "). It is understood that any RNAi and dsRNA molecule of the present invention can be linked to GLS-1, GLS-2, GLS-3, GLS-4, GLS-5, GLS-6, GLS-7, GLS-8, GLS-9, GLS-10, GLS-11, GLS-12, GLS-13, GLS-14, GLS-15, GLS-16, GLO-1, GLO-2, GLO-3, GLO-4, GLO-5, GLO-6, GLO-7, GLO-8, GLO-9, GLO-10, GLO-11, GLO-12, GLO-13, GLO-14, GLO-15, and GLO-16. The structures of GLO-1 through GLO-16 and GLS-1 through GLS-16 are shown below.
[0100] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka]
[0101] In some embodiments of the present invention, in vivo delivery can also be by beta-glucan delivery system, such as those described in U.S. Pat. Nos. 5,032,401 and 5,607,677, and U.S. Pat. Publication No. 2005 / 0281781, the entire contents of which are incorporated herein by reference. In vitro introduction of HBV RNAi agents into cells can be performed using methods known in the art, such as electroporation and lipofection. In certain embodiments of the method of the present invention, HBV dsRNA is delivered without a targeting agent. These RNAs can be delivered as "naked" RNA molecules. As a non-limiting example, HBV dsRNA of the present invention can be administered to a subject in a pharmaceutical composition that includes an RNAi agent but does not include a targeting agent, such as a GalNAc targeting compound, to treat the subject's HBV-related disease or HBV-related pathology, such as liver disease.
[0102] In addition to the specific delivery means described herein, it is understood that RNAi delivery means, such as, but not limited to, those described herein and used in the art, can be used in combination with the embodiments of the HBV RNAi agents and methods of treatment described herein.
[0103] The HBV dsRNA agent of the present invention can be administered to a subject in an amount and manner effective to reduce the level and activity of HBV polypeptide in a cell and / or a subject.In some embodiments of the method of the present invention, one or more HBV dsRNA agents are administered to a cell and / or a subject to treat a disease or condition associated with HBV expression and activity.In some embodiments, the method of the present invention comprises administering one or more independently selected HBV dsRNA agents to a subject in need of such treatment to reduce a disease or condition associated with HBV expression in the subject.The HBV dsRNA agent or HBV antisense polynucleotide agent of the present invention can be administered to reduce the expression and / or activity of HBV in another in vitro cell, ex vivo cell and in vivo cell.
[0104] In some embodiments of the present invention, the level of HBV polypeptide in a cell, and therefore the activity, and therefore the function of the virus, is reduced by delivering (e.g., introducing) an HBV dsRNA agent into the cell. Targeting agents and methods can be used to help deliver HBV dsRNA agents to specific cell types, cell subtypes, organs, spatial regions, and / or subcellular regions within a cell in a subject. HBV dsRNA agents can be administered alone or in combination with one or more additional HBV dsRNA agents in certain methods of the present invention. In some embodiments, two, three, four or more independently selected HBV dsRNA agents are administered to a subject. Some embodiments of the compositions and methods of the present invention include two, three or more independently selected therapeutic molecules. In some embodiments of the methods of the present invention, two, three, four or more HBV siRNAs that target one, two or more different positions / regions of HBV mRNA are administered to a cell and / or a subject. In such cases, the compositions of the invention may contain two, three, four or more independently selected HBV siRNAs, each conjugated to an independently selected delivery compound. Certain embodiments of the agents and / or compositions of the invention include bivalent siRNA compounds (also referred to herein as linked siRNA compounds) that contain two independently selected HBV siRNAs, both conjugated to the same delivery compound.
[0105] In certain embodiments of the present invention, the HBV dsRNA agent is administered to a subject to treat HBV-related disease or HBV-related pathology in combination with one or more additional therapeutic regimens for treating HBV-related disease or HBV-related pathology. Such combinations may produce synergistic effects. Non-limiting examples of additional therapeutic regimens include administering one or more HBV antisense polynucleotides of the present invention, administering non-HBV dsRNA therapeutic agents, and behavioral modification. The additional therapeutic regimen may be administered at one or more of the following times: before, simultaneously with, and after administration of the HBV dsRNA agent of the present invention. As used herein, it is understood that simultaneously with, within 5 minutes of time 0, within 10 minutes of time 0, within 30 minutes of time 0, within 45 minutes of time 0, and within 60 minutes of time 0, "time 0", the time of administration of the HBV dsRNA agent of the present invention to a subject.
[0106] In a non-limiting example, in some embodiments of the invention, the additional therapeutic regimen administered to the subject includes one or more of one or more HBV antisense polynucleotides, one or more additional HBV dsRNA therapeutics, one or more non-HBV dsRNA and / or siRNA therapeutics, and behavioral modification. Non-limiting examples of non-HBV dsRNA therapeutic regimens include administering to the subject one or more of the following: antiviral agents; antiviral nucleoside or nucleotide analogs (NUCs) (non-limiting examples of which include tenofovir disoproxil fumarate (TDF), tenofovir alafenamide, lamivudine, adefovir dipivoxil, entecavir (ETV) and telbivudine); viral polymerase inhibitors; reverse transcriptase inhibitors; immunostimulants; therapeutic vaccines; viral entry inhibitors; oligonucleotides that inhibit the secretion or release of HBsAg; capsid inhibitors; covalently closed circular (ccc) HBV DNA inhibitors, as well as other therapeutic agents and / or procedures, such as, but not limited to, liver transplantation and chemotherapy. Non-limiting examples of immune stimulants that may be used in the methods of the invention include pegylated interferon alpha 2a (PEG-IFN-a2a), interferon alpha-2b, recombinant human interleukin-7, and Toll-like receptor 7 (TLR7) agonists, and checkpoint inhibitors (e.g., PD1 inhibitors).
[0107] Non-limiting examples of behavioral modification include dietary regimen, rest regimen, isolation regimen and counseling.These and other therapeutic agents and behavioral modifications are known in the art and can be used to treat HBV-related disease or HBV-related pathology of a subject, and can be administered to a subject in combination with administration of one or more HBV dsRNA agents of the present invention to treat HBV-related disease or HBV-related pathology.The HBV dsRNA agents of the present invention administered to a cell or subject to treat HBV-related disease or HBV-related pathology can act synergistically with one or more other therapeutic agents or activities, can increase the effectiveness of one or more therapeutic agents or activities, and / or can increase the effectiveness of HBV dsRNA agents in treating HBV-related disease or HBV-related pathology.
[0108] The therapeutic method of the present invention, comprising the administration of HBV dsRNA agent, can be used for asymptomatic subjects infected with HBV, and / or when one or more symptoms of HBV-related disease or HBV-related pathology are present, including early, middle and late stages of HBV-related disease or HBV-related pathology, and any time before and after any of these stages.The method of the present invention can also be to treat a subject who has previously been treated for HBV-related disease or HBV-related pathology with one or more other therapeutic agents and / or therapeutic activities that have not been successful, have had minimal success, and / or are no longer successful in treating the subject's HBV-related disease or HBV-related pathology.
[0109] Vector-encoded dsRNA In certain embodiments of the present invention, HBV dsRNA agents can be delivered into cells using vectors. HBV dsRNA agent transcription units can be included in DNA or RNA vectors. The preparation and use of such vectors encoding transgenes for delivering sequences into cells and / or subjects is well known in the art. For example, vectors that cause the transient expression of HBV dsRNA for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 hours or more, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 weeks or more can be used in the methods of the present invention. The length of transient expression can be determined using routine methods based on factors such as, but not limited to, the specific vector construct selected and the target cell and / or tissue. Such transgenes can be introduced as linear constructs, circular plasmids, or viral vectors that can be integrative or non-integrative vectors. The transgene can also be constructed to allow it to be inherited as an extrachromosomal plasmid (Gassmann, et al., Proc. Natl. Acad. Sci. USA (1995) 92:1292).
[0110] The individual strand or strands of HBV dsRNA agent can be transcribed from the promoter on the expression vector.For example, when expressing two separate strands to generate dsRNA, two separate expression vectors can be simultaneously introduced into cells using means such as transfection or infection.In certain embodiments, each individual strand of the HBV dsRNA agent of the present invention can be transcribed by the promoter that is both contained in the same expression vector.In certain embodiments of the present invention, the HBV dsRNA agent is expressed as an inverted repeat polynucleotide linked by a linker polynucleotide sequence, so that the HBV dsRNA agent has a stem-loop structure.
[0111] Non-limiting examples of RNA expression vector include DNA plasmid or viral vector.The expression vector useful in the embodiment of the present invention can be compatible with eukaryotic cells.Eukaryotic cell expression vectors are routinely used in the art and are available from several commercial sources.The delivery of HBV dsRNA expression vector can be systemic, for example, by intravenous or intramuscular administration to target cells transplanted from the subject and then reintroduced into the subject, or by any other means that allows introduction into desired target cells.
[0112] Viral vector systems that may be included in one embodiment of the method include, but are not limited to, (a) adenoviral vectors; (b) retroviral vectors, including, but not limited to, lentiviral vectors, Moloney murine leukemia virus, and the like; (c) adeno-associated virus vectors; (d) herpes simplex virus vectors; (e) SV 40 vectors; (f) polyoma virus vectors; (g) papilloma virus vectors; (h) picornavirus vectors; (i) poxvirus vectors, such as orthopox, e.g., vaccinia virus vectors, or avipox, e.g., canarypox or fowlpox; and (j) helper-dependent adenovirus or gutless adenovirus. Constructs for recombinant expression of HBV dsRNA agents may include regulatory elements, such as promoters, enhancers, and the like, which may be selected to provide constitutive or regulated / inducible expression. The use of viral vector systems, and promoters and enhancers, and the like, are routine in the art and can be used with the methods and compositions described herein.
[0113] Certain embodiments of the present invention include the use of viral vectors for the delivery of HBV dsRNA agents into cells.Many adenovirus-based delivery systems are routinely used in the art for delivery to, for example, lung, liver, central nervous system, endothelial cells and muscle.Non-limiting examples of viral vectors that can be used in the method of the present invention include AAV vectors, poxviruses such as vaccinia virus, avipox such as modified virus Ankara (MVA), NYVAC, fowlpox or canarypox.
[0114] Certain embodiments of the present invention include a method of using a vector to deliver HBV dsRNA agent into cells, and such vector may be in a pharma- ceutically acceptable carrier that may or may not include a slow-release matrix in which the gene delivery vehicle is embedded.In some embodiments, the vector for delivering HBV dsRNA can be produced from recombinant cells, and the pharmaceutical composition of the present invention may include one or more cells that have produced HBV dsRNA delivery system.
[0115] Pharmaceutical Compositions Containing HBV dsRNA Certain embodiments of the present invention include the use of pharmaceutical compositions containing HBV dsRNA agents and pharma- ceutical acceptable carriers. Pharmaceutical compositions containing HBV dsRNA agents can be used in the methods of the present invention to reduce HBV gene expression and HBV activity in cells, and are useful for treating HBV-related diseases or HBV-related pathologies. Such pharmaceutical compositions can be formulated based on the mode of delivery. Non-limiting examples of formulations for the mode of delivery include compositions formulated for subcutaneous delivery, compositions formulated for systemic administration by parenteral delivery, compositions formulated for intravenous (IV) delivery, compositions formulated for intrathecal delivery, compositions formulated for direct delivery into the brain, and the like. Administration of the pharmaceutical compositions of the present invention for delivering HBV dsRNA agents into cells may be performed using one or more means, such as topically (e.g., by transdermal patch), pulmonary, for example, by inhalation or insufflation of powder or aerosol, including by nebulizer, intratracheal, intranasal, epidermal and transdermal, oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion, subdermal, for example, by implanted device, or intracranial, for example, by intraparenchymal, intrathecal or intraventricular administration.HBV dsRNA agent can also be delivered directly to target tissue (for example, directly into liver, directly into kidney, etc.).It is understood that "delivering HBV dsRNA agent" into cells includes directly delivering HBV dsRNA agent or HBV antisense polynucleotide agent, respectively, and expressing HBV dsRNA agent in cells from a coding vector delivered into cells, or by any suitable means that HBV dsRNA becomes present in cells.The preparation and use of formulations and means for delivering inhibitory RNA are well known and are routinely used in the art.
[0116] As used herein, a "pharmaceutical composition" comprises a pharmacologically effective amount of the HBV dsRNA agent of the present invention and a pharmaceutically acceptable carrier. The term "pharmaceutically acceptable carrier" refers to a carrier for administering a therapeutic agent. Such carriers include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol and combinations thereof. The term specifically excludes cell culture medium. For orally administered drugs, pharmaceutically acceptable carriers include, but are not limited to, pharmaceutically acceptable excipients, such as inert diluents, disintegrants, binding agents, lubricants, sweeteners, flavoring agents, coloring agents and preservatives. Suitable inert diluents include sodium and calcium carbonate, sodium and calcium phosphate, and lactose, with cornstarch and alginic acid being suitable disintegrants. Binders can include starch and gelatin, while lubricants, if present, are generally magnesium stearate, stearic acid or talc. If desired, the tablets may be coated with a material such as glyceryl monostearate or glyceryl distearate, to delay absorption in the gastrointestinal tract. Agents contained in the formulations are further described herein below.
[0117] As used herein, terms such as "pharmacologically effective amount", "therapeutically effective amount" and "effective amount" refer to the amount of the HBV dsRNA agent of the present invention to produce the intended pharmacological, therapeutic or preventive results.For example, if a given clinical treatment is considered effective when there is at least a 10% reduction in the measurable parameters associated with a disease or disorder, the therapeutically effective amount of the drug for treating that disease or disorder is the amount required to produce at least a 10% reduction in that parameter.For example, a therapeutically effective amount of the HBV dsRNA agent can reduce HBV polypeptide level by at least 10%.
[0118] Effective dose In some aspects, the method of the present invention comprises contacting a cell with an effective amount of an HBV dsRNA agent to reduce HBV gene expression in the contacted cell. Particular embodiments of the method of the present invention comprise administering to a subject an HBV dsRNA agent or an HBV antisense polynucleotide agent in an effective amount to reduce HBV gene expression and treat the subject's HBV-related disease or HBV-related pathology. The "effective amount" used in relation to reducing the expression of HBV and / or treating HBV-related disease or HBV-related pathology is the amount necessary or sufficient to achieve a desired biological effect. For example, the effective amount of an HBV dsRNA agent for treating HBV-related disease or HBV-related pathology may be the amount necessary to (i) slow or stop the progression of the disease or condition, or (ii) reverse, reduce or eliminate one or more symptoms of the disease or condition. In some aspects of the invention, an effective amount is an amount of an HBV dsRNA agent that, when administered to a subject in need of treatment for HBV-related disease or HBV-related pathology, results in a therapeutic response that prevents and / or treats the disease or pathology. According to some aspects of the invention, an effective amount is an amount of an HBV dsRNA agent of the invention that, when administered in combination with or simultaneously with another therapeutic treatment for HBV-related disease or HBV-related pathology, results in a therapeutic response that prevents and / or treats the disease or pathology. In some embodiments of the invention, the biological effect of treating a subject with an HBV dsRNA agent of the invention can be an improvement and / or absolute elimination of symptoms caused by HBV-related disease or HBV-related pathology. In some embodiments of the invention, the biological effect is a complete abrogation of HBV-related disease or HBV-related pathology, for example, as evidenced by a diagnostic test that indicates that the subject does not have HBV-related disease or HBV-related pathology. Additional means known in the art for assessing the status of HBV-related disease or HBV-related pathology can be used to determine the effect of the agent and / or method of the invention on HBV-related disease or HBV-related pathology.
[0119] Typically, the effective amount of HBV dsRNA agent for reducing HBV polypeptide activity to a level that treats HBV-related disease or HBV-related pathology is determined in clinical trials, and the effective dose of the test population is established in blinded trials relative to the control population.In some embodiments, the effective amount is the amount that produces the desired response, for example, the amount that reduces HBV-related disease or HBV-related pathology in cells, tissues and / or subjects with HBV-related disease or HBV-related pathology.Therefore, the effective amount of HBV dsRNA agent for treating HBV-related disease or HBV-related pathology that can be treated by reducing HBV polypeptide activity can be an amount that, when administered, reduces the amount of HBV polypeptide activity in a subject to an amount less than the amount that would be present in cells, tissues and / or subjects that are not administered with HBV dsRNA agent or HBV antisense polynucleotide agent.In certain aspects of the present invention, the level of HBV polypeptide activity and / or HBV gene expression present in cells, tissues and / or subjects that are not contacted with or administered with the HBV dsRNA agent of the present invention is referred to as "control" amount. In some embodiments of the method of the present invention, the control amount of the subject is the pre-treatment amount of the subject, in other words, the level in the subject before administration of the HBV agent can be the control level of the subject, and can be compared to the level of HBV polypeptide activity and / or HBV gene expression in the subject after siRNA is administered to the subject. When treating HBV-related disease or HBV-related pathology, the desired response can be to reduce or eliminate one or more symptoms of the disease or pathology in the cell, tissue, and / or subject. The reduction or elimination can be temporary or permanent. It is understood that the status of HBV-related disease or HBV-related pathology can be monitored using methods to determine HBV polypeptide activity, HBV gene expression, symptom evaluation, clinical testing, and the like. In some aspects of the present invention, the desired response to treating HBV-related disease or HBV-related pathology is to delay the onset of the disease or pathology, or even prevent the onset of the disease or pathology.
[0120] The effective amount of a compound that reduces HBV polypeptide activity can also be determined by evaluating the physiological effect of administration of an HBV dsRNA agent to a cell or subject, for example, the reduction of HBV-related disease or HBV-related pathology after administration. Subject assays and / or symptomatic monitoring can be used to determine the effectiveness of the HBV dsRNA agent of the present invention that can be administered in the pharmaceutical compound of the present invention, and to determine the presence or absence of a response to treatment. A non-limiting example is one or more tests known in the art of serum profile. Another non-limiting example is one or more tests known in the art of liver function can be used to determine the status of a subject's HBV-related liver disease or HBV-related liver pathology before and after treatment of the subject with the HBV dsRNA agent of the present invention. In another non-limiting example, one or more tests known in the art of HBV viral load levels can be used to determine the status of a subject's HBV-related disease. In this example, the disease includes a level of HBV viral load, and tests are used to determine the subject's HBV viral load level before and after treatment of the subject with the HBV dsRNA agent of the present invention.
[0121] Some embodiments of the present invention include a method for determining the effectiveness of the dsRNA agent of the present invention administered to a subject for treating HBV-related disease or HBV-related pathology by evaluating and / or monitoring one or more "physiological characteristics" of the subject's HBV-related disease or HBV-related pathology.Non-limiting examples of physiological characteristics of HBV-related disease or HBV-related pathology include the level of alanine aminotransferase (ALT) in the subject, the level of aspartate aminotransferase (AST) in the subject; the HBV viral load in the subject; the level of HBV covalently closed circular DNA (cccDNA) in the subject; the level of one or more HBV antigens in the subject; the level of one or more of HBcAg, HBsAg and HBeAg in the subject; the presence, absence and / or level of one or more anti-hepatitis B virus antibodies in the subject, and one or more physical symptoms, such as, but not limited to, pain, fever, etc.The routine means for determining such physiological characteristics are known in the art and include, but are not limited to, blood tests, serum analysis, tissue biopsy, imaging test, physical examination, etc.
[0122] It is understood that the amount of HBV dsRNA agent administered to a subject may be modified, at least in part, based on such determination of the disease and / or condition state and / or physiological characteristics determined for the subject. The amount of treatment may be varied, for example, by increasing or decreasing the amount of HBV-dsRNA agent or HBV antisense polynucleotide agent, by changing the composition in which the HBV dsRNA agent or HBV antisense polynucleotide agent is administered, by changing the route of administration, by changing the timing of administration, etc. The effective amount of HBV dsRNA agent varies according to the specific condition being treated, the age and physical condition of the subject being treated; the severity of the condition, the duration of treatment, the nature of the concomitant therapy (if any), the specific route of administration, and additional factors within the knowledge and expertise of the medical practitioner. For example, the effective amount may depend on the desired level of HBV polypeptide activity and / or HBV gene expression effective for treating HBV-related disease or HBV-related condition. Those skilled in the art can empirically determine the effective amount of a particular HBV dsRNA agent of the present invention for use in the method of the present invention without undue experimentation. In combination with the teachings provided herein, by selecting from among the various HBV dsRNA agents or HBV antisense polynucleotide agents of the present invention and considering factors such as potency, relative bioavailability, patient weight, severity of adverse side effects, and preferred mode of administration, an effective prophylactic or therapeutic treatment regimen can be designed that is effective for treating a particular subject. When used in embodiments of the present invention, an effective amount of the HBV dsRNA agent of the present invention can be an amount that produces a desired biological effect in a cell when contacted with the cell.
[0123] It is recognized that HBV gene silencing can be determined in any cell expressing HBV, constitutively or by genome engineering, and by any suitable assay. In some embodiments of the present invention, HBV gene expression is reduced by at least 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% by administration of the HBV dsRNA agent of the present invention. In some embodiments of the present invention, HBV gene expression is reduced by 5%-10%, 5%-25%, 10%-50%, 10%-75%, 25%-75%, 25%-100%, or 50%-100% by administration of the HBV dsRNA agent of the present invention.
[0124] Administration The HBV dsRNA agent and HBV antisense polynucleotide agent are delivered in a pharmaceutical composition in a dosage sufficient to inhibit expression of the HBV gene. In certain embodiments of the invention, the dose of the HBV dsRNA agent is in the range of 0.01 to 200.0 milligrams per kilogram of recipient body weight per day, generally in the range of 1 to 50 mg per kilogram of body weight per day, 5 to 40 mg / kg body weight, 10 to 30 mg / kg body weight, 1 to 20 mg / kg body weight, 1 to 10 mg / kg body weight, 4 to 15 mg / kg body weight inclusive. For example, HBV dsRNA agents are approximately 0.01mg / kg, 0.05mg / kg, 0.1mg / kg, 0.2mg / kg, 0.3mg / kg, 0.4mg / kg, 0.5mg / kg, 1mg / kg, 1.1mg / kg, 1.2 mg / kg, 1.3mg / kg, 1.4mg / kg, 1.5mg / kg, 1.6mg / kg, 1.7mg / kg, 1.8mg / kg, 1.9mg / kg, 2mg / kg, 2.1mg / kg, 2.2mg / kg , 2.3mg / kg, 2.4mg / kg, 2.5mg / kg, 2.6mg / kg, 2.7mg / kg, 2.8mg / kg, 2.9mg / kg, 3.0mg / kg, 3.1mg / kg, 3.2mg / kg, 3. 3mg / kg, 3.4mg / kg, 3.5mg / kg, 3.6mg / kg, 3.7mg / kg, 3.8mg / kg, 3.9mg / kg, 4mg / kg, 4.1mg / kg, 4.2mg / kg, 4.3mg / kg , 4.4mg / kg, 4.5mg / kg, 4.6mg / kg, 4.7mg / kg, 4.8mg / kg, 4.9mg / kg, 5mg / kg, 5.1mg / kg, 5.2mg / kg, 5.3mg / kg, 5.4m g / kg, 5.5mg / kg, 5.6mg / kg, 5.7mg / kg, 5.8mg / kg, 5.9mg / kg, 6mg / kg, 6.1mg / kg, 6.2mg / kg, 6.3mg / kg, 6.4mg / kg, 6.5mg / kg, 6.6mg / kg, 6.7mg / kg, 6.8mg / kg, 6.9mg / kg, 7mg / kg, 7.1mg / kg, 7.2mg / kg, 7.3mg / kg, 7.4mg / kg, 7.5mg / kg, 7.6mg / kg, 7.7mg / kg, 7.8mg / kg, 7.9mg / kg, 8mg / kg, 8.1mg / kg, 8.2mg / kg, 8.3mg / kg, 8.4mg / kg, 8.5mg / kg, 8.6mg / kg, 8.7mg / kg, 8.8mg / kg, 8.9mg / kg, 9mg / kg, 9.1mg / kg, 9.2mg / kg, 9.3mg / kg, 9.4mg / kg, 9.5mg / kg, 9.6mg / kg, 9.7mg / kg, 9.8mg / kg, 9.9 mg / kg, 10mg / kg, 11mg / kg, 12mg / kg, 13mg / kg, 14mg / kg, 15mg / kg, 16mg / kg, 17mg / kg, 18mg / kg, 19mg / kg, 20mg / kg, 21mg / kg, 22mg / kg, 23mg / kg , 24mg / kg, 25mg / kg, 26mg / kg, 27mg / kg, 28mg / kg, 29mg / kg, 30mg / kg, 31mg / kg, 32mg / kg, 33mg / kg, 34mg / kg, 35mg / kg, 36mg / kg, 37mg / kg, 38mg / kg, 39mg / kg, 40mg / kg, 41mg / kg, 42mg / kg, 43mg / kg, 44mg / kg, 45mg / kg, 46mg / kg, 47mg / kg, 48mg / kg, 49mg / kg to 50mg / kg body per single dose.
[0125] Various factors can be considered when determining the dosage and delivery timing of the HBV dsRNA agent of the present invention.The absolute amount of the HBV dsRNA agent delivered depends on various factors, including concurrent treatment, number of doses, and individual subject parameters, including age, physical condition, size and weight.These are factors well known to those skilled in the art and can be addressed only by routine experimentation.In some embodiments, the maximum dose can be used, i.e., the highest safe dose according to sound medical judgment.
[0126] The method of the present invention may, in some embodiments, include administering 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses of an HBV dsRNA agent or an HBV antisense polynucleotide agent to a subject. In some examples, a pharmaceutical compound (e.g., including an HBV dsRNA agent or including an HBV antisense polynucleotide agent) may be administered to a subject at least daily, every other day, weekly, biweekly, monthly, etc. A dose may be administered once a day, or more than once a day, for example, two, three, four, five or more times in a 24-hour period. The pharmaceutical composition of the present invention may be administered once a day, or the HBV dsRNA agent may be administered as two, three or more subdoses at appropriate intervals throughout the day, or even using continuous infusion or delivery with a controlled release formulation. In some embodiments of the method of the present invention, the pharmaceutical composition of the present invention is administered to a subject at least once a day, at least once a week, at least once a month, or at least once a year.
[0127] The method of the present invention, in some embodiments, includes administering a pharmaceutical compound alone, in combination with one or more other HBV dsRNA agents or HBV antisense polynucleotide agents, and / or in combination with other medications or therapeutic activities or regimens administered to a subject with HBV-related disease or HBV-related pathology. The pharmaceutical compound may be administered in a pharmaceutical composition. The pharmaceutical composition used in the method of the present invention may be sterile and may contain an amount of HBV dsRNA agent that reduces the activity of HBV polypeptide to a level sufficient to produce a desired response in a unit of weight or volume suitable for administration to a subject. The dose of the pharmaceutical composition containing an HBV dsRNA agent for reducing HBV protein activity administered to a subject may be selected according to various parameters, in particular according to the mode of administration used and the condition of the subject. Other factors include the desired duration of treatment. If the subject's response is insufficient with the initial dose applied, a higher dose (or effectively a higher dose by a different, more localized delivery route) may be used to the extent that the patient's tolerance allows.
[0128] treatment HBV-related diseases and HBV-related conditions in which the reduction of the level and / or activity of HBV polypeptide is effective for treating HBV-related diseases or HBV-related conditions can be treated using the method of the present invention for inhibiting the expression of HBV and the HBV dsRNA agent. Examples of diseases and conditions that can be treated by the HBV dsRNA agent of the present invention and the treatment method of the present invention include, but are not limited to, hepatitis B, HBV infection, chronic hepatitis B, hepatitis D virus infection (δ hepatitis or HDV), liver injury, liver cirrhosis, acute hepatitis B, acute fulminant hepatitis, hepatitis, liver fibrosis and hepatocellular carcinoma. Such diseases and conditions can be referred to herein as "HBV-related diseases and HBV-related conditions" and "diseases and conditions caused and / or regulated by HBV". It is understood that hepatitis D virus (HDV) infection in a subject is an HBV-related disease because it does not infect the patient by itself, but HDV can co-infect a subject infected with HBV.
[0129] In certain aspects of the present invention, the subject can be administered the HBV dsRNA agent of the present invention at one or more times before or after the diagnosis of HBV-related disease or HBV-related pathology.In some aspects of the present invention, the subject has or is at risk of developing HBV-related disease or HBV-related pathology.The subject at risk of developing HBV-related disease or HBV-related pathology is the subject with a high probability of developing HBV-related disease or HBV-related pathology compared with the control risk of developing HBV-related disease or HBV-related pathology.In some embodiments of the present invention, the level of risk can be statistically significant compared with the control level of risk. At-risk subjects may include, for example, (1) subjects who have been in close contact with and / or are at risk of being in close contact with subjects carrying HBV, (2) subjects who have been in contact with and / or are at risk of being in contact with the blood, semen and / or vaginal fluid of subjects infected with HBV, (3) subjects with pre-existing diseases and / or abnormalities, such as, but not limited to, immunodeficiencies that make subjects more susceptible to HBV infection and resulting HBV-related disease or pathology than control subjects without pre-existing diseases or abnormalities; (4) subjects with a personal history of HBV-related disease or pathology; (5) and subjects who have been previously treated for HBV-related disease or pathology. It is understood that pre-existing diseases and / or abnormalities that predispose subjects to HBV-related disease or pathology may be diseases or abnormalities that have been previously identified as being correlated with an increased likelihood of developing HBV-related disease or pathology when present.
[0130] It is understood that HBV dsRNA agents can be administered to subjects based on the medical condition of each individual subject. For example, the health care provided to the subject can evaluate the ALT level measured in a sample obtained from the subject and determine that it is desirable to reduce the subject's ALT level by administering the HBV dsRNA agent of the present invention. In this example, the ALT level can be considered to be a physiological characteristic of HBV-related pathology, even if the subject has not been diagnosed with HBV-related disease as disclosed herein. The health care provider can monitor the change in the subject's ALT level as a measure of the effectiveness of the administered HBV dsRNA agent of the present invention. In a non-limiting example, a biological sample such as a blood or serum sample is obtained from the subject, and the subject's HBV viral load is determined in the sample. If the presence of the subject's HBV viral load is found, the HBV dsRNA agent is administered to the subject, and a subsequent blood or serum sample is obtained from the subject after administration, and the subsequent sample is used to determine the HBV viral load, and the result is compared to the result determined in the subject's pre-administration (pre) sample. A reduction in the subject's HBV viral load level in the subsequent sample compared to the pre-administration level indicates the effectiveness of the administered HBV dsRNA agent in reducing the subject's HBV viral load level.
[0131] Certain embodiments of the method of the present invention include adjusting the treatment, which comprises administering an HBV dsRNA agent or HBV antisense polynucleotide agent of the present invention to a subject, based at least in part on the evaluation of one or more changes in the physiological characteristics of the subject of HBV-related disease or HBV-related pathology resulting from the treatment.For example, in some embodiments of the present invention, the effect of the administered dsRNA agent of the present invention is determined for the subject and can be used to help adjust the amount of the dsRNA agent of the present invention that is subsequently administered to the subject.In a non-limiting example, the subject is administered a dsRNA agent of the present invention, and the presence and / or level of one or more HBV viral antigens is determined in a biological sample obtained from the subject after administration, and based at least in part on the determined level, it is determined that a larger amount of the dsRNA agent is desired to increase the physiological effect of the administered agent, for example, to reduce or further reduce the presence and / or level of one or more HBV viral antigens in the subject. In another non-limiting example, a subject is administered a dsRNA agent of the present invention, the subject's HBV viral load is determined after administration, and it is desirable to administer a lesser, greater, or the same amount of the dsRNA agent to the subject based at least in part on the determined HBV viral load.
[0132] Therefore, some embodiments of the present invention include evaluating the change in one or more physiological characteristics resulting from previous treatment of the subject, so as to adjust the amount of the dsRNA agent of the present invention that is subsequently administered to the subject.Some embodiments of the method of the present invention include determining one, two, three, four, five, six or more physiological characteristics of HBV-related disease or HBV-related pathology to evaluate and / or monitor the effectiveness of the administered HBV dsRNA agent of the present invention, and optionally using the determination to adjust one or more of the dose, administration regimen and / or administration frequency of the dsRNA agent of the present invention to treat the HBV-related disease or HBV-related pathology of the subject.In some embodiments of the method of the present invention, the desired result of administering an effective amount of the dsRNA agent of the present invention to the subject is one or more of the following reductions in the subject: ALT; AST; HBV viral load, HBV covalently closed circular DNA (cccDNA); one or more HBV antigens; HBcAg; HBsAg; and HBeAg. In certain embodiments of the methods of the present invention, the desired result of administering to a subject an effective amount of an HBV dsRNA agent of the HBV antisense polynucleotide agent of the present invention is an increase in anti-Hepatitis B virus antibodies in the subject compared to baseline pre-treatment physiological characteristics of HBV-related disease or HBV-related pathology and / or control physiological characteristics of HBV-related disease or HBV-related pathology.
[0133] As used herein, the terms "treat," "treated," or "treating" when used in reference to HBV-related disease or a HBV-related condition can refer to prophylactic treatment to reduce the likelihood of a subject developing HBV-related disease or a HBV-related condition, as well as treatment after a subject has developed HBV-related disease or a HBV-related condition to eliminate or reduce the level of HBV-related disease or a HBV-related condition, to prevent HBV-related disease or a HBV-related condition from progressing further (e.g., becoming more severe), and / or to delay the progression of HBV-related disease or a HBV-related condition in a subject compared to a subject in the absence of treatment to reduce the activity of an HBV polypeptide in the subject.
[0134] Certain embodiments of the agents, compositions and methods of the present invention can be used to inhibit HBV gene expression.When used herein with reference to the expression of HBV gene, the terms "inhibit", "silence", "reduce", "downregulate" and "knockdown" refer to the expression of HBV gene, which is measured by one or more of the following: the level of RNA transcribed from gene, the level of HBV activity expressed, and the level of HBV polypeptide, protein or protein subunit translated from mRNA in a cell, a group of cells, a tissue, an organ or a subject that is transcribed with HBV gene, and that is reduced compared to the control level of RNA transcribed from HBV gene, the level of HBV activity expressed, or the level of HBV translated from mRNA, respectively, when the cell, a group of cells, a tissue, an organ or a subject is contacted with the HBV dsRNA agent of the present invention (e.g., treated with the HBV dsRNA agent of the present invention). In some embodiments, the control level is the level in a cell, tissue, organ or subject that has not been contacted with an HBV dsRNA agent or an HBV antisense polynucleotide agent (e.g., not treated with an HBV dsRNA agent or an HBV antisense polynucleotide agent).
[0135] Method of administration A variety of administration routes for HBV dsRNA agents are available for use in the methods of the present invention. The particular delivery mode selected will depend at least in part on the particular condition being treated and the dosage required for therapeutic efficacy. The methods of the present invention may be carried out using any medically acceptable mode of administration, which means any mode that results in an effective level of treatment of HBV-related disease or HBV-related condition without causing clinically unacceptable adverse effects. In some embodiments of the present invention, the HBV dsRNA agent may be administered via oral, enteral, mucosal, subcutaneous and / or parenteral routes. The term "parenteral" includes subcutaneous, intravenous, intrathecal, intramuscular, intraperitoneal and intrasternal injection or infusion techniques. Other routes include, but are not limited to, intranasal (e.g., via a stomach-nasal tube), dermal, vaginal, rectal, sublingual and inhalation. Delivery routes of the present invention may include intrathecal, intraventricular or intracranial. In some embodiments of the present invention, the HBV dsRNA agent may be placed in a sustained release matrix and administered by placing the matrix in a subject. In some embodiments of the present invention, the HBV dsRNA agent may be delivered to a subject cell using nanoparticles coated with a delivery agent that targets a specific cell or organelle. A variety of delivery means, methods, and agents are known in the art. Non-limiting examples of delivery methods and delivery agents are further provided elsewhere herein. In some embodiments of the present invention, the term "delivering" in reference to an HBV dsRNA agent may refer to administration of one or more "naked" HBV dsRNA agent sequences to a cell or subject, and in certain embodiments of the present invention, "delivering" refers to administration to a cell or subject via transfection means, delivery of a cell containing an HBV dsRNA agent to a subject, delivery of a vector encoding an HBV dsRNA agent into a cell and / or subject, and the like. Delivery of an HBV dsRNA agent using transfection means may include administration of a vector to a cell and / or subject.
[0136] In some methods of the present invention, one or more HBV dsRNA agents or HBV antisense polynucleotide agents can be administered in a formulation that can be administered in a pharma- ceutically acceptable solution that may routinely contain pharma- ceutically acceptable concentrations of salts, buffers, preservatives, compatible carriers, adjuvants, and optionally other therapeutic ingredients. In some embodiments of the present invention, the HBV dsRNA agent can be formulated with another therapeutic agent for simultaneous administration. According to the methods of the present invention, the HBV dsRNA agent can be administered in a pharmaceutical composition. In general, a pharmaceutical composition includes an HBV dsRNA agent and, optionally, a pharma- ceutically acceptable carrier. Pharmaceutically acceptable carriers are well known to those skilled in the art. As used herein, a pharma-ceutically acceptable carrier refers to a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredient, for example, the ability of the HBV dsRNA agent to inhibit HBV gene expression in a cell or subject. Numerous methods of administering and delivering dsRNA agents or HBV antisense polynucleotide agents for therapeutic use are known in the art and can be utilized in the methods of the present invention.
[0137] Pharmaceutically acceptable carriers include diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials well known in the art. Exemplary pharma-ceutically acceptable carriers are described in U.S. Pat. No. 5,211,657, and others are known to those skilled in the art. Such preparations may routinely contain salts, buffers, preservatives, compatible carriers, and optionally other therapeutic agents. When used in pharmaceutical products, salts should be pharma-ceutically acceptable, but pharma-ceutically unacceptable salts may be conveniently used to prepare pharma-ceutically acceptable salts thereof and are not excluded from the scope of the present invention. Such pharmacologically and pharma-ceutically acceptable salts include, but are not limited to, those prepared from the following acids: hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, maleic acid, acetic acid, salicylic acid, citric acid, formic acid, malonic acid, succinic acid, and the like. Pharmaceutically acceptable salts may also be prepared as alkali metal or alkaline earth salts, for example, sodium, potassium, or calcium salts.
[0138] Some embodiments of the method of the present invention include administering one or more HBV dsRNA agents or HBV antisense polynucleotide agents directly to a tissue. In some embodiments, the tissue to which the compound is administered is a tissue where HBV-related disease or HBV-related pathology is present or likely to occur, non-limiting examples of which are the liver or kidney. Direct tissue administration can be achieved by direct injection or other means. Many orally delivered compounds naturally travel to and pass through the liver and kidney, and some embodiments of the therapeutic method of the present invention include oral administration of one or more HBV dsRNA agents to a subject. The HBV dsRNA agents or HBV antisense polynucleotide agents may be administered once or in multiple doses, alone or in combination with other therapeutic agents. When administered multiple times, the HBV dsRNA agents may be administered via various routes. For example, and not intended to be limiting, the first (or first few) administrations may be administered via subcutaneous means, and one or more additional administrations may be administered orally and / or systemically.
[0139] In the embodiment of the present invention where it is desired to administer HBV dsRNA agent systemically, the HBV dsRNA agent can be formulated for parenteral administration by injection, for example, by bolus injection or continuous infusion.The formulation for injection can be provided in unit dosage form, for example, in ampoules or multi-dose containers, with or without preservatives.HBV dsRNA agent formulation (also called pharmaceutical composition) can take the form of suspension, solution or emulsion in oily or aqueous vehicle, and can contain formulating agents such as suspending agents, stabilizing agents and / or dispersing agents.
[0140] Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions and emulsions. Examples of non-aqueous solvents include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic / aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives may also be present, such as antibacterial agents, antioxidants, chelating agents, and inert gases. In other forms of administration, such as intravenous administration, the dose is reduced. If the subject's response is inadequate with the initial dose applied, higher doses (or effectively higher doses by different, more localized delivery routes) may be used to the extent that patient tolerance allows. Multiple doses per day may be used as necessary to achieve adequate systemic or local levels of one or more HBV dsRNA agents or HBV antisense polynucleotide agents and to achieve an appropriate reduction in HBV protein activity.
[0141] In yet other embodiments, the methods of the invention include the use of a delivery vehicle, such as a biocompatible microparticle, nanoparticle, or implant, suitable for implantation into a recipient, e.g., a subject. Exemplary bioerodible implants that may be useful according to this method are described in PCT Publication No. WO 95 / 24929 (herein incorporated by reference), which describes biocompatible, biodegradable polymeric matrices for containing biological macromolecules.
[0142] Both non-biodegradable and biodegradable polymer matrices can be used in the methods of the invention to deliver one or more HBV dsRNA agents or HBV antisense polynucleotide agents to a subject. In some embodiments, the matrix can be biodegradable. The matrix polymer can be a natural or synthetic polymer. The polymer can be selected based on the period of time over which release is desired, generally from about several hours to a year or more. Typically, release over a period ranging from a few hours to 3-12 months can be used. The polymer is optionally in the form of a hydrogel that can absorb up to about 90% of its weight in water, and further, is optionally crosslinked with multivalent ions or other polymers.
[0143] In general, HBV dsRNA agents or HBV antisense polynucleotide agents can be delivered in some embodiments of the present invention using bioerodible implants, by diffusion, or by degradation of polymer matrix. Exemplary synthetic polymers for such use are well known in the art. Using methods known in the art, biodegradable and non-biodegradable polymers can be used to deliver HBV dsRNA agents or HBV antisense polynucleotide agents. Bioadhesive polymers such as bioerodible hydrogels (see H.S. Sawhney, C.P. Pathak and J.A. Hubell in Macromolecules, 1993, 26, 581-587, the teachings of which are incorporated herein by reference) can be used to deliver HBV dsRNA agents or HBV antisense polynucleotide agents for treating HBV-related disease or HBV-related pathology. Additional suitable delivery systems can include time-release, delayed release or sustained release delivery systems. Such systems can avoid repeated administration of HBV dsRNA agents or HBV antisense polynucleotide agents, increasing convenience for subjects and medical care professionals. Many kinds of release delivery systems are available and known to those skilled in the art. (See, for example, U.S. Patent No. 5,075,109, U.S. Patent No. 4,452,775, U.S. Patent No. 4,675,189, U.S. Patent No. 5,736,152, U.S. Patent No. 3,854,480, U.S. Patent No. 5,133,974 and U.S. Patent No. 5,407,686, the teachings of each of which are incorporated herein by reference.) In addition, pump-based hardware delivery systems can be used, some of which are adapted for implantation.
[0144] The use of long-term sustained release implants can be suitable for the prophylactic treatment of subjects and for subjects at risk of developing recurrent HBV-related disease or HBV-related pathology.As used herein, long-term release means that implants are constructed and arranged to deliver therapeutic levels of HBV dsRNA agents for at least up to 10 days, 20 days, 30 days, 60 days, 90 days, 6 months, 1 year or more.Long-term sustained release implants are well known to those skilled in the art and include some of the above-mentioned release systems.
[0145] Therapeutic formulations of HBV dsRNA agents or HBV antisense polynucleotide agents can be prepared for storage by mixing the molecules or compounds having the desired purity with any pharma- ceutically acceptable carriers, excipients or stabilizers in the form of a lyophilized formulation or aqueous solution [Remington's Pharmaceutical Sciences 21 stAcceptable carriers, excipients or stabilizers are nontoxic to recipients at the dosages and concentrations employed and include buffers, such as phosphates, citrates and other organic acids; antioxidants, including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzylammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens, such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin; hydrophilic polymers, such as polyvinylpyrrolidone; amino acids, such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates, including glucose, mannose, or dextrins; chelating agents, such as EDTA; sugars, such as sucrose, mannitol, trehalose, or sorbitol; salt-forming counterions, such as sodium; metal complexes (e.g., Zn-protein complexes); and / or non-ionic surfactants, such as TWEEN®, PLURONICS®, or polyethylene glycol (PEG).
[0146] Cells, subjects and controls The method of the present invention can be used with cells, tissues, organs and / or subjects. In some aspects of the present invention, the subject is a human or a vertebrate mammal, including but not limited to dogs, cats, horses, cows, goats, mice, rats and primates, such as monkeys. Thus, the present invention can be used to treat HBV-related diseases or HBV-related conditions in human and non-human subjects. In some aspects of the present invention, the subject can be a livestock animal, a zoo animal, a domestic animal or a non-domestic animal, and the method of the present invention can be used in veterinary prophylactic and therapeutic regimes. In some embodiments of the present invention, the subject is a human, and the method of the present invention can be used in human prophylactic and therapeutic regimes.
[0147] Non-limiting examples of subjects to which the present invention can be applied include subjects who have been diagnosed with, suspected of having, or are at risk of having a disease or condition associated with higher than desirable HBV expression and / or activity, also referred to as "elevated HBV expression levels". Non-limiting examples of diseases and conditions associated with higher than desirable levels of HBV expression and / or activity are described elsewhere herein. The method of the present invention can be applied to subjects who, upon treatment, have been diagnosed with a disease or condition associated with higher than desirable HBV expression and / or activity, or who are believed to be at risk of having or developing a disease or condition associated with higher than desirable HBV expression and / or activity. In some embodiments of the present invention, the disease or condition associated with higher than desirable HBV expression and / or activity is an acute disease or condition, and in certain embodiments of the present invention, the disease or condition associated with higher than desirable HBV expression and / or activity is a chronic disease or condition.
[0148] In a non-limiting example, the HBV dsRNA agent of the present invention is administered to a subject who is diagnosed with, suspected of having, or at risk of having acute hepatitis B, which is a disease that is desired to reduce the expression of HBV.The method of the present invention can be applied to a subject who is diagnosed with a disease or condition during treatment, or a subject who is considered to have or at risk of developing a disease or condition.
[0149] In another non-limiting example, the HBV dsRNA agent of the present invention is administered to a subject who is diagnosed with, suspected of having, or at risk of having Hepatitis D (HDV), which is a disease for which it is desirable to reduce the expression of HBV.The method of the present invention can be applied to a subject who is diagnosed with a disease or condition during treatment, or a subject who is considered to have or at risk of developing a disease or condition.
[0150] The cells to which the methods of the invention can be applied include cells that are in vitro, in vivo, or ex vivo cells. The cells can be in a subject, in culture and / or in suspension, or in any other suitable state or condition. The cells to which the methods of the invention can be applied can be liver cells, hepatocytes, cardiac cells, pancreatic cells, cardiovascular cells, renal cells, or other types of vertebrate cells, including human cells and non-human mammalian cells. In certain aspects of the invention, the cells to which the methods of the invention can be applied are healthy normal cells that are not known to be diseased cells. In certain embodiments of the invention, the cells to which the methods and compositions of the invention can be applied are liver cells, hepatocytes, cardiac cells, pancreatic cells, cardiovascular cells, and / or renal cells. In certain aspects of the invention, the control cells are normal cells, although it is understood that cells with a disease or condition can also serve as control cells in certain situations, such as, for example, to compare the results of a treated cell with a disease or condition to an untreated cell with a disease or condition. Cells suitable for treatment using embodiments of the present invention may be cells that express HBV genes, including cells infected with HBV, or cells that contain an expression vector that includes the HBV genome, or a portion of an HBV gene.
[0151] The level of HBV polypeptide activity may be determined according to the method of the present invention and compared to a control level of HBV polypeptide activity. The control may be a predetermined value that may take various forms. The control may be a single cut-off value, such as a median or mean value. The control may be established based on a comparison group, for example, a group with a low level of HBV polypeptide and / or HBV polypeptide activity, and a group with an increased level of HBV polypeptide and / or HBV polypeptide activity. Another non-limiting example of a comparison group may be a group with one or more symptoms or diagnosis of HBV-related disease or HBV-related pathology; a group without one or more symptoms or diagnosis of disease or pathology; a group of subjects to which the siRNA treatment of the present invention has been administered; a group of subjects to which the siRNA treatment of the present invention has not been administered. Typically, the control may be based on apparently healthy normal individuals of an appropriate age group, or apparently healthy cells. It is understood that the control according to the present invention may be a sample of material tested in parallel with the experimental material in addition to a predetermined value. Examples include samples from a control population, or a control sample produced by manufacturing that is tested in parallel with the experimental sample. In some embodiments of the invention, a control may include a cell or subject that has not been contacted with or treated with an HBV dsRNA agent of the invention, in which case the control level of HBV polypeptide and / or HBV polypeptide activity may be compared to the level of HBV polypeptide and / or HBV polypeptide activity in a cell or subject that has been contacted with an HBV dsRNA agent of the invention.
[0152] In some embodiments of the present invention, the level of HBV polypeptide determined for a subject can be a control level to which the level of HBV polypeptide determined for the same subject at different time points is compared. In a non-limiting example, the level of HBV is determined in a biological sample obtained from a subject who has not been administered the HBV treatment of the present invention. In some embodiments, the biological sample is a serum sample or a tissue sample. The level of HBV polypeptide determined in a sample obtained from a subject can serve as the baseline or control value for the subject. In the treatment method of the present invention, after one or more administrations of an HBV dsRNA agent to the subject, one or more additional serum samples can be obtained from the subject, and the level of HBV polypeptide in the subsequent sample or samples can be compared to the subject's control / baseline level. Such a comparison can be used to evaluate the onset, progression or regression of a subject's HBV-related disease or HBV-related pathology. For example, a higher level of HBV polypeptide or HBV viral load in a baseline sample obtained from a subject than that obtained from the same subject after administering the HBV dsRNA agent of the present invention indicates regression of HBV-related disease or HBV-related pathology, and indicates the effectiveness of the administered HBV dsRNA agent of the present invention for treating HBV-related disease or HBV-related pathology.In some embodiments, a statistically significant decrease in the level of HBV polypeptide in a sample from a subject compared to the level determined in a sample previously obtained from the subject indicates regression of HBV-related disease or HBV-related pathology.
[0153] In some embodiments of the invention, one or more values of the level of HBV polypeptide and / or HBV polypeptide activity determined for a subject may serve as a control value for subsequent comparison of the level of HBV polypeptide and / or HBV activity in the same subject, thus allowing for assessment of changes from a "baseline" HBV polypeptide activity in the subject. Thus, an initial HBV polypeptide level and / or an initial HBV polypeptide activity level may be present in and / or determined in a subject, and the methods and compounds of the invention may be used to reduce the level of HBV polypeptide and / or HBV polypeptide activity in the subject, with the initial level serving as the control level for that subject.
[0154] The method of the present invention may be used to administer the HBV dsRNA agent of the present invention to a subject.The efficacy of the administration and treatment of the present invention can be evaluated when the level of HBV polypeptide or HBV viral load in serum samples and / or tissue samples obtained from a subject is reduced by at least 0.5%, 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% compared to the pre-administration level of HBV polypeptide or HBV viral load in serum samples and / or tissue samples obtained from a subject at a previous time point, or compared to the level of HBV polypeptide or HBV viral load in non-contact control level, for example, the level of HBV polypeptide or HBV viral load in control serum sample.It is understood that the level of HBV polypeptide, HBV viral load, the presence of one or more HBV antigens, the level of HBV polypeptide activity, and other physiological characteristics described herein are correlated with the level of HBV gene expression. Certain embodiments of the methods of the present invention include administering to a subject an HBV dsRNA of the present invention in an amount effective to inhibit HBV gene expression, thereby reducing the level of HBV polypeptide and reducing the level of HBV polypeptide activity in the subject.
[0155] Some embodiments of the present invention include determining the presence, absence and / or amount (also referred to herein as level) of HBV polypeptide in one or more biological samples obtained from one or more subjects. This determination can be used to evaluate the effectiveness of the treatment method of the present invention. For example, the methods and compositions of the present invention can be used to determine the level of HBV polypeptide and / or HBV viral load in a biological sample obtained from a subject previously treated by administering an HBV dsRNA agent of the present invention. The level of HBV polypeptide and / or HBV viral load determined in the biological sample obtained from the treated subject is at least 0.5%, 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, 99.9%, 99.99% or more lower than the pre-treatment level of HBV polypeptide or HBV viral load determined for the subject, respectively, or compared to the unexposed control biological sample level, indicating the level of effectiveness of the treatment administered to the subject. In some embodiments of the methods of the invention, contacting a cell with an siRNA agent of the invention (also referred to herein as treatment) results in at least about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 101%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109%, 110%, 111%, 112%, 113%, 114%, 115%, 116%, 11 %, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or about 100% inhibition of HBV gene expression in the cells, for example, to below the level of detection of the assay.
[0156] In some embodiments of the present invention, the physiological characteristics of HBV-related disease or HBV-related pathology determined for a subject can be a control determination, in which the determination of physiological characteristics in the same subject at different time points is compared.In a non-limiting example, physiological characteristics such as ALT level, AST level and / or viral load level are determined in a biological sample obtained from a subject who is not administered the HBV treatment of the present invention.The ALT level, AST level and / or viral load level (and / or other physiological characteristics of HBV disease or HBV pathology) determined in a sample obtained from a subject can serve as the baseline or control value of the subject.In the treatment method of the present invention, after one or more administrations of an HBV dsRNA agent to the subject, one or more additional biological samples can be obtained from the subject, and the ALT level, AST level and / or viral load level in the subsequent sample or samples are compared with the subject's control / baseline level and / or ratio, respectively.Such comparisons can be used to evaluate the onset, progression or regression of the subject's HBV-related disease or HBV-related pathology. For example, a higher ALT level, AST level and / or viral load level in a baseline sample obtained from a subject than a higher ALT level, AST level and / or viral load level determined in a sample obtained from the same subject after administration of an HBV dsRNA agent of the present invention to the subject indicates regression of HBV-related disease or HBV-related pathology and indicates the effectiveness of the administered HBV dsRNA agent of the present invention for treating HBV-related disease or HBV-related pathology.
[0157] In some embodiments of the present invention, the value of one or more of the physiological characteristics of HBV-related disease or HBV-related pathology determined for a subject can serve as a control value for subsequent comparison of the physiological characteristics in the same subject, thus allowing for evaluation of changes from a "baseline" physiological characteristic in the subject. Thus, an initial physiological characteristic may be present in and / or determined in a subject, and the method and compound of the present invention may be used to reduce the level of HBV polypeptide and / or HBV polypeptide activity in the subject, with the initial physiological characteristic serving as a control for the subject.
[0158] The HBV dsRNA agent of the present invention may be administered to a subject in an amount effective for treating HBV disease or HBV pathology using the method of the present invention.The effectiveness of the administration and treatment of the present invention can be evaluated by determining the change in one or more physiological characteristics of HBV disease or HBV pathology.In a non-limiting example, the ALT level, AST level, HBV covalently closed circular DNA (cccDNA); one or more HBV antigens; one or more of HBcAg, HBsAg and HBeAg; and viral load level determined in the biological sample obtained from the subject after treatment with the method of the present invention are at least 0.5%, 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, 99.9%, 99.99% or 100% lower than the pre-administration level of the physiological characteristics in the biological sample obtained from the subject at the pre-treatment time point or the physiological characteristics determined in the non-contact control, demonstrating the effectiveness of the treatment administered to the subject. It is understood that the determination of the physiological characteristics of HBV described herein is correlated with the level of HBV gene expression.A particular embodiment of the method of the present invention comprises administering to subject the HBV dsRNA agent of the present invention in an amount effective to inhibit HBV gene expression, thereby reducing ALT level, AST level, HBV covalently closed circular DNA (cccDNA); one or more HBV antigens; one or more of HBcAg, HBsAg and HBeAg; and viral load level, or otherwise positively affect the physiological characteristics of subject's HBV-related disease or HBV-related pathology.
[0159] Some embodiments of the invention include, but are not limited to, (1) evaluating one or more biological samples from one or more subjects for physiological characteristics, (2) obtaining a cell and / or tissue biopsy from the subject (e.g., but not limited to, a liver biopsy), and (3) using methods such as a physical examination of the subject to determine the presence, absence, and / or change in physiological characteristics of an HBV-associated disease or HBV-associated pathology, which can be used to assess the effectiveness of the treatment methods of the invention.
[0160] kit Also within the scope of the present invention is a kit comprising one or more HBV dsRNA agents of the present invention and instructions for their use in the method of the present invention. The kit of the present invention may comprise one or more of HBV dsRNA agents, HBV sense polynucleotides and HBV antisense polynucleotide agents that can be used to treat HBV-related disease or HBV-related pathology. The kit containing one or more HBV dsRNA agents, HBV sense polynucleotides and HBV antisense polynucleotide agents can be prepared for use in the treatment method of the present invention. The components of the kit of the present invention can be packaged in either aqueous media or lyophilized form. The kit of the present invention may comprise a carrier compartmentalized to receive one or more container means or a series of container means, such as test tubes, vials, flasks, bottles, syringes, etc., in close confinement therein. A first container means or a series of container means may contain one or more compounds, such as an HBV dsRNA agent, and / or one or more HBV sense polynucleotide molecules or HBV antisense polynucleotide molecules. A second container means, or series of container means, may house a targeting agent, labeling agent, delivery agent, etc. which may be included as part of the HBV dsRNA agent administered in a method of treatment embodiment of the present invention.
[0161] The kits of the invention may also include instructions, typically in written form, that provide guidance for carrying out the treatment embodied by the kit and for making decisions based on that treatment.
[0162] The following examples are provided to illustrate specific embodiments of the practice of the invention and are not intended to limit the scope of the invention. As will be apparent to those of skill in the art, the present invention will find use in a variety of compositions and methods. EXAMPLES
[0163] Example 1. Synthesis of HBV RNAi Agents The HBV RNAi agent duplexes shown in Tables 2-4 above were synthesized according to the following general procedure:
[0164] The sense and antisense strand sequences of siRNA were synthesized using an oligonucleotide synthesizer using a well-established solid-phase synthesis method based on phosphoramidite chemistry. Oligonucleotide propagation is accomplished through a four-step cycle: deprotection, coupling, capping, and oxidation or sulfurization steps for each nucleotide addition. Synthesis was performed on a solid support made of controlled pore glass (CPG, 500 or 1000 Å). Monomeric phosphoramidites were purchased from commercial sources. Phosphoramidites bearing GalNAc ligand clusters (GLPA1 and GLPA2 as non-limiting examples) were synthesized according to the procedures of Examples 2-3 herein. Synthesis was performed on a 20 nmol scale for siRNAs used in in vitro screening (Table 2) and on a 1 μmol scale or larger for siRNAs used in in vivo testing (Tables 3, 4, and 5). When a GalNAc ligand (GLO-0 as a non-limiting example) was attached to the 3' end of the sense strand, a GalNAc ligand-linked CPG solid support was used. When the GalNAc ligand (GLS-1 or GLS-2 as non-limiting examples) was attached to the 5'-end of the sense strand, a GalNAc phosphoramidite (GLPA1 or GLPA2 as non-limiting examples) was used for the final coupling reaction. Trichloroacetic acid (TCA) 3% in dichloromethane was used for deprotection of the 4,4'-dimethoxytrityl protecting group (DMT). 5-Ethylthio-1H-tetrazole was used as the activator. I2 in THF / Py / H2O and phenylacetyl disulfide (PADS) in pyridine / MeCN were used for the oxidation and sulfurization reactions, respectively. After the final solid-phase synthesis step, the cyanoethyl protecting group was removed with 20% diethylamine in acetonitrile. The nucleobase protecting groups were removed and the solid support-bound oligomer was cleaved by treatment with 28% ammonium hydroxide solution at 65°C for 2 hours. The aqueous solution containing the crude single-stranded product was concentrated and purified by ion-pair reversed-phase HPLC (IP-RP-HPLC).The purified single-stranded oligonucleotide products from IP-RP-HPLC were converted to the sodium salt by dissolving in 1.0 M NaOAc and precipitating by adding ice-cold EtOH. Equimolar complementary sense and antisense strand oligonucleotides were annealed in water to form the double-stranded siRNA product, which was lyophilized to give a fluffy white solid.
[0165] Example 2. Preparation of Intermediate-A and Intermediate-B. Intermediate-A was synthesized by treating commercially available galactosamine pentaacetate with a solution of trimethylsilyl trifluoromethanesulfonate (TMSOTf) in dichloromethane (DCM) as shown in Scheme 1 below. This was followed by glycosylation with Cbz-protected 2-(2-aminoethoxy)ethan-1-ol to give compound II. The Cbz-protecting group was removed by hydrogenation to give intermediate-A as a trifluoroacetate (TFA) salt. Intermediate B was synthesized based on the same scheme, except that Cbz-protected 2-(2-(2-aminoethoxy)ethoxy)ethan-1-ol was used as the starting material.
[0166] [ka]
[0167] Scheme 1 To a solution of compound I (20.0 g, 51.4 mmol) in 100 mL of 1,2-dichloroethane (DCE), TMSOTf (17.1 g, 77.2 mmol) was added. The resulting reaction solution was stirred at 60° C. for 2 h and then at 25° C. for 1 h. A solution of Cbz-protected 2-(2-aminoethoxy)ethan-1-ol (13.5 g, 56.5 mmol) dried over 4 Å powdered molecular sieves (10 g) in DCE (100 mL) was added dropwise to the above reaction solution at 0° C. under N2 atmosphere. The resulting reaction mixture was stirred at 25° C. for 16 h under N2 atmosphere. The reaction mixture was filtered and washed with saturated NaHCO3 (200 mL), water (200 mL) and saturated brine (200 mL). The organic layer was dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give the crude product, which was triturated with 2-methyltetrahydrofuran / heptane (5 / 3, v / v, 1.80 L) for 2 h. The resulting mixture was filtered and dried to give compound II (15.0 g, 50.3% yield) as a white solid.
[0168] To a dried, argon-purged hydrogenation bottle, 10% Pd / C (1.50 g) was carefully added, followed by 10 mL of tetrahydrofuran (THF), and then a solution of compound II (15.0 g, 26.4 mmol) in THF (300 mL) and TFA (trifluoroacetic acid, 3.00 g, 26.4 mmol). The resulting mixture was degassed and purged with H2 three times and stirred under H2 (45 psi) atmosphere at 25 °C for 3 h. Thin layer chromatography (TLC, solvent: DCM:MeOH = 10:1) showed that compound II was completely consumed. The reaction mixture was filtered and concentrated under reduced pressure. The residue was dissolved in anhydrous DCM (500 mL) and concentrated. This process was repeated three times to give intermediate-A (14.0 g, 96.5% yield) as a foamy white solid. 1H NMR (400 MHz DMSO-d6): δ ppm 7.90(d,J=9.29 Hz,1 H),7.78(br s,3 H),5.23(d,J=3.26 Hz,1 H),4.98(dd,J=11.29,3.26 Hz,1 H),4.56(d,J=8.53 Hz,1 H),3.98-4.07(m,3 H),3.79-3.93(m,2 H),3.55-3.66(m,5 H),2.98(br d,J=4.77 Hz,2 H),2.11(s,3 H),2.00(s,3 H),1.90(s,3 H),1.76(s,3 H).
[0169] A similar procedure for the synthesis of Intermediate-A was used to synthesize Intermediate-B. 1 H NMR (400 MHz DMSO-d6): δ ppm 7.90(br d,J=9.03 Hz,4 H),5.21(d,J=3.51 Hz,1 H),4.97(dd,J=11.1 Hz,1 H),4.54(d,J=8.53 Hz,1 H),3.98-4.06(m,3 C 20 H 34 N2O 11 Calculated mass: 478.22; Measured mass: 479.3 (M+H + ).
[0170] Example 3. Synthesis of GalNAc ligand cluster phosphoramidites GLPA1, GLPA2 and GLPA15. GLPA1 and GLPA2 were prepared according to the following scheme 2. Starting from benzyl-protected propane-1,3-diamine, alkylation with tert-butyl 2-bromoacetate gave triester compound I. The benzyl protecting group was removed by hydrogenation to give secondary amine compound II. Amide coupling with 6-hydroxyhexanoic acid gave compound III. The tert-butyl protecting group was then removed upon treatment with a solution of HCl in dioxane to give triacid compound IV. Amide coupling between triacid compound IV and intermediate-A or intermediate-B gave compound Va or Vb. Phosphoramidite GLPA1 or GLPA2 was synthesized by phosphitylation of compound Va or Vb with 2-cyanoethyl N,N-diisopropylchlorophosphoramidite and a catalytic amount of 1H-tetrazole.
[0171] [ka]
[0172] Scheme 2 To a solution of N-benzyl-1,3-propanediamine (5.00 g, 30.4 mmol) in dimethylformamide (DMF, 100 mL) was added tert-butyl 2-bromoacetate (23.7 g, 121 mmol), followed by dropwise addition of diisopropylethylamine (DIEA, 23.61 g, 182 mmol). The resulting reaction mixture was stirred at 25-30 °C for 16 h. LCMS showed that N-benzyl-1,3-propanediamine was completely consumed. The reaction mixture was diluted with H2O (500 mL) and extracted with EtOAc (500 mL × 2). The combined organics were washed with saturated brine (1 L), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give the crude product, which was purified by silica gel column chromatography (gradient: petroleum ether: ethyl acetate 20:1 to 5:1). Compound I (12.1 g, 78.4% yield) was obtained as a colorless oil. 1H NMR(400 MHz,CDCl3):δ ppm 7.26-7.40(m,5 H),3.79(s,2 H),3.43(s,4 H),3.21(s,2 H),2.72(dt,J=16.9,7.34 Hz,4 H),1.70(quin,J=7.2 Hz,2 H),1.44-1.50(m,27 H).
[0173] A dried hydrogenation bottle was purged with argon three times. Pd / C (200 mg, 10%) was added, followed by MeOH (5 mL), followed by a solution of compound I (1.00 g, 1.97 mmol) in MeOH (5 mL). The reaction mixture was degassed under vacuum and refilled with H2. This process was repeated three times. The mixture was stirred at 25° C. under an atmosphere of H2 (15 psi) for 12 h. LCMS showed that compound I was completely consumed. The reaction mixture was filtered under reduced pressure under an atmosphere of N2. The filtrate was concentrated under reduced pressure to give compound II (655 mg, 79.7% yield) as a yellow oil, which was used in the next step without further purification. 1 H NMR (400 MHz, CDCl3): δ ppm 3.44(s,4 H),3.31(s,2 H),2.78(t,J=7.1 Hz,2 H),2.68(t,J=6.9 Hz,2 H),1.88(br s,1 H),1.69(quin,J=7.03 Hz,2 H),1.44-1.50(s,27 H).
[0174] A mixture of compound II (655 mg, 1.57 mmol), 6-hydroxyhexanoic acid (249 mg, 1.89 mmol), DIEA (1.02 g, 7.86 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI, 904 mg, 4.72 mmol), and 1-hydroxybenzotriazole (HOBt, 637 mg, 4.72 mmol) in DMF (6 mL) was degassed and purged with N2 three times, then stirred under N2 atmosphere at 25 °C for 3 h. LCMS showed the desired product. The reaction mixture was diluted with H2O (10 mL) and extracted with 20 mL of EtOAc (10 mL x 2). The organics were combined, washed with saturated brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated to give the crude product, which was purified by silica gel column chromatography (gradient: petroleum ether:ethyl acetate 5:1 to 1:1) to give compound III (650 mg, 77.8% yield) as a yellow oil. 1 H NMR(400 MHz,CDCl3):δ ppm 3.90-3.95(s,2 H),3.63(t,J=6.40 Hz,2 H),3.38-3.45(m,6 H),2.72(t,J=6.65 Hz,2 H),2.40(t,J=7.28 Hz,2 H),1.55-1.75(m,8 H),1.44(s,27 H).C 27 H 50 Calculated mass of N2O8: 530.36; Found: 531.3 (M+H + ).
[0175] A mixture of compound III (5.5 g, 10.3 mmol) in HCl / dioxane (2 M, 55 mL) was stirred at 25° C. for 3 h. LCMS showed complete consumption of compound III. The reaction mixture was filtered, washed with EtOAc (50 mL), and dried under reduced pressure to give the crude product, which was dissolved in CH3CN (50 mL) and the volatiles were removed under vacuum. This process was repeated three times to give compound IV (2.05 g, 54.5% yield) as a white solid. 1H NMR(400 MHz,D2O):δ ppm 4.21(s,1 H),4.07(d,J=4.5 Hz,4 H),3.99(s,1 H),3.45-3.52(m,3 H),3.42(t,J=6.5 Hz,1 H),3.32-3.38(m,1 H),3.24-3.31(m,1 H),2.37(t,J=7.4 Hz,1 H),2.24(t,J=7.4 Hz,1 H),1.99(dt,J=15.5,7.53 Hz,1 H),1.85-1.94(m,1 H),1.85-1.94(m,1 H),1.39-1.56(m,4 H),1.19-1.31(m,2 H).
[0176] A mixture of compound IV (500 mg, 1.05 mmol), intermediate-A (2.02 g, 3.67 mmol), DIEA (813 mg, 6.30 mmol), EDCI (704 mg, 3.67 mmol), and HOBt (496 mg, 3.67 mmol) in DMF (10 mL) was degassed and purged with N2 three times, then the mixture was stirred under N2 atmosphere at 25 °C for 3 h. LCMS showed the desired product. The reaction mixture was quenched by adding H2O (10 mL) and extracted with DCM (10 mL x 2). The combined organics were extracted with 10% citric acid (20 mL). The aqueous phase was neutralized with saturated NaHCO3 solution and re-extracted with DCM (10 mL x 2). The organics were dried over sodium sulfate, filtered, and concentrated under reduced pressure to give compound Va (570 mg, 0.281 mmol, 26.8% yield) as a white solid. 1H NMR:(400 MHz,CDCl3)ppm δ 7.84-8.12(m,3 H),6.85-7.15(m,2 H),6.66-6.81(m,1 H),5.36(br d,J=2.7 Hz,3 H),5.11-5.27(m,3 H),4.63-4.85(m,3 H),3.90-4.25(m,18 H),3.37-3.75(m,28 H),3.15-3.28(m,4 H),2.64(br d,J=6.53 Hz,2 H),2.30-2.46(m,2 H),2.13-2.18(m,9 H),2.05(s,9 H),1.94-2.03(m,18 H),1.68(br s,2 H),1.45(br s,2 H),1.12(br t,J=7.0 Hz,2 H).
[0177] To a solution of compound Va (260 mg, 0.161 mmol) in anhydrous DCM (5 mL) was added diisopropylammonium tetrazolide (30.3 mg, 0.177 mmol) followed by dropwise addition of 3-bis(diisopropylamino)phosphanyloxypropanenitrile (194 mg, 0.645 mmol) under N2 at ambient temperature. The reaction mixture was stirred at 20-25 °C for 2 h. LCMS showed that compound Va was completely consumed. After cooling to -20 °C, the reaction mixture was added to a stirred solution of brine / saturated aqueous NaHCO3 (1:1, 5 mL) at 0 °C. After stirring for 1 min, DCM (5 mL) was added. The layers were separated. The organics were washed with brine / saturated aqueous NaHCO3 (1:1, 5 mL), dried over Na2SO4, filtered and concentrated to a volume of approximately 1 mL. The residual solution was added dropwise to 20 mL of methyl tert-butyl ether (MTBE) with stirring. This caused a white solid to precipitate. The mixture was centrifuged and the solid was collected. The solid was redissolved in 1 mL of DCM and precipitated by adding MTBE (20 mL). The solid was again isolated by centrifugation. The collected solid was dissolved in anhydrous CH3CN. The volatiles were removed. This process was repeated two more times to give the GalNAc ligand phosphoramidite compound GLPA1 (153 mg, 84.4 μmol) as a white solid. 1H NMR(400 MHz,CDCl3):ppm δ 7.71-8.06(m,2 H),6.60-7.06(m,3 H),5.37(br d,J=3.0 Hz,3 H),5.18-5.32(m,3 H),4.70-4.86(m,3 H),3.92-4.25(m,18 H),3.42-3.85(m,30 H),3.25(m,4 H),2.59-2.75(m,4 H),2.27-2.44(m,2 H),2.15-2.20(s,9 H)2.07(s,9 H),1.96-2.03(m,18 H),1.65(br s,4 H),1.44(br d,J=7.28 Hz,2 H), 1.14-1.24(m,12 H). 31 P NMR(CDCl3): ppm δ 147.15.
[0178] The same procedure was used except for using intermediate-B to synthesize the GalNAc ligand phosphoramidite compound GLPA2. 1 H NMR(400 MHz,CDCl3):ppm δ 7.94-8.18(m,1 H),7.69(br s,1 H),6.66-7.10(m,3 H),5.35(d,J=3.5 Hz,3 H),5.07-5.25(m,3 H),4.76-4.86(m,3 H),4.01-4.31(m,10 H),3.91-4.01(m,8 H),3.74-3.86(m,4 H),3.52-3.71(m,30 H),3.42-3.50(m,6 H),3.15-3.25(m,4 H),2.52-2.70(m,4 H),2.22-2.45(m,2 H),2.15-2.22(s,9 H),2.06(s,9 H),1.95-2.03(m,18 H),1.77(br s,2 H),1.58-1.66(m,4 H),1.40(m,2 H),1.08-1.24(m,12 H). 31 P NMR(CDCl3): ppm δ 147.12.
[0179] GLPA15 was prepared according to Scheme 3 below.
[0180] [ka]
[0181] Scheme 3 Starting from secondary amine compound I (compound II in scheme 2), Cbz protection was introduced to give compound II. The tert-butyl group of compound II was removed by treatment with acid to give triacid compound III. Amide coupling of compound III with intermediate-A gave compound IV. The Cbz protecting group of compound IV was removed by hydrogenation to give secondary amine compound V, which was reacted with glutaric anhydride to give carboxylic acid compound VI. Compound VI was reacted with piperidin-4-ol under amide coupling reaction conditions to give compound VII. Phosphoramidite compound GLPA15 was synthesized by treating compound VII with 2-cyanoethyl N,N-diisopropylchlorophosphoramidite and a catalytic amount of 1H-tetrazole. 1 H NMR (400 MHz in DMSO-d6): δ ppm 8.05(br d,J=6.50 Hz,2 H),7.81(br d,J=9.01 Hz,3 H),5.22(d,J=3.25 Hz,3 H),4.98(dd,J=11.26,3.25 Hz,3 H),4.55(br d,J=8.50 Hz,3 H),4.03(s,9 H),3.64-3.97(m,12 H),3.55-3.63(m,6 H),3.50(br s,5 H),3.40(br d,J=6.13 Hz,6 H),3.17-3.30(m,9 H),3.07(br d,J=14.26 Hz,4 H),2.76(t,J=5.82 Hz,2 H),2.18-2.47(m,6 H),2.10(s,9 H),1.99(s,9 H),1.89(s,9 H),1.78(s,9 H),1.52-1.74(m,6 H),1.12-1.19(m,12 H).31P NMR(DMSO-d6):ppm δ 145.25.
[0182] In certain studies, the method used to attach a GalNAc-containing targeting group (also referred to herein as a GalNAc delivery compound) to the 5' end of the sense strand included the use of a GalNAc phosphoramidite (GLPA1) in the final coupling step of solid phase synthesis using a synthetic process such as that used when an oligonucleotide growth reaction is performed to add nucleotides to the 5' end of the sense strand.
[0183] In some studies, the method of attaching a GalNAc-containing targeting group to the 3'-end of the sense strand included the use of a solid support (CPG) containing GLO-n. In some studies, the method of attaching a GalNAc-containing targeting group to the 3'-end of the sense strand included attaching the GalNAc targeting group to a CPG solid support via an ester bond, and using the resulting CPG with the attached GalNAc targeting group in synthesizing the sense strand, resulting in a GalNAc targeting group attached to the 3'-end of the sense strand.
[0184] Example 4. In vitro screening of HBV siRNA duplexes HBV transfected HepG2.2.15 cell line was used for in vitro evaluation of HBV siRNA agents. HepG2.2.15 cells were seeded in 96-well plates and transfected with HBV siRNA agents at final concentrations of 0.04 nM, 0.2 nM, and 1 nM using Lipofectamine® RNAiMax as the transfecting agent. Supernatants were harvested 72 hours after seeding. HBsAg levels were determined by ELISA assay. Knockdown activity was calculated by comparing HBsAg levels obtained from samples transfected with HBV siRNA agents with untransfected control samples (Lipofectamine® RNAiMax only). Experiments were performed in triplicate. Results are summarized in Tables 5 and 7. Even at 0.04 nM, multiple siRNAs showed good activity in suppressing HBsAg expression. A subset of siRNAs showing good to excellent activity was selected for in vivo testing.
[0185] Table 5 provides experimental results of in vitro studies using various HBV RNAi agents to inhibit HBsAg expression. The studies are described elsewhere herein.
[0186] [Table 5-1] [Table 5-2]
[0187] Table 7 provides experimental results of in vitro studies using various HBV RNAi agents to inhibit HBsAg expression. The studies are described elsewhere herein.
[0188] [Table 7-1] [Table 7-2]
[0189] Example 5. In vivo screening of siRNA agents The AAV-HBV mouse model was used to evaluate the in vivo efficacy of HBV siRNA agents. Five-week-old male C57BL / 6 mice were infected with 1x10^11 rAAV8-1.3 HBV viral genomes via tail vein injection. 14 days after infection, blood samples were collected and HBsAg in mouse serum was measured by ELISA assay. Mice with high expression levels of HBsAg (log HBsAg IU / ml>4.9) were selected for testing. On day 18 post-infection, each mouse was subcutaneously administered a single 3mg / kg dose of HBV siRNA or PBS control. Blood samples were collected on days 7 and 14 post-infection. Serum HBsAg was measured by ELISA assay. To determine the ratio of "normalized to pre-treatment" expression, the HBsAg level of each animal at a time point was divided by the pre-treatment level of expression in that animal (day 14 post-infection). Knockdown activity was calculated by dividing the "normalized to pretreatment" ratio of each individual animal by the average "normalized to pretreatment" ratio of all mice in the PBS control group. The results are summarized in Table 6. Highly effective HBV siRNAs were identified. In particular, mice treated with siRNA agents AD00170, AD00263, AD00265, AD00267, AD00268, AD00269, AD00173 and AD00176 showed more than 96% reduction in HBsAg (normalized to pretreatment). In this example, GLO-0 in the compounds in Table 3 refers to compound GalNAc3 in Jayaprakash, et al., (2014) J.Am.Chem.Soc., 136, 16958-16961.
[0190] Table 6. HBV siRNA single 3 mpk subcutaneous dose screening in AAV-HBV transduced mice. The percentage reduction of HBsAg in mouse serum was normalized to the HBsAg levels before administration of siRNA and to the PBS control group.
[0191] [Table 6]
[0192] Example 6. In vivo testing of siRNA agents in the AAV-HBV mouse model The AAV-HBV mouse model was used to evaluate the in vivo efficacy of HBV siRNA agents. Five-week-old male C57BL / 6 mice were infected with 1x10^11 rAAV8-1.3 HBV viral genomes via tail vein injection. 14 days after infection, blood samples were collected and HBsAg in mouse serum was measured by ELISA assay. Mice with high expression levels of HBsAg (log HBsAg IU / ml>4.9) were selected for testing. On day 18 post-infection, each mouse was subcutaneously administered a single 3mg / kg dose of HBV siRNA or PBS control. Blood samples were collected on days 7, 14, and 21 post-infection. Serum HBsAg and HBeAg were measured by ELISA assay. To determine the ratio of "normalized to pre-treatment" expression, the HBsAg and HBeAg levels of each animal at a time point were divided by the pre-treatment level of expression in that animal (day 14 post-infection). Knockdown activity was calculated by dividing the "normalized to pretreatment" ratio of each animal by the average "normalized to pretreatment" ratio of all mice in the PBS control group. The results are summarized in Table 8 and Table 9. Highly effective HBV siRNA was identified. In particular, mice treated with siRNA agents AD00170, AD00263, AD00267, AD00378, AD00383 and AD00384 showed more than 96% reduction in HBsAg (normalized to pretreatment). In this example, GLO-0 in the compounds in Table 3 refers to compound GalNAc3 in Jayaprakash, et al., (2014) J Am.Chem.Soc., 136, 16958-16961.
[0193] Table 8. HBV siRNA single 3 mpk subcutaneous dose screening in AAV-HBV transduced mice. The percentage reduction of HBsAg in mouse serum was normalized to the HBsAg levels before administration of siRNA and to the PBS control group.
[0194] [Table 8]
[0195] Table 9. HBV siRNA single 3 mpk subcutaneous dose screening in AAV-HBV transduced mice. The percentage reduction of HBeAg in mouse serum was normalized to the HBeAg levels before administration of siRNA and to the PBS control group.
[0196] [Table 9]
[0197] Example 7. In vivo testing of siRNA agents in the AAV-HBV mouse model The AAV-HBV mouse model was used to evaluate the in vivo efficacy of HBV siRNA agents. Five-week-old male C57BL / 6 mice were infected with 1x10^11 rAAV8-1.3 HBV viral genome via tail vein injection. 14 days after infection, blood samples were collected and HBsAg in mouse serum was measured by ELISA assay. Mice with high expression levels of HBsAg (log HBsAg IU / ml>4.9) were selected for testing. On day 18 after infection, each mouse was subcutaneously administered a single 3mg / kg dose of HBV siRNA or PBS control. Blood samples were collected on days 7, 14, 21, 28, 35, 42, 49, 56, 63, 70, 77, 84, and 91 after administration. HBsAg levels were measured by ELISA assay and HBV DNA levels were determined by qPCR. The results are summarized in Figures 1 and 2. In this example, the positive control is AD-81890 in WO2020036862.
[0198] Equivalent Although several embodiments of the present invention have been described and illustrated herein, those skilled in the art will readily envision various other means and / or structures for performing the functions and / or obtaining one or more of the results and / or advantages described herein, and each of such variations and / or modifications are deemed to be within the scope of the present invention. More generally, those skilled in the art will readily appreciate that all parameters, dimensions, materials and configurations described herein are meant to be exemplary, and that the actual parameters, dimensions, materials and / or configurations will depend on the particular application or applications for which the teachings of the present invention are used. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the present invention described herein. Accordingly, it should be understood that the foregoing embodiments are presented by way of example only, and are within the scope of the appended claims and their equivalents. The present invention may be practiced otherwise than as specifically described and claimed. The present invention relates to each individual feature, system, article, material and / or method described herein. Moreover, any combination of two or more such features, systems, articles, materials and / or methods is included within the scope of the present invention, if such features, systems, articles, materials and / or methods are not mutually inconsistent.
[0199] All definitions and those used herein should be understood to govern any dictionary definitions, definitions in documents incorporated by reference, and / or ordinary meanings of the defined terms.
[0200] The indefinite articles, as used in the specification and claims, unless clearly indicated otherwise, should be understood to mean "at least one."
[0201] The term "and / or" as used in the specification and claims should be understood to mean "either or both" of the elements so conjoined, i.e., elements that are conjunctively present in some cases and disjunctively present in other cases. Unless expressly indicated otherwise, other elements may optionally be present other than the elements specifically identified by the "and / or" clause, whether or not associated with the specifically identified elements.
[0202] All references, patents and patent applications and publications cited or referred to in this application are hereby incorporated by reference in their entirety.
Claims
1. 1. A double-stranded ribonucleic acid (dsRNA) agent for inhibiting expression of Hepatitis B virus (HBV) in a cell, said dsRNA agent comprising a sense strand and an antisense strand, wherein nucleotide positions 2-18 of said antisense strand comprise a region of complementarity to an HBV RNA transcript, said region comprising at least 15 contiguous nucleotides that differ by 0, 1, 2 or 3 nucleotides from one of the antisense sequences listed in one of Tables 1-4, and optionally comprising a targeting ligand.
2. The dsRNA agent of claim 1, wherein the region of complementarity to the HBV RNA transcript comprises at least 15, 16, 17, 18, or 19 contiguous nucleotides that differ by no more than 3 nucleotides from one of the antisense sequences listed in one of Tables 1-4.
3. 3. The dsRNA agent of claim 1 or 2, wherein the antisense strand of the dsRNA is at least substantially complementary to any one of the target regions of SEQ ID NO: 673 and provided in any one of Tables 1-4.
4. 4. The dsRNA agent of claim 3, wherein the antisense strand of the dsRNA is perfectly complementary to any one of the target regions of SEQ ID NO: 673 and provided in any one of Tables 1-4.
5. 2. The dsRNA agent of claim 1, wherein the dsRNA agent comprises a sense strand sequence set forth in any one of Tables 1-4, and wherein the sense strand sequence is at least substantially complementary to the antisense strand sequence in the dsRNA agent.
6. 2. The dsRNA agent of claim 1, wherein the dsRNA agent comprises a sense strand sequence set forth in any one of Tables 1-4, and the sense strand sequence is perfectly complementary to the antisense strand sequence in the dsRNA agent.
7. The dsRNA agent of claim 1, comprising an antisense strand sequence as set forth in any one of Tables 1-4.
8. The dsRNA agent of claim 1, comprising a sequence set forth as a duplex sequence in any of Tables 1-4.
9. The dsRNA of claim 1, wherein the dsRNA agent comprises at least one modified nucleotide.
10. The dsRNA agent of claim 1, wherein all or substantially all of the nucleotides of the antisense strand are modified nucleotides.
11. 11. The dsRNA agent of claim 9 or 10, wherein the at least one modified nucleotide comprises a 2'-O-methyl nucleotide, a 2'-fluoro nucleotide, a 2'-deoxy nucleotide, a 2'3'-seco nucleotide mimic, a locked nucleotide, a non-locked nucleic acid nucleotide (UNA), a glycol nucleic acid nucleotide (GNA), a 2'-F-arabino nucleotide, a 2'-methoxyethyl nucleotide, an abasic nucleotide, a ribitol, an inverted nucleotide, an inverted abasic nucleotide, an inverted 2'-OMe nucleotide, an inverted 2'-deoxy nucleotide, a 2'-amino modified nucleotide, a 2'-alkyl modified nucleotide, a morpholino nucleotide, and a 3'-OMe nucleotide, a nucleotide comprising a 5'-phosphorothioate group, or a terminal nucleotide linked to a cholesteryl derivative or a dodecanoic acid bisdecylamide group, a 2'-amino modified nucleotide, a phosphoramidate, or a non-natural base containing nucleotide.
12. The dsRNA agent of claim 9 or 10, comprising an E-vinyl phosphonate nucleotide at the 5'-end of the antisense strand.
13. 2. The dsRNA agent of claim 1, comprising at least one phosphorothioate internucleoside linkage.
14. The dsRNA agent of claim 1, wherein the sense strand comprises at least one phosphorothioate internucleoside linkage.
15. The dsRNA agent of claim 1, wherein the antisense strand comprises at least one phosphorothioate internucleoside linkage.
16. The dsRNA agent of claim 1, wherein the sense strand comprises 1, 2, 3, 4, 5, or 6 phosphorothioate internucleoside linkages.
17. The dsRNA agent of claim 1, wherein the antisense strand comprises 1, 2, 3, 4, 5, or 6 phosphorothioate internucleoside linkages.
18. The dsRNA agent of claim 1, wherein all or substantially all of the nucleotides of the sense strand and the antisense strand are modified nucleotides.
19. The dsRNA agent of claim 1, wherein the modified sense strand is a modified sense strand sequence set forth in one of Tables 2-4.
20. The dsRNA agent of claim 1, wherein the modified antisense strand is a modified antisense strand sequence set forth in one of Tables 2-4.
21. The dsRNA agent of claim 1, wherein the sense strand is complementary or substantially complementary to the antisense strand, and the region of complementarity is 16-23 nucleotides in length.
22. The dsRNA agent of claim 1, wherein the complementary region is 19-21 nucleotides in length.
23. The dsRNA agent of claim 1, wherein each strand is 30 nucleotides or less in length.
24. The dsRNA agent of claim 1, wherein each strand is 25 nucleotides or less in length.
25. 2. The dsRNA agent of claim 1, wherein each strand is 23 nucleotides or less in length.
26. The dsRNA agent of claim 1, comprising at least one modified nucleotide and further comprising one or more targeting or linking groups.
27. 27. The dsRNA agent of claim 26, wherein the one or more targeting or linking groups are conjugated to the sense strand.
28. 28. The dsRNA agent of claim 26 or 27, wherein the targeting group or linking group comprises N-acetyl-galactosamine (GalNAc).
29. 28. The dsRNA agent of claim 26 or 27, wherein the targeting group has the structure: 【Chemistry 1-1】 【Chemistry 1-2】 【Chemistry 1-3】 【Chemistry 1-4】 【Chemistry 1-5】 【Chemistry 1-6】 【Chemistry 1-7】 【Chemistry 1-8】 【Chemistry 1-9】 【Chemistry 1-10】 【Chemistry 1-11】
30. The dsRNA agent of claim 1, comprising a targeting group conjugated to the 5'-end of the sense strand.
31. The dsRNA agent of claim 1, comprising a targeting group conjugated to the 3'-end of the sense strand.
32. The dsRNA agent of claim 1, wherein the antisense strand comprises an inverted abasic residue at the 3' end.
33. The dsRNA agent of claim 1, wherein the sense strand comprises one or two inverted abasic residues at the 3' and / or 5' end.
34. The dsRNA agent of claim 1, which has two blunt ends.
35. The dsRNA agent of claim 1 , wherein at least one strand comprises a 3' overhang of at least 1 nucleotide.
36. The dsRNA agent of claim 1 , wherein at least one strand comprises a 3' overhang of at least 2 nucleotides.
37. 2. The dsRNA agent of claim 1, wherein the sense strand comprises one of SEQ ID NOs: 281, 290, 295, 300, 304, 306, 307, 331, 557, 567, 569, 571, 572, 573, 560, 563, 607, 628-637, or 918-921, preferably SEQ ID NOs: 557, 607, 631, 918, 919, or 921.
38. 2. The dsRNA agent of claim 1, wherein the antisense strand comprises one of SEQ ID NOs: 419, 428, 433, 438, 442, 444, 445, 469, 582, 592, 594, 596, 597, 598, 585, 588, 642, 663-672, or 922-925, preferably SEQ ID NOs: 582, 642, 666, 922, 923 or 925.
39. SEQ ID NO:281 and SEQ ID NO:419; SEQ ID NO:290 and SEQ ID NO:428; SEQ ID NO:295 and SEQ ID NO:433; SEQ ID NO:300 and SEQ ID NO:438; SEQ ID NO:304 and SEQ ID NO:442; SEQ ID NO:306 and SEQ ID NO:444; SEQ ID NO:307 and SEQ ID NO:445; SEQ ID NO:331 and SEQ ID NO:469; SEQ ID NO:557 and SEQ ID NO:582; SEQ ID NO:567 and SEQ ID NO:592; SEQ ID NO:569 and SEQ ID NO:594; SEQ ID NO:571 and SEQ ID NO:596; SEQ ID NO:572 and SEQ ID NO:597; SEQ ID NO:573 and SEQ ID NO:598; SEQ ID NO:560 and SEQ ID NO:585; SEQ ID NO:563 and SEQ ID NO:588; SEQ ID NO:607 and SEQ ID NO:642; SEQ ID NO:628 and SEQ ID NO:663; SEQ ID NO:629 and SEQ ID NO:664; SEQ ID NO:630 and SEQ ID NO:665; SEQ ID NO:631 and SEQ ID NO:666; SEQ ID NO:632 and SEQ ID NO:667; SEQ ID NO:633 and SEQ ID NO:668; SEQ ID NO:634 and SEQ ID NO:669; SEQ ID NO:635 and SEQ ID NO:670; SEQ ID NO:636 and SEQ ID NO:671; or SEQ ID NO:637 and SEQ ID NO:672, SEQ ID NO:918 and SEQ ID NO:922, SEQ ID NO:919 and SEQ ID NO:923, SEQ ID NO:920 and SEQ ID NO:924, or SEQ ID NO:921 and SEQ ID NO:925; preferably SEQ ID NO:557 and SEQ ID NO:582; SEQ ID NO:607 and SEQ ID NO:642, SEQ ID NO:631 and SEQ ID NO:666, SEQ ID NO:918 and SEQ ID NO:922, SEQ ID NO:919 and SEQ ID NO:923, or SEQ ID NO:921 and SEQ ID NO:
925.
40. A composition comprising one, two, three or more dsRNA agents of any one of claims 1-39.
41. 41. The composition of claim 40, further comprising a pharma- ceutically acceptable carrier.
42. 42. The composition of claim 41, further comprising one or more additional therapeutic agents.
43. 43. The composition of claim 42, packaged in a kit, container, pack, dispenser, pre-filled syringe or vial.
44. 41. The composition of claim 40, formulated for subcutaneous administration or formulated for intravenous (IV) administration.
45. 41. The composition of claim 40, wherein the sense strand of at least one of the dsRNA agents comprises one of SEQ ID NOs: 281, 290, 295, 300, 304, 306, 307, 331, 557, 567, 569, 571, 572, 573, 560, 563, 607, 628-637, or 918-921, preferably SEQ ID NOs: 557, 607, 631, 918, 919, or 921.
46. 41. The composition of claim 40, wherein the antisense strand of at least one of said dsRNA agents comprises one of SEQ ID NOs: 419, 428, 433, 438, 442, 444, 445, 469, 582, 592, 594, 596, 597, 598, 585, 588, 642, 663-672, or 922-925, preferably SEQ ID NOs: 582, 642, 666, 922, 923, or 925.
47. At least one of said dsRNA agents is selected from the group consisting of SEQ ID NO:281 and SEQ ID NO:419; SEQ ID NO:290 and SEQ ID NO:428; SEQ ID NO:295 and SEQ ID NO:433; SEQ ID NO:300 and SEQ ID NO:438; SEQ ID NO:304 and SEQ ID NO:442; SEQ ID NO:306 and SEQ ID NO:444; SEQ ID NO:307 and SEQ ID NO:445; SEQ ID NO:331 and SEQ ID NO:469; SEQ ID NO:557 and SEQ ID NO:582; SEQ ID NO:567 and SEQ ID NO:592; SEQ ID NO:569 and SEQ ID NO:594; SEQ ID NO:571 and SEQ ID NO:596; SEQ ID NO:572 and SEQ ID NO:597; SEQ ID NO:573 and SEQ ID NO:598; SEQ ID NO:560 and SEQ ID NO:585; SEQ ID NO:563 and SEQ ID NO:588; SEQ ID NO:628 and SEQ ID NO:663; SEQ ID NO:629 and SEQ ID NO:664; 41. The composition of claim 40, comprising SEQ ID NO:630 and SEQ ID NO:665; SEQ ID NO:631 and SEQ ID NO:666; SEQ ID NO:632 and SEQ ID NO:667; SEQ ID NO:633 and SEQ ID NO:668; SEQ ID NO:634 and SEQ ID NO:669; SEQ ID NO:635 and SEQ ID NO:670; SEQ ID NO:636 and SEQ ID NO:671; SEQ ID NO:637 and SEQ ID NO:672, SEQ ID NO:918 and SEQ ID NO:922; SEQ ID NO:919 and SEQ ID NO:923; SEQ ID NO:920 and SEQ ID NO:924; or SEQ ID NO:921 and SEQ ID NO:925; preferably SEQ ID NO:557 and SEQ ID NO:582, SEQ ID NO:607 and SEQ ID NO:642, SEQ ID NO:631 and SEQ ID NO:666, SEQ ID NO:918 and SEQ ID NO:922, SEQ ID NO:919 and SEQ ID NO:923, or SEQ ID NO:921 and SEQ ID NO:
925.
48. A cell comprising the dsRNA agent of any one of claims 1 to 39.
49. 49. The cell of claim 48, which is a mammalian cell, optionally a human cell.
50. 1. A method for inhibiting expression of a Hepatitis B virus (HBV) gene in a cell, comprising: (i) preparing a cell comprising an effective amount of one or more double-stranded ribonucleic acid (dsRNA) agents according to any one of claims 1 to 39 or a composition according to any one of claims 40 to 47.
51. (ii) maintaining the cells prepared in claim 50(i) for a time sufficient to obtain degradation of the mRNA transcripts of HBV genes, thereby inhibiting expression of the HBV genes in the cells, inhibiting replication of the HBV in the cells, and reducing the levels of the HBV antigens in the cells.
51. The method of claim 50, further comprising:
52. 52. The method of claim 51, wherein the one or more HBV antigens are HBcAg, HBsAg and HBeAg.
53. 52. The method of claim 50 or 51, wherein the cell is in a subject and the dsRNA agent is administered subcutaneously to the subject.
54. 52. The method of claim 50 or 51, wherein the cell is in a subject and the dsRNA agent is administered to the subject by IV administration.
55. 55. The method of any one of claims 50-54, wherein two, three, four or more dsRNA agents are administered to the subject.
56. and further comprising evaluating the inhibition of the HBV gene following said administration of said dsRNA agent to said subject, said means for evaluating comprising: (i) determining one or more physiological characteristics of an HBV-associated disease or condition in said subject; and 56. The method of any one of claims 50 to 55, comprising (ii) comparing the determined physiological characteristic with a baseline pre-treatment physiological characteristic of the HBV-related disease or condition and / or a control physiological characteristic of the HBV-related disease or condition, wherein the comparison indicates one or more of the presence or absence of inhibition of expression of the HBV gene in the subject.
57. 57. The method of claim 56, wherein the control physiological characteristic is a physiological characteristic in a subject infected with HBV and not administered the dsRNA agent.
58. 58. The method of claim 57, wherein the determined physiological characteristics in the subject are one or more of the following: alanine aminotransferase (ALT) level in the subject, aspartate aminotransferase (AST) level in the subject; HBV viral load in the subject; HBV covalently closed circular DNA (cccDNA) level in the subject; the level of one or more HBV antigens in the subject; the level of one or more HBcAg, HBsAg and HBeAg in the subject; the presence, absence and / or level of one or more anti-Hepatitis B virus antibodies in the subject.
59. 57. The method of claim 56, wherein the physiological characteristic is determined in a biological sample obtained from the subject.
60. 60. The method of claim 59, wherein the biological sample comprises one or more of a serum sample, a tissue sample, a cell sample, and a liver sample.
61. 57. The method of claim 56, wherein the determined physiological characteristic in the subject is abnormal as compared to a control level of the physiological characteristic.
62. The method of claim 61, wherein the levels of one or more of ALT; AST; HBV viral load, HBV covalently closed circular DNA (cccDNA); one or more HBV antigens; one or more of HBcAg, HBsAg, and HBeAg; and one or more anti-Hepatitis B virus antibodies in the subject determined to be statistically significantly higher compared to a control physiological characteristic of the HBV-related disease or HBV-related condition and / or the baseline pre-treatment physiological characteristic of the HBV-related disease or HBV-related condition are indicative of the status of HBV gene expression in the subject.
63. 63. The method of claim 62, wherein the control physiological characteristic is the physiological characteristic in a subject infected with HBV and not administered the dsRNA agent.
64. The method of claim 56, wherein a decrease in one or more of the ALT; AST; HBV viral load, HBV covalently closed circular DNA (cccDNA); one or more HBV antigens; HBcAg; HBsAg; and HBeAg in the subject indicates a decrease in HBV gene expression in the subject.
65. The method of claim 56, wherein an increase in anti-Hepatitis B virus antibodies in the subject compared to a control physiological characteristic of the HBV-related disease or HBV-related condition and / or the baseline pre-treatment physiological characteristic of the HBV-related disease or HBV-related condition indicates a decrease in HBV gene expression in the subject.
66. 57. The method of claim 56, wherein the HBV-related disease or condition is one or more of the following: the disease or condition is one or more of hepatitis B, chronic hepatitis B, hepatitis D virus infection (delta hepatitis or HDV), liver injury, liver cirrhosis, acute hepatitis B, acute fulminant hepatitis, and liver fibrosis, hepatitis, and hepatocellular carcinoma.
67. 50. A method of inhibiting expression of an HBV gene in a subject, comprising administering to the subject an effective amount of one or more double-stranded ribonucleic acid (dsRNA) agents of any one of claims 1 to 39 or a composition of any one of claims 40 to 47.
68. 68. The method of claim 67, wherein two, three, four or more of said dsRNA agents are administered to the subject.
69. 69. The method of claim 67 or 68, wherein the dsRNA agent is administered to the subject subcutaneously.
70. 69. The method of claim 67 or 68, wherein the dsRNA agent is administered to the subject by IV administration.
71. and further comprising evaluating the inhibition of said HBV gene after said administration of said one or more dsRNA agents, said means for evaluating comprising: (i) determining one or more physiological characteristics of an HBV-associated disease or condition in said subject; and (ii) comparing the determined physiological characteristic with a baseline pre-treatment physiological characteristic of the HBV-related disease or condition and / or a control physiological characteristic of the HBV-related disease or condition; The method of any one of claims 67 to 70, wherein the comparison indicates one or more of the presence or absence of inhibition of expression of the HBV gene in the subject.
72. The method of claim 71, wherein the determined physiological characteristics in the subject are one or more of the following: alanine aminotransferase (ALT) level in the subject, aspartate aminotransferase (AST) level in the subject; HBV viral load in the subject; HBV covalently closed circular DNA (cccDNA) level in the subject; the level of one or more HBV antigens in the subject; the level of one or more of HBcAg, HBsAg and HBeAg in the subject; the presence, absence and / or level of one or more anti-Hepatitis B virus antibodies in the subject.
73. 72. The method of claim 71, wherein the physiological characteristic is determined in a biological sample obtained from the subject.
74. 74. The method of claim 73, wherein the biological sample comprises one or more of a serum sample, a cell sample, a tissue sample, and a liver sample.
75. The method of claim 71, wherein the determined physiological characteristic in the subject is more abnormal compared to a baseline pre-treatment physiological characteristic of the HBV-related disease or HBV-related condition and / or a control physiological characteristic of the HBV-related disease or HBV-related condition.
76. The method of claim 73, wherein the levels of one or more of ALT; AST; HBV viral load, HBV covalently closed circular DNA (cccDNA); one or more HBV antigens; one or more of HBcAg, HBsAg, and HBeAg; and one or more anti-Hepatitis B virus antibodies in the subject determined to be statistically significantly higher, lower, or unchanged compared to baseline pre-treatment physiological characteristics of the HBV-related disease or HBV-related condition and / or control physiological characteristics of the HBV-related disease or HBV-related condition are indicative of the status of HBV gene expression in the subject.
77. The method of claim 71, wherein a decrease in one or more of the ALT; AST; HBV viral load, HBV covalently closed circular DNA (cccDNA); one or more HBV antigens; HBcAg; HBsAg; and HBeAg in the subject indicates a decrease in HBV gene expression in the subject.
78. The method of claim 76, wherein an increase in anti-Hepatitis B virus antibodies in the subject compared to baseline pre-treatment physiological characteristics of the HBV-related disease or HBV-related condition and / or control physiological characteristics of the HBV-related disease or HBV-related condition indicates a decrease in HBV gene expression in the subject.
79. 72. The method of claim 71, wherein the HBV-related disease or condition is one or more of hepatitis B, chronic hepatitis B, acute hepatitis B, hepatocellular carcinoma, liver injury, liver cirrhosis, acute fulminant hepatitis, end-stage liver disease, liver fibrosis, hepatitis, and hepatitis D virus infection (delta hepatitis or HDV).
80. 50. A method of treating a disease or condition associated with the presence of a Hepatitis B Virus (HBV) protein, comprising administering to a subject an effective amount of one or more double-stranded ribonucleic acid (dsRNA) agents of any one of claims 1-39 or a composition of any one of claims 40-47 to inhibit expression of an HBV gene encoding said HBV protein.
81. 81. The method of claim 80, comprising administering to the subject two, three, four or more dsRNA agents.
82. 82. The method of claim 80 or 81, wherein the disease or condition is one or more of hepatitis B, chronic hepatitis B, hepatitis D virus infection (delta hepatitis or HDV), liver injury, liver cirrhosis, acute hepatitis B, acute fulminant hepatitis, hepatitis, liver fibrosis and hepatocellular carcinoma.
83. 82. The method of claim 80 or 81, further comprising administering to the subject an additional therapeutic regimen.
84. 82. The method of claim 81, wherein the additional therapeutic regimen comprises administering to the subject one or more of an HBV antisense polynucleotide, an additional HBV dsRNA therapeutic, a non-HBV dsRNA therapeutic, an HBV non-dsRNA therapeutic, and behavioral modification.
85. 85. The method of claim 84, wherein the non-HBV dsRNA therapeutic is one or more of an antiviral agent, an antiviral nucleoside or nucleotide analogue (NUC), a viral polymerase inhibitor, a reverse transcriptase inhibitor, an immunostimulant, a therapeutic vaccine, a viral entry inhibitor, an oligonucleotide that inhibits secretion or release of HBsAg, a capsid inhibitor, a covalently closed circular (ccc) HBV DNA inhibitor.
86. 86. The method of claim 85, wherein the NUC is tenofovir disoproxil fumarate (TDF), tenofovir alafenamide, lamivudine, adefovir dipivoxil, entecavir (ETV) or telbivudine.
87. 86. The method of claim 85, wherein the immunostimulant is pegylated interferon alpha 2a (PEG-IFN-a2a), interferon alpha-2b, recombinant human interleukin-7, a Toll-like receptor 7 (TLR7) agonist, or a checkpoint inhibitor (e.g., a PD1 inhibitor).
88. 81. The method of claim 80, wherein the one or more dsRNA agents are administered to the subject subcutaneously.
89. 81. The method of claim 80, wherein the one or more dsRNA agents are administered to the subject by IV administration.
90. 90. The method of any one of claims 80-89, further comprising determining the effectiveness of the administered one or more double-stranded ribonucleic acid (dsRNA) agents in the subject.
91. The means for determining the efficacy of a treatment in a subject comprises: (i) determining one or more physiological characteristics of the HBV-associated disease or HBV-associated condition in the subject; and (ii) comparing the determined physiological characteristic with a baseline pre-treatment physiological characteristic of the HBV-associated disease or HBV-associated condition; 91. The method of claim 90, wherein the comparison indicates one or more of the presence, absence, and level of efficacy of the administration of the double-stranded ribonucleic acid (dsRNA) agent to the subject.
92. The method of claim 91, wherein the determined physiological characteristics in the subject are one or more of the following: alanine aminotransferase (ALT) level in the subject, aspartate aminotransferase (AST) level in the subject; HBV viral load in the subject; HBV covalently closed circular DNA (cccDNA) level in the subject; the level of one or more HBV antigens in the subject; the level of one or more HBcAg, HBsAg and HBeAg in the subject; the presence, absence and / or level of one or more anti-Hepatitis B virus antibodies in the subject.
93. 92. The method of claim 91, wherein the physiological characteristic is determined in a biological sample obtained from the subject.
94. 94. The method of claim 93, wherein the biological sample comprises one or more of a serum sample, a cell sample, a tissue sample, and a liver sample.
95. 92. The method of claim 91, wherein the determined physiological characteristic in the subject differs from the baseline pre-treatment physiological characteristic of the HBV-associated disease or HBV-associated condition, or compared to a control level of the physiological characteristic.
96. The method of claim 95, wherein the levels of one or more of ALT; AST; HBV viral load, HBV covalently closed circular DNA (cccDNA); one or more HBV antigens; HBcAg, HBsAg and HBeAg in the subject determined to be statistically significantly lower compared to the baseline pre-treatment physiological characteristic of the HBV-related disease or HBV-related condition indicate a state of reduced HBV gene expression in the subject.
97. 96. The method of claim 95, wherein an increase in anti-Hepatitis B virus antibody in the subject compared to the baseline pre-treatment anti-Hepatitis B virus antibody or a control level of anti-Hepatitis B virus antibody indicates a decrease in HBV gene expression in the subject.
98. 98. The method of any one of claims 91 to 97, wherein the HBV-related disease or condition is one or more of hepatitis B, chronic hepatitis B, acute hepatitis B, hepatocellular carcinoma, liver injury, liver cirrhosis, end stage liver disease, acute fulminant hepatitis, hepatitis, liver fibrosis and hepatitis D virus infection (s-hepatitis or HDV).
99. 50. A method of reducing the level of an HBV protein in a subject compared to a baseline pre-treatment level of the HBV protein in the subject, comprising administering to the subject an effective amount of one or more double-stranded ribonucleic acid (dsRNA) agents of any one of claims 1-39 or a composition of any one of claims 40-47 to reduce the level of HBV gene expression.
100. 100. The method of claim 99, wherein the dsRNA agent is administered to the subject subcutaneously or by IV administration.
101. 50. A method of altering physiological characteristics of a Hepatitis B virus (HBV)-related disease or HBV-related condition in a subject compared to a baseline pre-treatment physiological characteristics of the HBV-related disease or HBV-related condition in the subject, comprising administering to the subject an effective amount of one or more double-stranded ribonucleic acid (dsRNA) agents of any one of claims 1-39 or a composition of any one of claims 40-47 to alter the physiological characteristics of the HBV-related disease or HBV-related condition in the subject.
102. 102. The method of claim 101, wherein the one or more dsRNA agents are administered to the subject subcutaneously or by IV administration.
103. The method of claim 101, wherein one or more of the determined physiological characteristics in the subject are one or more of the following: alanine aminotransferase (ALT) level in the subject, aspartate aminotransferase (AST) level in the subject; HBV viral load in the subject; HBV covalently closed circular DNA (cccDNA) level in the subject; the level of one or more HBV antigens in the subject; the level of one or more HBcAg, HBsAg and HBeAg in the subject; the presence, absence and / or level of one or more anti-Hepatitis B virus antibodies in the subject.
104. 102. The method of any one of claims 50, 67, 80, 99 and 101, wherein the sense strand of the dsRNA agent comprises one of SEQ ID NOs: 281, 290, 295, 300, 304, 306, 307, 331, 557, 567, 569, 571, 572, 573, 560, 563, 607, 628-637, or 918-921, preferably SEQ ID NOs: 557, 607, 631, 918, 919 or 921.
105. 102. The method of any one of claims 50, 67, 80, 99 and 101, wherein said antisense strand of said dsRNA agent comprises one of SEQ ID NOs: 419, 428, 433, 438, 442, 444, 445, 469, 582, 592, 594, 596, 597, 598, 585, 588, 642, 663-672, or 922-925, preferably SEQ ID NOs: 582, 642, 666, 922, 923 or 925.
106. The dsRNA agent is SEQ ID NO:281 and SEQ ID NO:419; SEQ ID NO:290 and SEQ ID NO:428; SEQ ID NO:295 and SEQ ID NO:433; SEQ ID NO:300 and SEQ ID NO:438; SEQ ID NO:304 and SEQ ID NO:442; SEQ ID NO:306 and SEQ ID NO:444; SEQ ID NO:307 and SEQ ID NO:445; SEQ ID NO:331 and SEQ ID NO:469; SEQ ID NO:557 and SEQ ID NO:582; SEQ ID NO:567 and SEQ ID NO:592; SEQ ID NO:569 and SEQ ID NO:594; SEQ ID NO:571 and SEQ ID NO:596; SEQ ID NO:572 and SEQ ID NO:597; SEQ ID NO:573 and SEQ ID NO:598; SEQ ID NO:560 and SEQ ID NO:585; SEQ ID NO:563 and SEQ ID NO:588; SEQ ID NO:607 and SEQ ID NO:642; SEQ ID NO:628 and SEQ ID NO:663; SEQ ID NO:629 and SEQ ID NO:664; SEQ ID NO:630 and The method of any one of claims 50, 67, 80, 99 and 101, comprising the sequence of: SEQ ID NO:665; SEQ ID NO:631 and SEQ ID NO:666; SEQ ID NO:632 and SEQ ID NO:667; SEQ ID NO:633 and SEQ ID NO:668; SEQ ID NO:634 and SEQ ID NO:669; SEQ ID NO:635 and SEQ ID NO:670; SEQ ID NO:636 and SEQ ID NO:671; or SEQ ID NO:637 and SEQ ID NO:672; SEQ ID NO:918 and SEQ ID NO:922; SEQ ID NO:919 and SEQ ID NO:923; SEQ ID NO:920 and SEQ ID NO:924; or SEQ ID NO:921 and SEQ ID NO:925; preferably SEQ ID NO:557 and SEQ ID NO:582; SEQ ID NO:607 and SEQ ID NO:642; SEQ ID NO:631 and SEQ ID NO:666; SEQ ID NO:918 and SEQ ID NO:922, SEQ ID NO:919 and SEQ ID NO:923, or SEQ ID NO:921 and SEQ ID NO:925.
